WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
8th Annual
Conference Guide 3rd – 4th March 2015 – 4th March 3rd
www.sachsforum.com CEO FORUM CEO FORUM Hilton Zurich Airport Hotel
PARTNERING & INVESTING for PARTNERING EUROPEAN LIFE SCIENCE EUROPEAN EUROPEAN LIFE SCIENCE CEO FORUM CEO SCIENCE LIFE EUROPEAN WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u . Please bring with The one-to-one meetings are being held in the La Place A and B. the laptop Should you have any queries about your schedule, you a copy of your diary. situated by the meeting tables is available for your assistance. The registration desk is open from 8am on both days to join the although you are welcome Please collect a copy of the agenda for information on timing and room event at any time. allocation for each session. Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk. General Information • • • Sachs Associates are delighted to welcome you to the 8th Annual European Life Science CEO Annual Associates are delighted to welcome you to the 8th Sachs the forum once Following its success from previous years, Forum for Partnering & Investing. againexciting cross-section of venture-funded and small-cap provides access to an companies with leading investors and pharmas. Annual Biotech in Europe Investor our This exclusive and transactional event compliments but with added focus Partnering & the pharmaceutical industry, on held later in the year, Forum, feature presentations from Big Pharma representatives demonstratingtheir current and future partnering strategies through thought-provoking case studies. programme features a series of panels and presentations from leading investment, This year’s the current issues surrounding the evolving highlighting pharmaceutical and biotech companies, Oncology and Biomedical Investment, Vaccines, Partnering activity, Finance and M&A market, Biotech providing an expert outlook on Europe’s and includes special keynote speeches, Presentations and more Workshop event holds exclusive Partnering the In addition, industry. than 60 exclusive company presentations and diverse range of publicly from an exciting listed looking to raise finance and/or find partners. and private life science companies, Sachs Associates are delighted to welcome you to the: are delighted to welcome you to Sachs Associates 8th Annual Science CEO Life European & Investing Partnering Forum for 3rd - 4th March 2015 Hotel Airport Hilton Zurich Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request will endeavour to send you the requested We to [email protected] after the conference. presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT havethat copies of the slides are shown during the conference. Welcome 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u
Events Diary Events and attending opportunities presenting sponsorship, For regular updates, regarding anyand further information contact of our future events please Silvia Kar on [email protected] 3rd Annual 3rd Summit Innovations Medtech & Diagnostics 2015 • Düsseldorf • Germany16th November The Summit is designed to bring together a specialist audience from leading and growth companies focused on The program will feature keynotes from industry leaders and plenary panels on alliances and Investment. M+A, The and diagnostics. company finance, venture investment and growth, industry acquisitions; public markets, subjects of regulation and reimbursement will also be covered. The program will also feature public and private company presentations focused on innovation and alliances/ Imaging, Cardiovascular, and Device companies track will cover; Oncology, The MedTech investment opportunities. with a separatetrack for Diagnostics. Surgical Devices & Implants, event at: www.sachsforum.com/mdis14 last year’s View The forum is recognised as the leading international stage for those interested in investing and partnering in the The Forum draws an exciting cross-section together biotech and life science industry and is highly transactional. money managers and analysts, late-stage and public companies with leading investors, of early-stage/pre-IPO, this event bio industry, Supported and designed by leading figures within Europe’s pharma licensing executives. 100 presenting expect over 600 delegates and We will once again be covered by our regular media partners. companies. Annual is again and the Congress being held in Basel to be close to the largest biopharma hub in Europe The 15th Center provides meeting space capable several thousand one-to-one meetings as well as significant of handling The Programme will feature plenaryBD & Licensing in the main panels/workshops covering exhibition space. networking opportunities There will be significant at the Forum and receptions. therapeutic areas. at: www.sachsforum.com/basel15 Event details available Sachs Immuno-Oncology: BD&L and Investment Forum Investment BD&L and Sachs Immuno-Oncology: • USA Hyatt Chicago Magnificent Mile 29th May 2015 • 15th Annual Forum Biotech in Europe & Investment Global Partnering For Center Basel • Switzerland 29th – 30th September 2015 • Congress 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Cell Therapy Cell Therapy Ltd Ajan Reginald, Chief Executive Officer, Therapy Ltd - the innovative regenerative medicine company that he founded with Co-Founder and Chief Executive of Cell Professor Martin Evans. Nobel Laureate, Therapy invents and develops Regenerative Medicines forcellular medicines that Life™ - breakthrough treat life Cell Therapytrials in End-stage completed Phase II clinical heart failure with Cell In 2014, threatening / life changing diseases. pipeline also includes consists of 2 more disease specific products in Phase The company’s Phase III trials starting in 2015. II trials for Orthopaedic and Dermatology indications. core technology and tissue specific regenerative the company’s medicine products and leads Ajan is an inventor of CTL’s commercial and operational activities. acquisition and development of the overseeing the identification, Technologies Global Head of Emerging Ajan was Roche’s Development Director He joined Roche as Business next generation of breakthrough Biopharma technologies and products. licensing transaction with where he led M&A teams and major licensing transactions including the $1.3B in Roche Pharma, Alnylam. and received a MBA from KelloggGroup with the Boston Consulting Ajan was a consultant Business School, Prior to Roche, he was awarded the UK Fulbright In 2002, Northwestern University where he was awardedthe Biotechnology scholarship. Scholarship. F.Hoffmann La Roche AG La Roche Global Business Development, F.Hoffmann Director, Breidenbach, Alexander Alexander has over 15 years experience in the pharma industry in research & development in multiple disease areas and in Alexander is Business Development Director for In his current role now specializing in neuroscience. business development, Roche Partnering. around Trophos such as the recently announced acquisition of Alexander is project leader for licensing and M&A projects, olesoxime for the treatment of spinal muscular atrophy. opportunities and was “White Space” StrategicAlexander was project leader in Partnering being responsible for Prior to this Diligence Director supporting Alexander was Due Prior to that leading the in-license project of oral octreotide from Chiasma. all disease areas. Novimmune SA Novimmune CBO, Adrian Mills, recently Most their EU Commercial he was in JulyNovimmune joined Adrian Mills with GSK. extensive career 2014 after an for Diseases Business Unit where he was responsible Director in the Rare & Critical launching new orphan medicines for sales as well as leading the European rare diseases metabolic diseases and immuno-deficiencies, neuromuscular disorders, a portfolioand marketing teams promoting of orphan and critical care medicines. backgroundprofessional negotiating and medicines new in launching and pricing hurdles includes access market Adrian’s America. America and North Latin Japan, Europe, strategy and development functions in both R&D, Adrian has led commercial in life sciences, With over 20 years experience commercial operations. companies. advising life sciences he worked in consulting (Booz & Co) and investment banking (Schroders) Prior to GSK, School. Business London the from MBA an and Cambridge, Engineeringin (Hons) College, Queens’ from M.A. an holds Adrian
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Novartis Pharmaceuticals Novartis Oncology, Head Negotiation, Business Development, VP, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European SVP Corporate Development, Galapagos SVP Corporate Development, Hoekema, Andre where he was Managing of Corporate Director joined Galapagos Hoekema Corporation, in March 2005 from Invitrogen Dr. positions at He brings 20 years of biotech experience from Molecular Probes Europe (Managing Development Europe. Management)Project and (Research MOGEN and Sciences Life DSM Development), Business of (Director Crucell Director), of series 20 over of inventor degreethe PhD is a and has University Hoekema Leiden from Dr. (R&D). Inc Genentech, and in 15 patents resulting issued in the US. patent applications, Mission Therapeutics CEO, Mission Therapeutics Ltd. Lundemose, Anker corporateHe has extensive experience from business and development as well as R&D in several key therapeutic areas has and internationalcomprehensive a has He network, and experience diabetes anti-infectives. and oncology, including His background venture investments and licensing. been responsible for biotech, within successful mergers and acquisitions as well as an initial career in academia. large biotech and big pharma, includes biotech startups, Prosidion of Officer Executive Chief 2015, to 2013 from ASA Pharma Bionor of President and Officer Executive Chief was He in the US and President of Prosidion Vice President OSI Pharmaceuticals Inc. Executive Limited in the UK from 2003 to 2005, from OSI Pharmaceuticals Inc., President CorporateVice & Business Development, He was Executive Ltd from 2005 to 2009. He has previously held positions as Managing Director acquisition of OSI in 2010. Astellas Pharmaceutical Inc’s 2009 until Denmark. and as Business Development Director at Novo Nordisk, Switzerland, at OSI Pharmaceuticals venture arm in Zug, PhD and DMSc qualifications in medical microbiology. Anker has MD, Anne Altmeyer, Anne Altmeyer, Negotiations Head Global in Business Development & Licensing (BD&L) in the Oncology Vice President, Altmeyer is Anne her responsibilities are to in-license or acquire Oncology assets that can further In this capacity, Business Unit at Novartis. also oversees the group She responsible for Companion Diagnostics transactions strengthen the Novartis Oncology portfolio. and manages several ongoing alliances. experience in the Pharmaceutical IndustryAnne has over 15 years of of increasing responsibilities in working in positions Anne joined the Oncology Project Management group of Novartis in 2004 as a Project and BD&L. Development, Research, generationthe through implementationand strategiesof for Teams multidisciplinarynumerous led she Project There, Leader. Anne worked as a Project Manager in various Before joining Novartis, various compounds in development and on the market. Areas at Merck & Co. Therapeutic She then performed a postdoctoral France. in Molecular Immunology from Strasbourg University, Anne received her Ph.D. Associate at Cornell University and subsequently became a Research USA, University School of Medicine, York fellowship at New Anne also received a MBA and a MPH from the University In addition to her scientific training, USA. York, New Medical College, USA. of Medicine and Dentistry of New Jersey/Rutgers, Novartis Venture Venture Fund Novartis Managing Director, Anja König, Prior Switzerland and the rest of Europe. She is active in the UK, Switzerland. Anja König is a Managingin Basel, Director Dr. a global consultancy, York, Associate Partner at McKinsey and Company in New Fund she was an Venture to joining Novartis Anja holds a PhD in physics from Europe and Emerging Markets. the US, where she worked with healthcare companies in Therapeutics. Forendo Pharma and Heptares F2G, Therapeutics, Anja serves on the boards of Bicycle Cornell University.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
Oryx Translational Medicine Oryx Translational Rockport Venture Venture Rockport Partners Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Bernard Huber, CEO and Founder, Bernard Huber, biologistis a molecular Huber patent and attorney companies. biotech up several setting in involved has been who Dr. technology transfer and business He gained more than 20 years of experience in intellectual property right protection, he successfully represented the Among others, 1996 at since his own patent and law firm. management in the biotech sector, in patent/license Heidelberg matters regarding cervical cancer vaccines Gardasil® German Cancer Research Center (DKFZ), and Cervarix®. Beat Merz, Managing Director, Beat Merz, Dr. Head of European Equity. Securities and Venture Merz joined Rockport in 2013 as Managing Director of Rockport Dr. including and growthMerz brings 15 years of experience in venture stage equity financing and operations to Rockport, Merz was a Partner with Dr. Prior to joining Rockport, management in equity financings. and leadership of over $150 million for he was responsible venture and private equity investment management as Investment Previously, Ares Life Sciences. where Technologies, Managingwas he New Medical NMT of Director HBM Partners, to joining Prior HBM Partners. of Advisor During management professional forstart-up support and consulting device companies. young medical he provided capital, has served Europe and Israel-domiciled companies and as co-founder or his career he has directed investments in the US, He currently serves or has servedhas held board seats for many of them. of Directors of Micrus Endovascular on the Boards Precimed (acquired by Asthmatx (acquired by BSX), (acquired byThommen Medical private investors), (acquired by JNJ), and several other medical Technologies South Eastern BioControl Medical, Devax (acquired by BioSensors), Greatbach), of from the University MBA an and Zurich/Switzerland ETH from biomechanics in Ph.D. a holds Merz Dr. companies. device Glasgow/UK. Strathclyde, Dr Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, and Amersham (now part of GE Healthcare), and pharmaceuticals for industry leaders such as in vivo and in vitro diagnostics, CEO from 2003 until 2011. Agendia and has served as the company’s He is a co-founder of Takeda). Nycomed (now part of and a PhD from Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry University, from Ludwig Maximilians Germany. both in Munich, University, Technical the Bernhard Sixt, President and CEO, ImmunID Bernhard Sixt, Partner, Gilde Healthcare Partner, Arthur Franken, FlowCardia Conatus He led the investments in Pharmaceuticals (IPO on NASDAQ), in 2001. Arthur Franken joined Gilde Therapeuticson (IPO LaboratoriesMTM by (acquired ProQR and Roche) Moximed, Levicept, Bard), R. by(acquired C. Agendia, Ablynx (IPO on Euronext), including involved in numerous investments and divestments He has been NASDAQ). BG Medicine (IPO on NASDAQ) and Pieris. uniQure (IPO on NASDAQ), MTM He served as a board member for FlowCardia, Moximed and Symphogen. boards of Levicept, He represents Gilde on the Therapeutics until the trade sales or IPO. Laboratories and ProQR TNO. active in cardiovascular research atPrior to joining Gilde he was Center for the Leiden/Amsterdam Drug Research and He is a Dutch national. the Netherlands. He holds a masters degree from Leiden University, in Biopharmaceutical Sciences
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Wellcome Trust Wellcome Athera Athera AB Biotechnologies Ability Pharmaceuticals Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Boris L. Zaïtra is the Global Head of Group M&A at Hoffmann-La Roche and is based in Basel, Switzerland: in this role he Switzerland: Zaïtra is the Global Head of Group M&A at Hoffmann-La Roche and is based in Basel, Boris L. the from 2012 April in Roche joined He strategic businesses. Group Roche the across acquisitions and mergers Roche’s leads he was a Partner Prior to joining EADS in 2005, worked forGroup where he Airbus the M&A department. years as Head of six he Previously, with the mid-market private Capital equity firm Duke Street and was involved in deals in the UK and France. focusing primarily on the Oil & Gas industry. Associate with JP Morgan in London, was an M&A Advanced Management Programme in 2009. Boris graduated from Ecole Polytechnique 1995 and the Harvard in France in Bethan Hughes, Senior Analyst, Bethan Hughes, Business Innovations Trust’s Wellcome scheme administered by a £24 million annual funding the Fund, Translation Interim Head of the universities and med-tech companies, large pharmaceutical small and medium-sized companies, Applicants from division. organisations from any geographical region are welcome to apply. and not-for-profit is to develop innovative and ground new technologies breaking in the biomedical area. Awards Translation The aim of Applications should bridge the supported by data. experimental Projects must havedemonstrated already proof of principle, technology funding gap in commercialisation of new technologies must plan to take the product, in the biomedical area and the see Please URL following interventionor stagea to at sufficientlyis it which be to developed party. another to attractive for more information. Ltd. Roche F.Hoffmann-La Head of Corporate M&A, Boris L. Zaïtra, Chief Executive Officer, Carina Schmidt, international mainly in business development and management, Ms Schmidt has nearly 30 years industrial experience, During 15 years she has worked with Pharmacia Biotech/ marketing and product management within the life science area. where positions included management AB, Later she founded Grasp Bioscience Amersham Biosciences (now GE HealthCare). Athera as the CEO She joined interim CEO and business advisor to several biotech start-ups. board director, consultant, companya that enzymes thatsells unique and develops facilitate (public), AB Genovis of director board Former 2007. in ALMI Invest Currently she is a delegate of the investment committee in development and quality control of biological drugs. Carina Schmidt holds a MSc Chem Eng from the Royal Institute of technology, a state funded seed investor. region Norr, Sweden. Stockholm, CEO, Carles Domènech, of Barcelona and also a Autonomous University Carles obtained a BSs/MSc degree in biology class honors) from the (first He has additional working at the Council of Science Research (CSIC). PhD degree in cellular biology from the same University, business training at business programs. ESADE business school and other atCarles started developing his career in cancer research CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering (1990-1992). York Cancer Center in New He Carles has 15 years international business development and licensing in the pharmaceutical industry. experience in Business Manager and Head, SA (1992-2003, Almirall, held senior positions at companies the Barcelona pharmaceutical and Licensing). Business Development Director, SA (2005-2007, Development and Licensing) and Lacer, Carles has also 4 years’ experience in biotech venture capital and business angels associations and has also been atInvestments Biotech the was Director, he 2005 2004 and Between collaboratinggovernment innovationwith agencies. During 2008-2009 he collaborated with agencies of the Government SCRSA. seed venture capital firm Barcelona Emprèn, Investment and Enterprise Growth. and as Managing Director, Valorization and Transfer Technology of Catalonia as Director, SA and the entrepreneurship finance programs He had under his responsibility the seed venture capital company Invertec, Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments. Genesis Capital and Concept Capital. September 2009. SL to become its Chief Executive Officer in Ability Pharmaceuticals, In 2009 Carles cofounded
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u BioConfidant Sàrl Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Head of Search & Evaluation, Neurosciences, Global Business Development & Licensing, Global Business Development & Neurosciences, Head of Search & Evaluation, Charles Bailey, Novartis Pharma AG HBM AB Partners Partner, Leo, Chandra He is a member clinical practice and biomedical research. than 15 years of experience in venture capital, Leo has more Dr. Leo is Dr. a healthcare-focused group investment managing >USD 1 billion in assets. of the private at equity team HBM, He previously served as a board i-Optics and Symbiomix. Gynesonics, Delenex, currently at a board member CardiacAssist, (acquired by ESBATech ChemoCentryx (IPO NASDAQ), (IPO NASDAQ), Anthera Pharmaceuticals member or board observer at he managed a strategic investment collaboration between Moreover, Affymetrix). (acquired byAlcon/Novartis) and Panomics and London Leo completed his medical studies in Berlin Dr. biopharmaceutical company. HBM Partners and a US-based His and holds a doctoral degree an MBA degree from the Freie Universität Berlin (Charité) and with distinction from INSEAD. as a physician at Hospital Leipzig and as a the University Partners, Wellington prior roles include working as a principal at postdoctoral scientist at Stanford University. Head, Business Development, Sanofi Pasteur MSD Business Development, Chris Britten, Head, Chris is currently Head of Business Development at Sanofi Pasteur-MSD with responsibility with responsibility for all business and corporate Chris is currently at Head of Business Development Sanofi Pasteur-MSD Therapeutics Ltd. He is also a Non-executive Director at Phico development activities. and is focused on the development and Venture between Sanofi Pasteur and Merck & Co. is a Joint Sanofi Pasteur-MSD offering strategic and Life Sciences, Vantage Chris is also the Managing Director of commercialisation of vaccines in Europe. Therapeutics Ltd. at and a Non-Executive Director Phico transaction advisory services sector, to the life science Astellas (Europe) in Business and Commercial Development in 2013 following positions at Chris joined Sanofi Pasteur-MSD Advisory practice assisting clients across and several years at Deloitte Corporate Finance where he headed up the Life Science Prior fund-raising). valuation, partnering, divestments, the life science sector in a wide range of transactional activities (M&A, Corporate Development, Business in responsibility increasing atof was roles Chris held he where GlaxoSmithKline Deloitte, to and R&D. Ventures Chris holds a PhD in Biochemistry Finance. and an MBA in Chris Maggos, Consultant, Chris Maggos, investor relations, Chris has over 20 years of experience in the life sciences industry covering business development, he founded BioConfidant Sàrl a strategic consulting firm Recently, investing and molecular neurobiology. communication, Institute Alpine for co-founder is also He the of goals. partnering and thatfinancing their achieve executives senior helps Previously, commercialize academic discoveries. is to help whose mission enterprise social a not-for-profit Drug Discovery, Chris was a member of the executive management board and held the positions of head of investor Therapeutics, Addex at a Before that he worked as: relations & communication (2007-2010) and director of business development (2010-2013). journalist for the leading biotechnology trade publication BioCentury (2001-2007); an investor at Casdin Life Science Partners biotechnologyNYC-based neurobiologistmolecular a a and (1997-2000); hedge-fund drug studying (laterHill), Cooper Chris holds publications. where he co-authored twelve peer-reviewed The Rockefeller University (1993-1997), dependence at where he also completed pre-medical studies. University, Yale a BA in English Literature from
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Novartis Novartis Pharma AG & Licensing, Head Business Development Corrine Savill, she has In her current position, and biotech arena. of broad experience in both the pharmaceutical Corinne has over 15 years responsibility for development and partnering deals within Novartis. all Business Ltd Corinne joined Imutran in Immunology research positions, and a number of academic and pharmaceutical After a Ph.D. She acquired by In 1996 Imutran was Novartis and Corinne made the COO. of Research. a UK based Biotech as Director In 2005 managing a CHF 100 million investment fund. Fund, Venture as the CEO of the Novartis Bio moved to Basel in 2001 up Global Search and EvaluationCorinne moved to head development where she was responsible with Novartis Business growing the Novartis development pipeline for the identification and evaluation of potential license-in or M&A opportunities, Access and Market Global Head of Pricing In 2010 Corinne became Novartis’s and supporting the business goals of Novartis. development and in Market responsible for the pricing and market access strategies for the portfolio of Novartis Pharma’s products world-wide. AG. In June 2013 Corinne was appointed and Licensing Novartis Pharma Head Business Development Protagonist Inc. President & Chief Executive Officer, Dinesh Patel, He joined and the biopharmaceutical industry. biotech, Dinesh Patel big pharma, has 30 years of experience spanning and CEO/Co- Therapeutics, Arête He was previously the CEO OF Protagonist therapeuticsin 2009. as its President & CEO Patel was a co-founder of the Dr. an oncology company acquired by Entremed in 2005. Therapeutics, founder of Miikana Patel was Dr. Vicuron, Prior to which was acquired by Pfizer in 2005 for $1.9 billion. Versicor/Vicuron anti-infective Company a director of chemistryAffymax (1993-96) which was acquired by at GSK for the combinatorial $533 M. chemistry company He started his career as a medicinal chemist at Bristol-Myers Squibb in 1985. New Jersey and conducted post-doctoral research at the University in chemistry from Rutgers University, He received his Ph.D. and has >100 patents and publications to his credit. Madison, Wisconsin, of S.R.One, Limited. S.R.One, Partner, Phillips, David David to incubate joined SR One in 2008 to pioneer a new function and spin-out technologies from GSK and subsequently including senior David SR One, brings a range of experience to joined the team focusing on European investments. Cephalon, Wellcome, commercial strategy at and business development Glaxo management roles in sales and marketing, David experience in has significant deal making Automation Galapagos. Partnership and The Management, Venture Medical deriving healthy exits forrun a number of successful businesses the pharmaceutical and biotech sectors and has investors. David has a BSc (Hons) in Pharmacology of London and is a member of the Charted Institute of Marketing. from the University David is based in London. Donnie McGrath is Vice President, Business Development at BMS. He has been working in academic medicine and the and medicine academic in working been has He atDevelopment Business BMS. President, Vice McGrathDonnie is evaluating and transacting for His heads a global team responsible for identifying, biopharmaceutical industry for 20 years. He works with senior R&D and commercial leadership to design all business development opportunites of interest to BMS. and execute the business development strategy for BMS. Bristol-Myers Squibb Bristol-Myers Vice President Business Development, Donnie Mcgrath,
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Debiopharm International S.A. Oxford BioTherapeutics Oxford COO, PharmaVentures Ltd PharmaVentures CEO, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Fabien Sebille, Head of Alliances, Fabien Sebille, CEO, MedLumics S.L CEO, Margallo, Eduardo Degree a M.Sc. from the Polytechnic University of Madrid, Telecommunications degree in his M.Eng. Eduardo Margallo obtained of Stuttgart Elektrotechnik) from the University degree in Electrical Engineering (Dipl.-Ing. a M.Eng. in Physics from UNED and instrumentation. (The Netherlands) in the area of biophotonic Technology his doctorate He completed at Delft University of (Germany). He has accumulated of biophotonic instrumentation of experience in the design and manufacturing 8 years and integrated sensor microfabrication silicon techniques and knowledge of the physics of light propagation with in-depth in tissue, optics, this time he participated During implementation in the definition and of clinically driven research projects photonic devices. in collaboration Italy. universities and hospitals in the Netherlands and with several having guided the company its seed and start-up through Eduardo co-founded MedLumics in 2009 and is currently its CEO, A-Round closed in November 2011. activities resulting in a 3.5M€ he led fund-raising In particular, phases. Fintan Walton, Fintan Walton, focused on assisting a predecessor company to PharmaVentures co-founded CONNECT Pharma, Walton In 1992 Dr Fintan In 1997 this company became pharmaceutical and biotechnology companies worldwide in all aspects of deal making. PharmaVentures. delivering more than 600 assignments has worked with blue chip clients on a global basis, PharmaVentures Since its inception, Clients have included major pharmaceutical and biotechnology companies as well as diversified for companies in 38 countries. investment/ Its clients have included major banks, generic and OTC companies. medical device, chemical corporations, and private equity and venture capital groups. merchant banks, Thousands of the leading database and publishing business related to dealmaking. In 1996 he also founded PharmaDeals, PharmaDeals was sold customers from around the world have either bought or subscribed to these PharmaDeals publications. Aug 2012. to IMS Health in Fintan subsequently gained broad commercial experience in biotechnology in Ireland), College (Dublin, Trinity Educated at management positions at Bass and Celltech plc (1982-1992). Fabian studied at Münster University, UCSB and the Max-Planck Institute for Molecular Physiologyand he in Dortmund Fabian studied at Münster University, Dario Neri at the Department he earned his PhD under Prof. In 2010, holds a diploma in Chemistry from Münster University. His dissertation focused on DNA-encoded chemical libraries was Applied Biosciences at ETH Zurich. of Chemistry and awarded with the ETH Zurich silver medal. Esteban Pombo Villar, Esteban Pombo Villar, was Dr Pombo-Villar at Novartis for over 20 Prior to joining OBT, Esteban is Chief Operations Officer for Oxford Biotherapeutics. Most recently he was Head of the last 12 years of which he focused on all aspects of creating and managing alliances. years, responsible for up to proof-of-concept alliances Alliance Management at the Novartis Institute for Research (NIBR), Biomedical He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz in man. on drug discoveryAt Sandoz he worked leading collaborative projects as well as in 1988. Basel Neuroscience Research in Royal Society of Chemistry. Dr Pombo-Villar is a Fellow of the projects investigating the potential of emerging technologies. AG / Johnson & Johnson Innovation Covagen New Ventures, Director, Fabian Buller, & Johnson Innovation of Johnson and Director of Business Development of Covagen Ventures Fabian Buller is a Director New he established After Fabian Covagen joined in 2011, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. AG, 2012 and concluded the sale of the Pharma in Tanabe a major strategic collaboration and licensing agreement with Mitsubishi Fabian led the immuno-oncology Prior to this, August 2014 in his business development role. company to Johnson & Johnson in research at Covagen as Director of Discovery Research with a focus on multi-specific protein therapeutics.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Inserm Transfert Initiative Inserm Transfert Managing Partner, Oncos Therapeutics President & Chief Executive Officer, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Frans Wuite, Wuite, Frans pharmaceutical in development drug and business commercialization, in experience of years 25 over has Wuite Frans Therapeutics Ltd and serves on the Board of Directors He is currently President and Chief Executive Officer of Oncos industry. Araim and he was co-founder and Chief Operating Officer of Previously, of Herantis Pharma and Faron Pharmaceuticals Ltd. European management team and director of marketing Amgen’s Prior to that he was member of Pharmaceuticals Inc. Warren pharmaceutical the in career His BV. Pharmacia-Leiras of President was Mr.Wuite Amgen Before joining Europe. Amgen at where he served in various international management and marketing roles. industry started at Organon International BV, Administration. is a Medical Doctor and Master of Business Mr.Wuite Boehringer Ingelheim Venture Fund Venture Boehringer Ingelheim Head, Kalkbrenner, Frank Over the last four years, Fund. Venture Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim Corporate Dr. Diagnostica in Barcelona, He serves as board member of STAT the fund. he has been involved in several investments of of the supervisorymember is he addition, In Tübingen. Therapeuticsin Acousia and Vienna in Hookipa Paris, in Eyevensys Initiative a French Seed Investment Fund based in Paris. Transfer and the advisory board of Inserm in years 10 than more spent He Toxicology. degreea holds and medicine Pharmacology studied in Kalkbrenner and Dr. academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the focused His academic research on gene regulation and signal transduction mediated by ion channels Berlin. Freie Universität, and G proteins. Kalkbrenner Dr. AG as senior scientist in Experimental Dermatology. In 1997 he began his industrial career by joining Schering In 2005 he took joined Boehringer Ingelheim in 1999 and held several positions in the department of Pulmonary Research. was responsible for he the of activities licensing the function, In this forthe responsibility over Department. Licensing the In German Boehringer Ingelheim organization as well as for information competitive assessment and scientific systems. he built up the NBE Research unit at the German Research site in Biberach. addition, fund shortly after its start in 2010. Venture Kalkbrenner joined the BI Dr. Chief Executive Officer, Histide AG Chief Executive Officer, Florian Kemmerich, Broad expertise investing in and/or managingBusiness leader and entrepreneur companies in different life science countries. build out and fundraising within global corporations as well as for small repositioning, turnaround, startup, strategy, in vision, and medical device implants drug device, pharma, More than two decades of expertise in biotech, to mid-size enterprises. of the healthcare industrywith a deep understanding associated a strong knowledge of market dynamics and cultures with around the globe. François Thomas, Thomas, François He is a medical oncologist and a former assistant Initiative (ITI). Transfert Thomas is managing partner of Inserm François Dr. Thomas was successively François He also holds an MBA from MIT (Boston). professor at the Gustave Roussy Institute. VP in charge of pharmacogenomic managing partner of Bioserve Ltd, vice president (VP) forof Ipsen, clinical development in charge of healthcare banking activities Venture, Atlas partner in the venture capital firm programs and licensing at Genset, the last 15 years has been dedicated His professional activity over to the creation of Cytheris . and president at Bryan Garnier, and development of biotech companies in Europe.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Director Business Development Oncology - Global Business Development and Licensing, Director Business Development Oncology - Global Business Development and Licensing, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Shire PharmaceuticalsShire Alliances, Head of Research Gary Clements, a He has BD Leadership team. Gary of Research Collaborations Clements is Head and a member if Shire’s and Divestments experience built up over greaterbroad range of BD transaction than 10 years at Shire. Graziano Seghezzi is a Partner. He joined the firm in 2006, and primarily invests in biopharmaceutical companies. Prior to and primarily invests in biopharmaceutical companies. He joined the firm in 2006, Graziano Seghezzi is a Partner. where he invested in biotechnology Switzerland, Ventures in Geneva, Graziano was a principal at Index joining Sofinnova, new investment opportunities identifying he worked for Sofinnova Partners, Before this, and biopharmaceuticals companies. York researcher at Graziano began his career as a biomedical New in Italian pharmaceutical and medical device companies. mechanism of where he gained five years of hands-on experience studying the molecular School of Medicine, University’s a specialty Therapeutics(Italy), in Creabilishas invested Graziano angiogenesisin oncology diseases. cardiovascular and a bacterial (Switzerland), a fragment antibody company; GlycoVaxyn dermatology company; Crescendo Biologics (UK), an oncology company; Therapeutics (UK), company; a viral vaccines Mission vaccines company; Hookipa Biotech (Austria), Graziano has a degree in Graziano is a board member of each company. in cardiovascular disorders. and Omthera (USA), Erasmus University (Netherlands). genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Partner, Sofinnova Partners AS Partner, Seghezzi, Graziano OCT - Clinical Trials OCT - Clinical Development, Business Regional Head, Birrell, Graham He has been with OCT since 2014 as Regional pharmaceutical industry. Graham Birrell has over 20 years experience in the forHead of Business Development with responsibility and the USA.. Europe Graham originally graduatedEdinburgh Medical School with a BSc and PhD in Neuropharmacology. from the University of He subsequently worked in discovery research with GSK in the UK and Parke-Davisbefore in the US heading up analgesia an MBA and moved into clinical development where he was successful in a Graham completed R&D at Servier in France. Graham has managed project managementnumber of senior business development and clinical roles within the CRO sector. Prior to programsclinical studies from Phase I-IV and lead global development across a wide range of therapeutic areas. Asia where he was responsible for management clinical project across the region for joining OCT Graham was based in SE a major global CRO. highlytogether pulling in of experience a wealth operationalbrings productive Graham and business collaborations and partnerships between sponsors and clinical service providers both in established globe. and new markets across the Guillaume Vignon is Director of Business Development Oncology at Merck/EMD Serono, responsible for leading business Development OncologyVignon is Director of Business at Merck/EMD Serono, Guillaume and negotiating terms of strategic partnerships in the field of Oncology. designing deal structures, development initiatives, all with increasing responsibilities in Licensing and Development Global Business within several positions hold Guillaume Guillaume closed successfully several complex transactions During his career at Merck/EMD Serono, aspects of deal making. strengthening Merck/ Antibody Discovery, and Companion Diagnostic, and forged key partnerships in the fields of Oncology, portfolio of innovative products and enhancing R&D capabilities in the field of Biologics. EMD Serono’s which has received Guillaume was the business development lead of the collaboration between Merck and BeiGene, Recently, recognizing a ground breaking pharmaceutical collaboration agreementAward Year Alliance of the the 2013 BayHelix Elsevier involving a Chinese entity. in Biochemistry and Molecular and a Ph.D. USA, Cambridge, Guillaume holds an MBA from Hult International Business School, France. Paris, Biology from the University of Paris 6/ Pasteur Institute, Guillaume Vignon, Guillaume Vignon, EMD Serono
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u AnaptysBio, Inc. AnaptysBio, CEO, Galecto AG Biotech Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Pre Pre AS Diagnostics CEO, Sæterøy, Håkon is shareholder Sæterøy corporate business development, and finance in management, experience years of 25 more than With member of Nansen Neuroscience Network He is a board life science companies in Norway. and board member of several Sæterøy was Executive Cluster (2007 - 2014). 2012) and was a board member of Oslo Cancer (chairman from 2010 – Norway. in Business from NHH in Bergen, He has a Master of Science ASA from 2002 – 2010. Chairman of DiaGenic CEO, Lanthio Pharma CEO, Heinz Schwer, Before he stepped in as CEO he was Senior is a highlyHeinz Schwer biotech entrepreneur. CEO and a successful experienced At MorphoSys he started as Strategic corporate venture activities. responsible for the company’s Director at MorphoSys, He joined this company M&A activities. Advisor where he was involved in several technology based deals and the company’s Heinz Schwer co-founded Sloning in 2000 and managed the in 2010 after he has sold Sloning Biotechnology to MorphoSys. he held the positions as Chief Operating Officer and Head of R&D. In the years before, company as CEO from 2005 until 2010. Institute in Heinz Schwer spent several years as postdoc at the Harvard Institute of Medicine and the Dana-Farber-Cancer fora fellowship including his research in the field of leukemia disease awards, he has received numerous In this time, Boston. clinical chemistry in from the University of Regensburg and Ph.D. He obtained his of blood platelets. and the biogenesis Vice President of the International He is also a founding member and holds an MBA from Henley Management College in UK. Association of Synthetic Biology. Hamza Suria, President & Chief Executive, Hamza Suria, transformation from its early platform technology AnaptysBio’s was appointed Suria has since led 2011 and CEO in Mr. Suria Mr. AnaptysBio, Prior to focusacross key pipeline to the development of a robust antibody product therapeutic areas. where he was responsible for partnering and alliance management of next-generation protein therapeutics was at Maxygen, Bayer and Sanofi-Aventis, including partnerships with Roche, hematology and autoimmunity, in oncology supportive care, immunology in from the University of an M.S. biochemistry in College, from Kalamazoo a B.Sc. Suria holds Mr. Astellas. M.D. Marco Londei, Ontario and an Executive MBA from the Richard Ivey School of Business. Western Hans T. Schambye, Schambye, Hans T. Previously, Hans Schambye with extensive experience in drug discovery is a seasoned biotech entrepreneur and development. A/S from Hans served from 2006 to 2009 and as the CEO of Gastrotech Pharma Executive Officer of ReceptIcon as the Chief he was Director of Biology and Pharmacology and Head of Portfolio Management at Before joining Gastrotech, 2004 to 2006. a Danish A/S, ProFound Pharma including Hans has co-founded several biotech companies, a US biotech company. Maxygen, Prior to this he had a successful research career at Stanford which was acquired by Maxygen in 2000. biotech company, a and University Odense from MD an holds Hans Copenhagen biology. and receptor of University field the within University PhD in Medical Sciences from Copenhagen University.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Global Licensing & Business Development, Director, Search & Evaluation, Search & Evaluation, Director, Global Licensing & Business Development, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Director, MS Ventures Director, Jasper Bos, the corporatearm of the prescription medicines division of Merck KGaA, venture Ventures, Jasper is Director with MS a private equity fund Jasper was instrumental in the founding of IFHA, Ventures, Prior to joining MS Germany. Darmstadt, Jasper worked as health economics Before IFHA, investing in the healthcare and insurance sectors in emerging economies. Institute. Vaccine and strategy manager at the Netherlands Neviah Genomics, Galecto Biotech, EpiTherapeutics, Asceneuron, he is a Member of the Board of Directors of Currently, He holds a PhD in Pharmacy from Vaximm. and an Observer to the Board of ObsEva, Calypso Biotech, Prexton therapeutics, the Netherlands. the University of Groningen, CEO, Oncopeptides AB CEO, Lindberg, Jakob was appointed as CEO in 2011. by physician training, Mr Jakob Lindberg, AB. Partner at Investor Venture AB he is also of Oncopeptides In addition to being CEO Engagement Manager for he also servedAB where as CEO, co-founderPrevious positions include; of Cellectricon & Co. and analyst for Merrill Lynch McKinsey&Co., medicine from the Karolinska Institutet and a an MSc in pre-clinical Lic in Molecular Immunology, Mr Lindberg holds a Med Administration from Stockholm University. BA in Finance and F.Hoffmann La Roche AG La Roche F.Hoffmann & Innovation at Roche Partnering, Venture Global Head Jason Coloma, and Innovation in Roche Partnering responsible for (1) external innovation with academia Venture Jason Coloma is the Head of and venture capitalists (2) new modalities or technology platforms that can potentially be applied across therapeutic areas (3) IT including healthcare opportunities in adjacent sectors that may translate into innovative solutions for patient care, Jason was previously Head of the Diagnostics Program Office responsible for supporting the Diagnostics Chief Operating including commercial Jason led a number of partnering activities Officer in various strategic initiativesactivities. and partnering He also oversaw Divisional Portfolio mergers and acquisitions as well as strategic investments. and academic agreements, ManagementIntelligence. as well as Market and Competitive Jason worked in the biopharmaceutical industry both as a strategy consultant and working in Prior to his time at Roche, primarily he biotechnologyworked with capitalcompanies venture start-up and strategyAs a consultant, operationalroles. evaluating the business opportunity of private equity firms working on a range of issues including partnering deal support, Jason also held research and business positions at innovative discoveries and implementing external innovationmodels. San Francisco as well as biotechnology startups. the University of California, Amgen, Berkeley as well as his MBA from the Jason completed his graduate studies in Immunology at the University of California, School of Business at Dartmouth. Tuck Jane is a member of Global Licensing and Business Development at Takeda heading effortsfor sourcing and transacting Takeda Development atJane is a member of Global Licensing and Business agomonths 14 Zürich. in based is and Takeda joined Jane technologiesEuropean-based earlyand stage programs. pipeline Mundipharma International and held various Business Development positions with Merck Serono, Jane Takeda, Prior to in Biochemistry and held research positions at from the University of Leicester the MRC Jane obtained her Ph.D. Hospira. UK. Laboratory of Molecular Biology and Cambridge Institute for Medical Research in Cambridge, Jane Atkins, Jane Atkins, Takeda Pharmaceuticals International GmbH Takeda
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Johnson & Johnson Innovation Johnson & Johnson Investments, Venture Vice President Jeanne Bolger, in February Investments, Venture Vice President, & Johnson Development CorporationJeanne joined Johnson (JJDC) as focusedare responsibilities on Jeanne’s atUK Innovation Johnson & Johnson the Centre. London, in based is She 2013. investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe. and Commercial of pharmaceutical industryJeanne has over 25 years in management experience roles across R+D, most recently Scientific Licensing as Global Head of Acquisition, She spent 11 years in Licensing and Business Development. having Family joined the Johnson & Johnson of Companies in 2005 from business, Pharmaceutical for Johnson & Johnson’s groupthe Business Development at GSK. working with Alzheimer Immunotherapy, Alliance Management and Board Director at Janssen VP Jeanne became In 2009, disease. Alzheimer’s Pfizer and Elan on immunotherapies targeting beta amyloid for in Child Health (NUI) and in She also holds diplomas Jeanne received her medical degree College Dublin. from University She has served as the Academy of Medicine of Ireland (RAMI). of the Royal She is a Fellow Accounting (ACCA). Finance and sole pharmaceutical industry representative on two Irish government taskforces commercialization seeking to enhance the of College Trinity curriculum at She is a visiting lecturer on the MSc Pharmaceutical Medicine IP from Irish academic centres. Ireland. in Dublin, Dr Phillips has a strong background in company leadership and business development, and is a physician by training. He byphysician a and is training. backgroundstrong a has Phillips Dr companyin development, business and leadership As President which was the first and cornerstone acquisition of EUSA Pharma in 2006. Pharma in 2004, Talisker founded Dr Phillips led the strategy resulting in Corporate Development of EUSA Pharma Inc., Vice President, of Europe and Senior Dr Phillips is currently a Non-executive the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. until joining Midatech, and, Insense Ltd (a private spin-out from Unilever), Director of Herantis Pharma plc (listed in Helsinki), transformation guiding its successful into a respiratory focused business. was Chairman of Prosonix Limited, he was in Clinical & At Novartis, Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. Haematology and Infectious Gastrointestinal, Bone, Arthritis, Business Development and was a Board Director of the $1.3bn Team. Clinical Leadership Diseases business unit and a member of the company’s Midatech Group Midatech Chief Executive Officer, Jim Phillips, Canbex Therapeutics Canbex Chief Executive Officer, Jesse Schulman, after working with the firm as a financing Therapeutics in 2012, Canbex Jesse Schulman took over as CEO of UCL spin-out A fundraising round led by In 2013 he helped the firm close a Series and business development consultant from 2009. which enabled a successful Phase I safety Trust, Wellcome also supported by UCL Business and the Ventures, Merck Serono aimed treatment the multiple at with people in spasticity of VSN16R, compound, lead firm’s the of volunteers healthy in trial and has worked extensively Jesse Schulman was trained as a Neuroscientist at UC San Diego and the Salk Institute, sclerosis. licensing and M&A transactions. assisting firms with fundraising, in corporate finance for the biotech sector, Founder and General Partner, Eclosion Founder and General Partner, Jesús Martin-Garcia, several technology- invested in and developed Jesus Martin-Garcia is a highly who has created, successful entrepreneur largest e-commerce company that he co-founded in Switzerland’s Silverwire and LeShop, VTX, focused start-ups such as his career atbegan Jesus McKinseyhe managedCo where & consumer goods industries. the pharma and teams in 1997. Administration and a Ms in Law from UNIGE and a MBA from Harvard Business School. Jesus holds a Bs in Business
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Founder & Chief Executive Officer, Atomo Diagnostics Officer, Founder & Chief Executive John Kelly, ASX and now NASDAQ Corporation listed Unilife has twenty years industryJohn Operatingwas Chief and experience Officer at degreesatholds MBA John Executive an as Engineeringwell both as in the Systems Manufacturing and 2005-2008. from in Leadership’ scholarship. ‘Excellence inaugural University of Sydneyhe was awarded where the Business School’s Head, Immunology Licensing, EMD Serono Immunology Licensing, Head, Kia Motesharei, Immunology at EMD Serono (Merck Serono Kia Motesharei is currently Head of Global Licensing & Business Development, for He is responsible Search & Evaluation and all transactions within the Immunology Franchise outside the US and Canada). ManagementAlliance atDyax, & Development Business of President Vice Kia was Serono, to EMD Prior atKGaA. Merck managed Kia US operation the French - a Genfit of Previously, biopharmaceutical companya rare disease. in specializing Prior Chief Business Officer. biotech companydevelopment as the company’s and led its global business – in Cambridge worked he has for multiple private and public biotech companies with increasing levels to Genfit and over the past 15 years, Alliance Business Development and Product Management, Marketing, Technical Technologies, New of responsibility in R&D, Management. product and technology licensing, Kia has a successful track record of transactions which include strategic alliances, Europe, agreementsM&A and and biotechnologypharmaceutical with major the US, companies in divestitures, distribution, he has been involved in a number of financing activities. In addition, and Middle East. LATAM, China, Japan, Chemistry in Organic from University of California, The Colorado College and his Ph.D. in Chemistry from Kia received his B.A. The Scripps Research Institute as an NIH Fellow. He completed his postdoctoral training at Angles. Los Capricorn Venture Partners NV Partners Venture Capricorn Partner, Katya Smirnyagina, she worked for ten to this, Prior Partners (Belgium) since 2012. Venture Dr Ekaterina Smirnyagina is a Partner at Capricorn She has a PhD in Cellular & Molecular CA. focused a healthcare venture capital fund in San Francisco, Alta Partners, years at Katya Russia). BS in Biochemistry (Lomonosov Moscow State University, USA), Wisconsin-Madison, Biology (University of then worked in management consulting and completed her scientific training at the Stanford School of Medicine, University servesand as Oy, Nexstim and SA Medical Capricornrepresents iSTAR She of board the on development. business biotech ADOC.PA) Adocia SA (NYSE Euronext: independent board member of Imanova Ltd Imanova CEO, Kevin Cox, Imanova has world-leading Imperial and UCL. a unique joint venture between the MRC and Kings, Kevin is CEO of Imanova, expertise in imaging sciences. is experienced in biopharmaceutical He academia. and NHS with the and worked lead high-growth has businesses, Kevin’s and technology translation. laboratory diagnostics, development, Marketing UK Life Sciences BioNow, Chair, Advisory Committee, Bio/Pharma UKTI’s Chair, public sector roles include: Kevin’s NED of the BNA and the BIA. TSB advisory board for stratified medicine, Strategy Board,
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ActoGeniX NV Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European RECORDATI S.A. RECORDATI VP and Group Licensing Director, Luca Bolliger, Luca Bolliger studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology. He institute for and then became Member of the Basel immunology. He graduated at the Biocenter in Basel in biochemistry, industrypharmaceutical the joined then discoverya Global as portfoliomanager the Pharma Strategyin at Unit Hoffmann-La and financial industry He then pursued his career in the as a Fundamental analyst at BT&T asset management, Roche Ltd. where he also participated in the creation of the Swiss marketing Ticino He established Biopolo as a freelance consultant. Luca Bolliger Actelion. platforms Swiss Biotech and Swiss Medtech before becoming Director Business Development at joined Recordati from Novimmune where he was director Business Development. Dr Lothar Steidler is the main inventor of the TopAct™ technology. TopAct™ Dr Lothar Steidler is the main inventor of the Lothar started his research career at of Ghent (Belgium) the University during the early 1990s and became principal Alimentary Pharmabiotic Centre atCollege University 2003 he relocated In to the prestigious VIB in 2001. investigator at the headed by Professor Fergus Shanahan. Cork (Ireland), ActoGeniX. Development at Technology Lothar returned to Belgium to take up the position of Director of In September 2006, and food-grade microorganisms and commensal bacteria in general, research has shown that Lactococcus lactis, Lothar’s can be genetically engineered to secrete biologically-active therapeutic molecules and can be applied as therapeutic products to treat diseases. Young European Prize for William Grant and Sons Lothar received the 2001 In recognition of this scientific breakthrough, His work has been he was also awarded a Science Foundation Ireland investigatorship. In 2003, Invention and Discovery. Nature Biotechnology and Gastroenterology. published in various high-level scientific journals such as Science, Lothar holds a PhD in Biotechnology from the University of Ghent and is currently at a guest professor Ghent University, teaching host-bacteria interactions. Vice President Technology, Vice President Technology, Lothar Steidler, Chief Executive Officer, Probiodrug AG Chief Executive Officer, Glund, Kondrad its DP-4 diabetesProbiodrug sold After assets foundedDr Glund Halle GmbH. IFB in 1997, up Probiodrug to setting Prior based the metabolic subsidiary of (OSI) Pharmaceuticals, he joined (OSI) Prosidion, in June 2004, to (OSI) Pharmaceuticals During this time at of Business and Corporate Vice President Development. as Chief Operating Officer and UK, in Oxford, integrate(OSI) Prosidion he helped the diabetes program for and has been responsible several licensing deals with pharma to Probiodrug in 2006 as CEO. He returned companies. in biochemistry, After completing his studies of Halle. Dr Glund holds a PhD in Biochemistry from the Martin-Luther-University he spent aboutin biochemistry as academic lecturer and conducted research 15 years at as project and team leader the Dr Glund is author or co-author of over sixty publications 10 patents. and is co-inventor on more than University of Halle. Lionel Carnot, MS, MBA, is a Managing Director of Bay City Capital and has been extensively involved in the firm’s activities is a Managing Director of Bay City Capital extensively and has been involved in the firm’s MBA, MS, Lionel Carnot, The Pritzker Prior to investments in Europe. He manages the firm’s The Pritzker Organization in 2000. since he joined the positions in held several He also fund. hedge a healthcare atwas a Principal Carnot Oracle Partners, Mr. Organization, Manager including Product for Prozac at Eli Lilly as well as several sales and marketing positions pharmaceutical industry, a strategy Carnot was also and management consultant to the biopharmaceutical industry while at Booz Mr. Aventis. at Genetics, Carnot is a member of the board of directors of Interleukin Mr. Accenture Strategic Services. Allen & Hamilton and and is a former member of the board of Reliant Pharmaceuticals, Tallikut and Madrigal Pharmaceuticals, Merus B.V., holds an MBA with Distinction from INSEAD and Carnot Mr. and Nexus Dx. BioSeek, Pathway Diagnostics, Pharmaceuticals, an MS with honors in Molecular Biology of Geneva. from the University Managing Director, Bay City Capital LLC Managing Director, Lionel Carnot,
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Heptares Therapeutics Heptares Executive Officer, Co-Founder and Chief Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European AbbVie Biotech Ventures, Inc. Inc. Ventures, AbbVie Biotech & Early Stage Collaborations, Ventures Director, Chavez, Margarita Margarita started her career as corporate and securities experience. of dealmaking Years Margarita Chavez has over 15 first with the M&As and IPOs, venture funds and investment banks in financings, advising startups, Valley lawyer in Silicon Margarita Winthrop) and then at Brobeck Phleger & Harrison. Parish & Isaacs (acquired by Pillsbury firm of Rosenblum, Abbottdiabetesits and division advising AbbottCorporate2005, as in Senior Counsel became and in 2004 Counsel joined Global Pharmaceutical Licensing Abbott’s Margarita joined In 2007, including licensing and acquisitions. on transactions, in-licensing of Elagolix among other dissolution (Lupron acquisition), TAP where she worked on the Acquisitions team, & where 2013), in Ventures AbbVieBiotech (became Ventures AbbottBiotech joined then Margarita strategictransactions. AM including she has been leading investments and managing portfolio companies in the US and Europe since 2010, Early& Stage Ventures AbbVie became Ventures AbbVieBiotech lateIn 2013, (US). Alvine and (US) AuraSense (NL), Pharma licenses and acquisitions. including options, Margarita closed a number of transactions, Since that time, Collaborations. Degree from and her Bachelor’s of LawClara University School her Juris Doctor from Santa Margarita received in 1997, Santa Clara University in 1994. Credit Credit Suisse AG Head of Healthcare M&A Europe, Head M&A Switzerland, Superina, Marco 1997 Joined Credit He joined Investment Banking: Head Healthcare Investment Banking Switzerland. Managing Director, French & Italian. German, English, Languages: 1997. Suisse: Managinga is Switzerland Superina of M&A Marco Head the as well Switzerland as Healthcare of Head the and Director from finance and banking in publ. oec. directlySuisse Credit Dr. joined his Superina receiving Marco after Zurich. in based the University of Zurich. he and industries of range broad a covers experience M&A His experience. banking investment extensive has Superina Marco ultimately acquired first public takeover battle (Centrepulse, has been involved in notable Switzerland’s transactions including defence acquisition of SIG Holding) and the first public LBO of a Swiss listed company Holding’s (Rank Group by Zimmer), Leica Geosystems (against Hexagon) or Converium (against Scor). assignments for Ciba (against activist investors), Selected transaction experience includes: Valeant’s Acquisition of • Sale of Synthes to Johnson & Johnson for • $21.3bn • Sale of Ciba to BASF (CHF6.1bn) M&A: dermatology assets byPreglem to Gedeon Richter for Galderma ($1.4bn) • Sale of CHF445m • Sale of Nutrition & Santé by the sale of Serono on the Special Committee of Advisor to • Alcon ($51bn) forNovartis of • Novartis acquisition Eur220m Associates • Synthes- Actelion against Elliott Advising ($3.2bn) • Merck KG ($12.9bn) • Zimmer acquisition of Centerpulse Acquisition of Stratec acquisition of Mathys acquisition of intellectual property rights (CHF 1bn) • (CHF 1.5bn) • Synthes Capital (undisclosed) • IPO of Partners Europe (EUR 300m) • Galderma acquisition of Spirig Pharma Vestar Groupe OGF by Ypsomed SelfCare Solutions. Malcolm Weir, Malcolm Weir, of the Biomolecular He was Head London. in biochemistryMalcolm has a BSc and PhD College, and biophysics from Imperial responsibility for with 300 people Division of GlaxoWellcome then the Molecular Sciences Structure Department and the application During this time he led of structural biology and modelling engaged in target validation and lead discovery. He joined the structural in the advancement of clinical candidates resulting a wide range of diseases. to to drug discovery, growingbioinformatics it from the spin-out stage to a and drug discovery company Inpharmatica 2000, Ltd as CEO in to order in 2006 in Technology MRC joined He Inpharmatica Galapagosto sold was 2006. in NV company. 100-person Professor of Visiting Malcolm was elected as co-founderand CEO. Therapeutics Ltd in July 2007, establish Heptares He Advisory Board at the same university. in 1997 and is on the Chemical Biology London Biochemistry at Imperial College, Malcolm received served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004-2011. Biological and Medicinal awarded by the UK Royal Society of Chemistry’s the Malcolm Campbell Memorial Prize 2015, his contribution to GPCR drug discovery. in recognition of Chemistry Sector,
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Edison Investment Research Edison Investment Research Healthcare, Head of Research, Cooper, Mick having in team healthcare the joined atHealthcare Research, Investment Edison Research, of Head the is Cooper Mick Dr Astaire Securities as the pharmaceuticals & biotechnology equity he worked for three years at Previously, January 2010. He holds a doctorate from Cambridge University and completed an covering a wide range of healthcare companies. analyst, MBA at INSEAD business school in France after working as a parliamentary researcher. Index Ventures Ventures Index Partner, Ollier, Michèle invested and sits on the board of a number of Michele’s as a Partner in 2006. Team Michèle joined the Index Life Sciences Minerva Neurosciences LinguaFlex, Therapeutics, FunXional Index Life Science portfolio 3 Bio, companies including Epsilon Michele was Investment Director at EDRIP (Edmond Prior to joining Index, Aegerion. She was also a Director at and OncoEthix. Before in several development and she spent more than 15 years de Rothschild Investment Partner) in Paris for years. three her experience spans international and Serono International, RPR/Aventis BMS, marketing positions at Sanofi International, oncology and reproductive health. cardiovascular, over different therapeutic areas as CNS, CMO, Silence Therapeutics CMO, Khan, Mike having Warwickshire, Mike is a consultant physician and the Director of the Lipid and Coronary Prevention Clinics for He is an expert advisor to the UK Clinical Warwick. previously been the Head of Molecular Medicine at the University of and has servedon numerous advisory The Nationalfor Institute (NICE), Excellence Clinical and Group Development Guidelines boards for pharmaceutical companies. Mike is a highlytrack record in metabolicwith a long clinician and experienced cited researcher medicine and cancer biology cholesterol problems and cancer He has written several books on diabetes, research as well as in the running of clinical trials. furthering to contributed has He biologypostgraduatesteaches and undergraduatesand biologicaland medicine in sciences. the understanding of cancer cell biology and diabetes and along with colleagues is currently on identifying novel working of the Royal a fellow is Mike forbiomarkers diagnostictissue-based of novel the development and cancer colorectal tools. UK and Diabetes UK. HEART Association of Physicians, College of Physicians of London and a member of the Senior drug development and discovery expert, with synthetic & medicinal chemistry Ph.D. and 23 years of pharmaceutical with synthetic & medicinal chemistry Ph.D. Senior drug development and discovery expert, Pharmaceuticals. Founder & CEO of Metys industry experience. Novartis Venture Venture Funds Novartis Partner, Markus Goebel, amongst others, An MD by certified, training and career in the Health Care IndustryMarkus Goebel started his in 1990. and Marketing in hematology/oncologyworked for he Farmitalia Germany and later global positions in R&D, held several worked and first 2000 Novartis in He joined Amgen. Strategyatwith alliance worldwide a include to headquarters Roche he joined the In 2004 A. as Global Head Nervous System BD&L Pharma and later Head Pharma Corporate as Global M& Previously an MD and he received Europe in 2009. moving back to a Managing Fund as Director in the US, Venture Novartis Markus serves on University in Munich and an MBA from Henley Management College. a PhD from the Ludwig Maximilian’s EraGen, FoldRx, Sirtris, from others amongst having exited, portfolioFund companies, Venture Novartis several of boards the Intellikine and LigoCyte. Metys Pharmaceuticals Chief Executive Officer, Scherz, Michael
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Les Laboratoires Servier Les Laboratoires Vice President - Scientific Cooperation & Business Development, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Chief Executive Officer, Spectromics Chief Executive Officer, Neil Butler, Founding CEO of Spectromics Atlas Genetics Chairman of Vision Supervisory Board Director of Genomic Director of Radisens Diagnostics founding CEO of Oxford Biosensors. Vivacta (acquired by in 2013), Novartis founding CEO of Past: Pascal Touchon, Pascal Touchon, General Marketing and Sales, industryin the pharmaceutical over 26 years’ experience has in Research, Touchon Pascal Management and Business Development. & Eastern Central internationalHe has extensive experience in managing operations commercial in France, and as CEO Africa. and South Canada, Australia, Asia, Northern Europe, Europe, of more than 18 partnerships with he led the closing As head of Business Development for Servier over the last 3 years, managed various existing alliances and conducted two company acquisitions. biotech companies and academic institutes, Servierprivateis a companypharmaceutical and activities in based worldwide research euros 3.9 billion sales of with rheumatology and oncology. psychiatry, neurology, type II diabetes, cardiovascular diseases, a DESS in Management and an MBA from INSEAD. Veterinary Medicine, Pascal holds a Doctorate in KineMed, Inc. KineMed, CBO, Doyle, Patrick and as a consultant from January Doyle has served 2014 to May as our Chief Business Officer since May 2014, Patrick J. a global Vice President of Strategic Partnerships for PPD Inc., he served as From March 2013 to January 2014, 2014. SA, Therapeutics, Doyle was the President of Kareus Mr. From October 2009 to March 2013, contract research organization. served he Executive Officer of as Chief 2009, June 2006 to September From a biopharmaceutical companySwitzerland. in Doyle served as Chief Corporate Development Officer Mr. Prior to joining Syntaxin, a biopharmaceutical company. Syntaxin, a global and Global Head of Pre-Clinical Partnering of Hoffmann La-Roche, a biopharmaceutical company, of Metabolex Inc., where he also (Hons.) in Pharmacology from University of Sunderland, Doyle received a B.Sc. Mr. healthcare company. post-doctoral specialization coursework and received a in the role of the brain in metabolic diseases from completed Ph.D. a DESS in Management and an MBA Medicine, Veterinary a Doctorateholds Switzerland.Pascal in of Geneva, the University from INSEAD. Edmond de Rothschild Investment Partners Edmond de Rothschild Life Sciences, Partner, Olivier Litzka, Novo A/S Novo Novo Seeds, Investment Director, Nanna Lüneborg, early Novo Seeds is a leading A/S. the early stage arm of Novo investment of Novo Seeds, Nanna is Investment Director actively creating new biotech companies primarily in Scandinavia through seed and venture investments. stage investor, a successful Capital, Apposite life science investment team at she was part of the Previously, A/S in 2012. Nanna joined Novo Earlier in medical devices and healthcare services. investing in drug development, venture fund, London-based healthcare in her PhD Oxford, of University atBA her completed Nanna Hughs College, St atwas she UK. Research Cancer career, her She currently serves the board of on and an MBA atof Cambridge. University Neuroscience at College London, University and she is an observer the board of Galecto Biotech. on Minervax and Pcovery, IO Biotech, Glionova, Affinicon, Directors of
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European 2013 to present – VP, Global Head BD Pharma, QIAGEN GmbH Global Head BD Pharma, VP, 2013 to present – D Nussloch, LEICA BIOSYSTEMS, Pharma Partnerships, VP, 2011 to 2013 – CH Basel, ROCHE PHARMA, Head Biomarker Ops, VP, 2007 to 2011 – CH Basel, ROCHE DIAGNOSTICS, Head BD Oncology, VP, 2002 to 2006 – D Hamburg, MEGAMEDICS, 2002 to 2002 – CEO, D Munich, AG, CELLCONTROL 1995 to 2002 – Founder & CEO, US D, DEVICES, MOLECULAR 1992 to 1995 – Product Manager, Educational Background Stockholm University of Heidelberg / Karolinska Institute, Molecular Biology & Pharmacology, • PhD, University of Heidelberg Biology, • Diploma (Masters), Vice President, Global Head Business Development Pharma, Qiagen GmbH Pharma, Global Head Business Development Vice President, Rainer Metzger, Philippe Lopes-Fernandes is the Senior Vice-President, Head of Global Licensing & Business Development for Merck Serono Vice-President, Philippe Lopes-Fernandes is the Senior high-quality global deals for His team provides end-to-end transactions support to ensure execution of all / EMD Serono. from early technology to clinical stage products. and marketed Merck Serono business units and all stages of development, pharmaceutical the in experience of years innovative20 than more with executive committed and driven, results a is Philippe project management, and M&A, He brings strong expertise in licensing fields). Generic and OTC industry (in Prescription, the acquisition including the in-licensing of Erbitux, having directly negotiated key deals for Merck KGaA, marketing and sales, He has lived and and most recently the alliance with Pfizer on PDL1. generic business to Mylan, the sale of Merck’s of Serono, Switzerland and the U.S. Germany, Portugal, worked in France, France. Administration from Institut Superieur de Gestion in Paris, Philippe holds a graduate degree in Business Senior Vice-President, Head of Global Licensing & Business Development, Head of Global Licensing & Business Development, Vice-President, Senior Philippe Lopes-Fernandes, Inc. EMD Serono, Provectus Biopharmaceuticals Provectus Inc. CFO & COO, Peter Culpepper, experience and working with high-growthMore than 20 years of finance start-up companies Led the national operating of a $1 billion publicly unit traded telecom company
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Actelion Pharmaceuticals, Ltd. Actelion Pharmaceuticals, Senior Director Business Development, Sodha, Ravi He spent several years in Research (London and MBA. Ph.D. in Pharmacology, Ravi studied in the UK obtaining B.Sc. (SmithKline Beecham) and Sales & Marketing Clinical Development Ciba Geigy Basel), University Hospitals, Zurich University, 8 years in various functions he spent where In 1999 RaviatLicensing & moved to Business Development Novartis, (Novartis). Asia-based Management Alliance for Franchise and a Business atlast responsibility His was Novartis therapeuticand areas. Taiwan. Korea and China, including India, job rotation for Business Development activities in the emerging markets, where his responsibilities include Business Development, Actelion Pharma Switzerland in 2008 as Senior Director, Ravi joined and enjoys Ravi has three women in his life, structuring and negotiating licensing deals across several therapeutic areas. and spiritual reading. soccer (from the comforts of his arm chair), cooking, Novartis Institutes for BioMedical Research, Inc. Research, Institutes for BioMedical Novartis Executive Director, Rao Movva, mycompleted He M.Sc degreeto leading studies his pursued in India and Nagpurwas born from Rao in India. university joined Subsequently,he in 1980. York New Graduate degree studies with a Ph.D in Molecular Biology at SUNY at StonyBrook, and worked Switzerland as a research scientist in 1980 a novel start-up biotech company in Geneva, then , Biogen S.A , Program executive and Senior research scientist focusing on cloning capacitiesthere until 1987 in various as Project leader, of recombinant protein of novel genes and the expression and have Switzerland in 1987 been with the organization in several research since AG in Basel, He moved to Sandoz capacities.environments and in various he had developed methods for of various recombinant successful production As a group leader in the Biotechnology (1987-92), LIF from E.coli. IL-6 and including lymphokines IL-3, proteins, he contributed to elucidate the of Mechanism of action as the head of Signal transduction Biology group, From 1992-1996, the as the target of Rapamycin, TOR protein notably the identification of including , of action of immunesuppressive drugs, and cancer(Affinitor) drug. active component of Novartis transplant (Certican) he led very early effortsAs the Head of Molecular biology and Gene therapy to evaluate the gene unit in the (1996-2004), therapy technologies and developed screening strategies for small molecules to identify tool and lead compounds for drug development. he focused his efforts in chemical biologywith their biological to connect the chemicals targes In the past 10 years, toaccelerate drug discovery. In addition he is involved in setting up multiple collaborations between Novartis and the various leading academic instituitions of the world by acting as a scout to identify and initiate new drug discovery microbiome efforts projects including the Human in Novartis Institute for Biomedical research (NIBR). Rao has more than 30 years of biotech and large pharma research and drug discovery experience and has authored Overall, several peer reviewed publications.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Wellington Partners Wellington General Partner, Regina Hodits, Partners funds on Wellington Partner and represents the She is a General Partners in spring 2010. Wellington Regina joined Respiratory an external director at and is GlaxoSmithKline’s Atopix, Sapiens and Ayoxxa, Medical, the Board of Middle Peak influential investor in the European venture capital she has become an industry, industry Since joining the in 2000, Board. TA focusing on early-stage growth and deals in Life Sciences. a leading transatlantic venture capital firm. in Europe, Venture Atlas Regina led the life sciences efforts of Until January 2010, Therapeutics, rounds and was the she led numerous financing Bicycle founding investor in Venture, Atlas As a Partner at which was acquired by including the Board of U3 Pharma, Regina served on several Boards, F-star and Jenavalve. Fibrex, which was acquired by SciClone in 2010. Ltd in 2008 and Novamed, Daiichi Sankyo Co. she was responsible for investments in Germany healthcare and was Apax Partners, while working for From 2000 to 2004, network extensive her build to started She Wilex. Therapeutics and Silence closelyGenmab, as such investments in involved in the global healthcare industry during her tenure at McKinsey from 1997 to 2000. Regina gained profound insights into the fast-growing lecturer and post-doctoral biotech sector as university In the 90s, collaboratedshe where emergingwith companies. biotech UK Cambridge, MRC the and Vienna atresearcher of University the in biochemistry. Vienna and holds a Ph.D. Regina studied chemical engineering in Tonix Pharmaceuticals Holding Corp Tonix Chief Executive Officer, Seth Lederman, from 2007- TONIX, Prior to founding specialty pharmaceuticals entrepreneur. and scientist, Seth Lederman is a physician, LLC and Konanda Pharma Lederman co-founded was a managing and partner of Konanda Pharma Partners, 2008 Dr. and Validus He co-founded and served as director and chairman of its wholly-owned operating companies LP. Fund I, Marplan® (isocarboxazid) Release), – Extended market Equetro® (carbamazepine which Inc., Fontus Pharmaceuticals late-stagedevelop to Pharmaceuticals oncology drugs Targent foundedLederman Dr. 2000 In (calcitriol). Rocaltrol® and which was sold to Spectrum Pharmaceuticals and is now FDA-approved and marketed including pure-isomer levofolinic acid, which developed several drugs Pharmaceuticals, Vela Lederman co-founded Dr. In 1998 as Fusilev® for colorectal cancer. VLD-cyclobenzaprine. including for central nervous system disorders, Lederman joined the faculty of Dr. Associate Professor at Columbia University. Lederman maintains an appointment as Dr. and Assistant Professor of Medicine in 1988, became College of Physicians and Surgeons in 1985, Columbia University’s From 1988 Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. infectious diseases and Lederman directed basic science research at Columbia in molecular immunology, Dr. to 2002, and articles, scientific numerous of author is Lederman Dr. therapeuticsof development the for diseases. autoimmune fundamental work on the CD40-Ligand Lederman’s Dr. inventor of technologies recognized by a number of issued patents. T cell helper function and has led to the development of therapeutic candidates for (CD154) elucidated the molecular basis of The successful diseases and organ transplant rejection in collaborationautoimmune with Biogen-IDEC and CellTech/UCB. defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular Lederman identified and Dr. David Baltimore (then at Rockefeller University and later MIT), In collaboration with Prof. targets. of earlyunderstanding His the to contributed HIV on work TRAF-3. functionallymolecule, signaling CD40 the characterized an early and essential event in viral entry fusion with CD4 cell membranes, V3 loop of HIV gp120 was involved in how the Arthritis and Lederman served as attending physician in the Edward Daniels Dr. In addition to his research, and infection. Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital 1988-1996. College of in ChemistryAB from Princeton an MD from Columbia University’s in 1979 and cum laude Lederman earned an Dr. Presbyterian rheumatologyand medicine internal in trained Lederman at Columbia’s Dr. 1983. in Surgeons and Physicians 1985-1990 at He was an NIH Physician-Scientist Columbia. Hospital. Chief Executive Officer, BerGenBio AS Chief Executive Officer, Godfrey, Richard industry He has more than 25 years’ experience leading Richard Godfrey Officer in 2008. joined BerGenBio as Chief Executive Formerly he served as Chief Executive Officer of many international drug development and commercialisation partnerships. Prior to this he was the Managing Director of DCC Healthcare Ltd and a specialist biopharmaceutical company. Aenova Inc., Eli Lilly in R&D and commercial and Reckitt Benckiser previously at he held positions of increasing responsibility Catalant, from Bath University He qualified as a Pharmacist from Liverpool University and received his M.B.A. roles.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Partner, Sunstone Capital A/S Partner, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Sten Verland, Sten Verland, and he has His primary investment focus is within drug development, is founding partner at Sunstone Capital. Verland Sten entrepreneur and venture investor in biotech companies as more than 20 years’ experience as an international executive, Anergis SA, A/S, Sten also serves as non-executive director of Orphazyme Currently, well as pre-clinical and clinical CROs. AG Vaximm and Minervax A/S. Sten held a number of academic positions in the field of biomedical research including the After completing his doctorate, Assistant Professor in Immunology at University of Copenhagen. the position of Sten headed a Management Buy-Out of a contract research organisation (CRO) specialising in laboratory animal In 1994, his leadership the company Under successfully introduced a range of new services science and non-clinical development. the merged Sten shareholder, a major as years After 4 technologiesand research. animal transgenic of field the within The company was acquired by A/S with a staff of 100. company with another Danish biotech company thus forming M&B in 2000. York, New Inc., Taconic, and served for 4½ years Inc.), San Francisco (now BioClinica, Inc., Sten participated in the foundation of Synarc, In 1998, from a small start-up clinical service Synarc developed provider into the During his tenure, General Manager Europe. VP, as With 6 offices around the world largest central radiology service company dedicated exclusively to global clinical trials. world’s involving more than 60,000 patients at 1,500 sites worldwide. Synarc managed trials, over 150 clinical and a staff of 220, Sten operated his own investment company where he co-founded or invested in 7 life science companies From 2003 to 2007, Immunologyin the from Biologyin Ph.D. a and M.Sc. a holds Sten servedand Boards. 16 on director non-executive as University of Copenhagen. Karus Therapeutics Karus Therapeutics Ltd Chief Executive Officer, Simon Kerry, with two decades’ experience of creatingSimon is a business professional and developing innovative life science companies. Ablynx NV (Ghent, of Business Development at he was Director CEO in 2006, Before the Company’s he joined Karus as and licensing agreements development with major pharmaceutical a number of research, where he secured Belgium), growth from early- Ablynx’s he played a key role in this time, During Wyeth (now Pfizer) and Novartis. companies including antibody companies. most promising stage to one of Europe’s Venture Partner, HADEAN VENTURES Partner, Venture Siro Perez, development, Siro has over fifteen years of scientific and international management experience across the whole research, and investment process in new technologies. commercialization, opportunities. where he advises the fund on due diligence and identifies investment Ventures, Partner at Hadean Venture He is a a boutique consulting firm he in 2013. founded He also actively advises and co-founds Roundcape, start-ups through the company leading from a development stage start-up to a fully ToxiMet, he served as CEO of Prior to foundingRoundcape, and raising £5m at increasing valuations in the process. commercial enterprise with sales in 5 continents, leading hedge biotech stocks forand in pharmaceutical investing he worked of the world’s one ToxiMet, Before joining ManagerInvestment as and for capitalsciences venture life global a under ($1.5B fund management), under ($14B funds management). managing The Boston Consulting Group, he worked as Project Leader in the Zurich office of Before his investment career, he led a group in drug Prior to that, and Financial Services companies. Biotech, strategy projects for global Pharma, career scientific his started and Cajal the at neurodegenerativein research conducted and atdevelopment diseases Novartis, journals. with several publications in peer-reviewed Institute of Neurobiology, in Molecular Biology and a PhD summa cum laude and a Business School, Siro holds a Masters in Finance from the London Computer Science Engineeringstudied also He at of Madrid. University Autonoma Chemistryin MSc the from honours with and Spanish fluently. German, and speaks English, UNED,
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u GlaxoSmithKline Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Nextech Venture Nextech Partner, Thilo Schroeder, Prior focused on investing inoncology companies. a global venture fund, Thilo Schroeder is Partner at Nextech Invest Ltd., a web based technology company Schroeder was president of SiROP Global, Dr. from 2007 to 2013, to joining Nextech, Pharmaceuticals Tracon observerwas Schroeder of board the of Dr. thatworld-wide. and Europe in universities connects and currentlyTherapeutics serves and as a board member of Blueprint Medicines and an observer board of Peloton of the University of Darmstadt in Technical in biology from the He received a B.Sc. all biopharmaceutical companies. ImaginAb, in and a Ph.D. in biotechnology from the Ecole Supérieure de Biotechnologie de Strasbourg in France, an M.Sc. Germany, biochemistry from the University of Zurich in Switzerland. CEO, Prokarium Ltd CEO, Fjällman, Ted Spun-out Prokarium from Cobra Biologics in 2012 and raised funds for 1 clinical study for pre-clinical R&D and phase Before worked in Strategy joining Prokarium Consulting and previously in the clinic at one of Europe’s travellers’ diarrhoea. Currently LEAP. a fellow of SynBio PhD in Biotechnology (Antibody Engineering) from Canada. largest hospitals. F.Hoffmann La Roche AG La Roche F.Hoffmann Commercial Lead Oncology/Immunology, Stephen Sands, in now specializing commercial experience in the pharma industryStephen has over 25 years in multiple disease areas, leading the acquisition process Stephen is the Oncology In his current role Lead for Commercial Roche Partnering, oncology. such as the recently and OryzonRoche between partnership announced compound epigenetic around the for key assets, this Stephen was the Commercial Director for Prior to Oncology Roche and prior to that the Commercial Director ORY-1001. and marketing strategies he developed and supported the commercial In these roles for some of the largest Avastin. for brands in the field of oncology. Director, Transactions, Transactions, Director, Kay, Stewart marketing and business Amersham International sales, (now part of GE) and held various Stewart started his career at He joined Evotec in 2002 as SVP Business Platforms division. Technology development positions in the Life Science and VP Commercial In 2005 he joined Pharmagene as Development for Europe and was part of the operational management team. Stewart Asterand. ManagementDevelopment and as a member of the Executive team took the company into a merger with Stewart hold s Pharma R&D. Business Development, Worldwide in Transactions joined GSK in 2008 and is currently Director Business School. Warwick Bsc in Biochemistry and a MBA from Torreya Partners (Europe) LLC Torreya Partners Europe, Torreya Principal and Head of Stephanie Léouzon, a life sciences boutique advisory firm which she joined Partners, Torreya is Partner and Head of Europe forStephanie Léouzon Previously she worked in Health Care Investment She also serves of Directors of Immunovaccine Inc. on the Board in 2012. Advisor. most recently at Credit Suisse as a Managing and Senior Director Banking in the US and Europe from 1989-2010, and been involved in valued at over $65billion, 20 strategicShe has advised life sciences clients on more than transactions, billion to health care clients. over 45financing transactions to provide over $10 Virginia in 1989 and a degree from the Darden Graduate School of Business at of the University Stephanie earned an M.B.A. from Mount Holyoke College in 1985. cum laude, degree, B.A.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CEO & CFO, Epigenomics CEO & CFO, Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Timothy Herpin heads a groupHerpin heads involved in all aspects of transactions negotiationprofessionals development of business Timothy Strategic Partnering and Business Vice-President, as AstraZeneca in 2011 joined Tim AstraZeneca. and execution at spent eight years in the Tim AstraZeneca, Prior to initially for CNS& Pain and more recently for Oncology. Development, business development organization at Squibb Bristol-Myers covering both search and evaluation as well as transaction in and Aventis worked in R&D at Bristol-Myers Squibb, Tim Before his business development career, multiple disease areas. in organic He also holds a Ph.D. grew up in Paris and is a graduate of Ecole Polytechnique in France. Tim Pharmacopeia. chemistry an MBA in Finance from NYU Stern. from University College London and KG GmbH & Co. AbbVie Deutschland & Early Stage Collaborations, Ventures Director, Sr. Vincent de Groot, He and scientist. entrepreneur, & licensing professional, Vincent is a business development CLP. Ph.D., Vincent de Groot, Vice- he served as Most recently, Abbvie. & Early Stage Collaborations atVentures currently servesas Senior Director, He joined Synthon via its acquisition of at& Licensing Business Development Biopharmaceuticals. Synthon President, his obtained He founderwas Vincent the companyled and of Syntarga M&A. its CEO from inception to as 2011. in Syntarga more than a dozen scientific He published degree cum laude from the Radboud University Nijmegen in the Netherlands. Ph.D. Vincent is a is inventor on several patentswas awarded and several national and international scientific awards. papers, (CLPT) credential member of the Licensing Executives Society (LES) and has received the Certified Licensing Professional from LES. Vice President, Head of Transactions (UK), Business Development, AstraZeneca Business Development, (UK), Transactions Head of Vice President, Herpin, Tim Abingworth LLP Abingworth Partner, Haines, Tim Abingworth Before joining more than 25 years of international has management experience in the life sciences industry. Tim Astex for more than was with Tim Therapeutics. Astex Abingworth portfolio company, in 2005 he was Chief Executive of the Tim was Chief Previously, five years and was instrumental in establishingone of the leading UK biotechnology it as companies. he held a Prior to Datascope, Datascope Corp. Executive of two divisions of the publicly-listed technology medical company, Thackray Inc and General Manager including CEO of number of other senior management the US and Europe, positions in Vision, Pixium Medical, Lombard Kspine, Fovea, Pharmaceuticals, Astex include positions board past and Current UK. Baxter At INSEAD. from MBA an and University Exeter from BSc a has Tim XCounter. and Implants Stanmore Sientra, PowderMed, he identifies and creates new businesses and provides support for portfolio companies. Abingworth, Thomas Taapken, Thomas Taapken, 2011 April 1, on He joined Epigenomics since September 2012. AG has served as CEO of Epigenomics Taapken Thomas Dr. of the he held the position of CFO and was a member where Therapies (Finland), from Biotie as Chief Financial Officer following combination a business between Biotie He was appointed this position in 2008, to Team. Executive Management His extensive international in the life sciences experience 2005. Thomas had been CFO since where Therapies and elbion NV, Capital and San from 2003 to 2005 Venture industry positions as investment partner at includes previous Deutsche DVC years several worked also He Sanofi-Aventis at capitalventure US Francisco-based & Company Burrill firm 1998-2002. from as well as in the areas of corporate & business managing corporate venture capital activities, and Germany, in the U.S.A. spanning acquisitions, he has been involved in numerous transactions his career, Throughout development and research. as well as private public offerings. and divestitures, mergers,
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Speakers 8th ANNUAL & Exhibition Forum CEO Science Life European Immunomic Therapeutics, Inc. Immunomic Therapeutics, Chief Executive Officer, William Hearl, he also founded Prior to founding Immunomics, Therapeutics. of Immunomic and CEO president Hearl is founder, William Dr. companya prooprietrarythat a using genes cancer novel identified platform (GeneSystem320) Capital2000, in Genomix He has worked at of leading companies in a number technology. and converted them to antibodies using ImmunoMouse He holds multiple patents (and patents Pharmacia Diagnostics and KPL. Technologies, the biotech industry including Life in 1984. Tennessee in Biochemistry the University of from He received a Ph.D. pending) in the field of genetic immunization. Inc. Vaxart, Chief Executive Officer, Latour, Wouter Global including roles as vice president and director, Vaxart, Latour brings more than 20 years of industry experience to Dr. and as a strategic advisor for Vaccines) Strategy and Business Development at Beecham Biologicals SmithKline (now GSK Trinity Latour served atdirector and CEO as Dr. recently, Most Novavax J&J/Crucell). (now Biotech Berna and Pharma, Novartis Latour earned his MD from the University of Dr. a company focusingoral delivery on of biopharmaceuticals. Inc., Biosystems, Amsterdam and his MBA from Stanford University. Torreya Partners (Europe) LLC Torreya Principal, Wilder Fulford, internationalan advisory Partners, Torreya of branch London the Europe, Partners Torreya foundingthe is Wilder of partner Fulford has had Dr. financings and other transactions. alliances, licensing, companies with M&A, firm assisting Life Science his PhD in molecular biologyAfter completing at of all kinds around the globe. companies a long career advising healthcare before an as career a on embarking forcapitalist, worked venture he a as years few a 1986, in University Rockefeller the Merrill Lynch, and London at Salomon Brothers, York He has run healthcare M&A or coverage groups in New M&A advisor. He has participated in close to 100 financing and M&A transactions (most recently)America and Deutsche Bank. Bank of aboutand mandatesdozen a in London, in team full a has Partners Torreya aggregatean with billion. $100 of excess in value and devices, medical vaccines, specialty pharma, and has closed five transactions so far in 2013 in biotechnology, execution, since inception. in the 6 years Partners has completed over 100 Life Sciences assignments Torreya Globally, OTC.
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Owner and Principal 4D Lifetec AG 4D Lifetec www.4dlifetec.com COMPANY PROFILE COMPANY 4D Lifetec is a company for and promoting test and screening systems developing diagnostics molecular of relatedincluding the production consumables. gel electrophoreses assayBased on the single cell principle the company has recently the highly developed a molecular diagnostic cancer therapy system improving personalized by quantifying innovative 4D Lifetest™, Due to its improved technique it generates potential patient benefit by its non-invasive DNA repair mechanisms. It also offers cost savings by to healthcare providers outstanding precision and its and time saving approach. to its high-throughput Due high degree of standardization both leading to a reduction of false positive results. 4D Lifetest™ also offers a unique solution for DNA defect and repair based capacity and its high precision, screening programs and is therefore the diagnostic of first choice. method Lifetest™ which are fullySo far 4D Lifetec owns two utility models of the 4D functional and IP protected. The analytical part including software application the outcome is an integral to quantify part of the on-going development process. Direct contacts to several Key Opinion 4D Lifetec profits from different and healthcare. networks within science national international and normative bodies as well as within the market Assay, Leaders within the field of Comet leading Contact Research Labs exist. and theyContacts to software developing companies exist be used to further foster could a potential co- operation on development level. The company is currently backed by risk capital of the founders to ensure thorough preparation of first phase of The company is run by equivalents who co-ordinate 2 full time the specific project management capitalization. steps for the first 18 months. MANAGEMENT Arne-C. Faisst, Dr. CO-CEO Business Giancarlo Rizzoli, Dr. CO-CEO Development Oliver Schicht, Dr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2014 EMAIL [email protected] TELEPHONE +41 79 434 10 49 ADDRESS 4D Lifetec AG Gebwerbestrasse 10 6330 Cham Switzerland CONTACT Arne-C. Faisst Dr. Owner and Principal WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Oral antitumor efficacy in human xenografts as single agent, comparable or higher than reference compounds Oral antitumor efficacy in human xenografts as single agent, cisplatin), gemcitabine, erlotinib, (docetaxel, ABTL0812 is an Akt/mTOR inhibitor through a novel mechanism of action, fully differentiated PI3K/ from other novel mechanism of action, Akt/mTOR inhibitor through a ABTL0812 is an Akt/mTOR inhibitors. Akt phosphorylation by mTORC2 and inhibits mTORC1 resulting in the inhibition of the ABTL0812 prevents phosphorylation of the ribosomal protein S6. AUTOPHAGY. ABTL0812 induces cell death by Action on several steps of the PI3K/Akt/mTOR signaling pathway anticipates activity in tumors with different approved or under mutation profiles and less probability to develop resistance than with other inhibitors, development hepatoma, pancreatic cancer, lung cancer, NSCLC Active in a broad range of human cancer cell lines: lymphoma. neuroblastoma and colon cancer, breast cancer, glioma, melanoma, ABTL0812 - Differentiated mechanism of action • • • Akt/mTOR feedback loop associated with mTORC1 inhibitors. ABTL0812 likely avoids the positive • • ABTL0812 - Antitumor activity • • Pharmaceuticals Ability www.abilitypharma.com FINANCIAL SUMMARY the phase IIa programA round (2015) to conduct with The company is currently a $ 12 million series raising Billion in all cancer types. with sales potential over $ 1.5 drug candidate, its first ABTL0812, 2009 it has raised $ 4,6 Million Since founders and private Investors. Capital Inveready Company, Shareholders: soft loans. in equity and government PROFILE COMPANY a clinical stageAbility Pharmaceuticals is biopharmaceutical company focused based in Barcelona on the development of a new drug class for cancer treatment. A round (2015) to conduct the phase IIa program with The company is currently raising a $ 12 million series potential over $ 1.5 Billion in all cancer types. with sales its first drug candidate, ABTL0812, signals with good safety and efficacy ABTL0812 is currently phase I/Ib clinical trial, finishing the first in humans (several disease stabilizations and activity on biomarkers). It fully differentiated form other ones marketed o being commercialized. Akt/mTOR inhibitor, ABTL0812 is an tumor cells and it is active over resistant reference compounds, or higher than, has efficacy comparable to, It has an excellent safety profile. synergistic toxicity. with other anticancer drugs without increasing In the phase II program pancreatic and gynecological cancers. ABTL0812 is developed for the treatment of lung, the patients mutations/deletions will be selected based on PI3K/PTEN/AKT and amplifications. PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2009 EMAIL [email protected] ADDRESS Edifici Eureka – Campus de la UAB 08193 Bellaterra (Barcelona) Catalonia Spain CONTACT PhD Carles Domènech, Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u VP Research & Development Synergy with gold-standard treatments: docetaxel (85x) and gemcitabine (8x) in cell culture. At low doses docetaxel (85x) and gemcitabine culture. (8x) in cell Synergy treatments: with gold-standard ABTL0812 potentiates antitumor activity in xenografts docetaxel toxicity. without increasing April 2015. in Ending Currently ongoing at Clinic Barcelona and Institut Català Hospital Oncologia. pancreatic and with enrichment in lung, Phase I/Ib (First in Humans) in patients tumors, with advanced solid gynecological cancer patients. Activity in the inhibition of the one lasting more than 11 month. several patients with stable disease, Efficacy: Mild adverse events – High safety and tolerability. Akt in platelets (biomarker). phosphorylation of ...continued Formerly Chief Financial Officer of Sevibe Cells. Formerly Chief Financial Officer of Sevibe Cells. 13 yrs Business Dev & Licensing at Almirall & Lacer, 3 yrs Biotech VC, 8 yrs Cancer Research Memorial Sloan-Kettering VC, 3 yrs Biotech Almirall & Lacer, 13 yrs Business Dev & Licensing at Barcelona. Autònoma of CSIC & Univ. Cancer Center, José Alfón, PhD, drug development (pre-clinical and clinical) at Palau Pharma & Uriach - 6 yrs Research at Hebrew Univ. 12 yrs drug discovery, of Barcelona. of Jerusalem and Univ. Biology Research Director, PhD, Mariana Gómez, CIB CSIC (Madrid) and CRG Toronto, Mount Sinai Hospital Albert Einstein College of Medicine NY, 12 yrs cancer research at (Barcelona). Clinical Research Director, MD, Marc Cortal, Middlesex Hospital Saint Mary London Terrassa, Hospital Mútua de Clinical Practice and Health Management - Clínica Quirón , / Red Cross Geneva. Administration. Finance & Director, Ruz, Vanessa • non-responder cell lines: • Efficacy in resistant and pathway• Superiority over other PI3K/Akt/mTOR cell lines. inhibitors in drug resistant cancer trial I/Ib clinical ABTL0812 – ongoing phase • • Oral administration. open-label and single-agent study. • Multi-center, i) dose escalation (15 patients - completed) and ii) expansion phase (12 patients - ongoing). parts: Two • • 28-day cycles of treatment. • Phase II program starting in 4Q2015 - 1Q2016. Akt overexpression PTEN mutations and deletions and • Patient will be stratified according to PI3K mutations, squamous cell lung carcinoma and pancreatic cancer. • Phase II program with trials in endometrial cancer, OPPORTUNITIES A financing round of € 10 Million • Raising series • ABTL0812 Out-licensing MANAGEMENT Chief Executive Officer - Co-founder. PhD, Carles Domènech, Pharmaceuticals Ability www.abilitypharma.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2009 EMAIL [email protected] ADDRESS Edifici Eureka – Campus de la UAB 08193 Bellaterra (Barcelona) Catalonia Spain CONTACT PhD Carles Domènech, Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Ltd. Therapeutics ADDEX www.addextherapeutics.com Dipraglurant-IR : Preparing Phase IIb trials Addex in Dipraglurant is a negative allosteric modulator of the metabotropic glutamate receptor 5 discovered at oral small molecule and has potential to be used in combination with levodopa or It is a highly selective, 2003. disease. dopamine agonists for the treatment of Parkinson’s disease The Dipraglurant immediate release formula is being developed for the treatment of Parkinson’s Dipraglurant-IR acheived key objectives in a Phase IIa trial that was co-funded by Levodopa induced dyskinesia. A phase IIb trial is currently being prepared. the Michael J Fox foundation. COMPANY PROFILE COMPANY company is a biopharmaceutical focused on the development Therapeutics (www.addextherapeutics.com) Addex Addex small molecule allosteric modulators for central nervous system disorders. orally available, of novel, dipraglurant (mGluR5 negative allosteric modulatorhas successfully or NAM) completed lead drug candidate, prepared to enter and is being levodopa-induced dyskinesia (PD-LID), disease a Phase 2A POC in Parkinson’s therapeutic treatment use in dystonia and resistant depression dipraglurant’s In parallel, Phase 2B for PD-LID. (mGluR2 positive allosteric modulatorADX71149 Addex second clinical program, is being investigated. Addex also has several Inc. in collaboration is being developed with Janssen Pharmaceuticals, or PAM) which has received regulatory approval to receptor PAM) ADX71441 (GABAB preclinical programs including: alcohol 1A) disease, (Type start Phase 1 and is being investigated for therapeutic Charcot-Marie-Tooth use in disease Parkinson’s for drug abuse and dependence, use disorder and nicotine dependence; mGlu4PAM and other neurodegenerative diseases; mGlu2NAM for treatment resistant depression and cognitive deficits; for type 2 for neurodegenerativeand GLP1PAM disorders; TrkBPAM mGlu7NAM for psychosomatic disorders, Allosteric modulators are an emerging class of small molecule drugs which have the potential to be diabetes. small molecule or “orthosteric” more specific and confer significant therapeutic advantages over conventional Addex allosteric modulator discovery drug platform proteins that targets receptors and other biological drugs. Addex pipeline was generated from this pioneering are recognized as essential for therapeutic intervention – the allosteric modulator drug discovery platform. PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL investor.relations @addextherapeutics.com TELEPHONE +41 22 884 1555 ADDRESS Aulx chemin des 12, 1228 Plan-les-Ouates, Geneva Switzerland CONTACT Dyer, Tim Co-founder and Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ...continued Ltd. Therapeutics ADDEX www.addextherapeutics.com ADX71149/mGluR2 PAM : Phase II ADX71149/mGluR2 PAM Partner ADX71149 as an add-on therapy for treating schizophrenia. were reported forPositive proof-of-concept is reviewing which indication(s) to puruse. Inc. Janssen Pharmaceuticals IIa Dipraglurant-ER : Phase Dipraglurant formulation extended release is being developed for the treatment dystonia. of non-parkinsonian proof Two with the Dystonia Medical Research FoundationAddex has a partnership use in dystonia. to explore its results in 2016. of concept trials are planned to start in 2015 with ADX71441-CMT1A : Preclinical small molecule activator acid subtype of the gamma-aminobutyric oral, first-in-class, ADX71441 is a novel, Activation of the GABAb receptor is modulation. B (GABAb) receptor functioning through positive allosteric clinically and commercially validated in a number of indications through the use of baclofen. preclinically, a rare Subtype 1A (CMT1A) syndrome, ADX71441 is being developed for the treatment of Charcot-Marie-Tooth A Phase I trial is planned to shown efficacy in CMT1A ratADX71441 has models. neurodegenerative disease. start in 2015 with results in 2016. ADX71441-Addiction : Preclinical Addex has a partnership with the ADX71441 is also being explore for treating alcohol addiction. nicotine and/or will be evaluatedADX71441 in a number where Alcoholism), and Abuse Alcohol US NIAAA (National Institute on partnership is in place with NIDA (NationalAnother Institute on Drug of preclinical models of alcohol addiction. of nicotine addiction. to a number of tests in preclinical models ADX71441 will be subjected where Abuse), MANAGEMENT co-founder and Chief Executive Officer Dyer, Tim Chief Scientific Officer Sonia Poli, Head of Discovery Robert Lutjens, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL investor.relations @addextherapeutics.com TELEPHONE +41 22 884 1555 ADDRESS Aulx chemin des 12, 1228 Plan-les-Ouates, Geneva Switzerland CONTACT Dyer, Tim Co-founder and Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u B.V. Amphera www.amphera.nl/en COMPANY PROFILE COMPANY (established December 2012) is a Dutch life sciences company that immunotherapies develops for Amphera B.V. the treatment of cancer. lead product focuses malignant mesothelioma. on Amphera’s but fatal disease with a survival after diagnosis of 9 is a rare, asbestos induced cancer, Malignant mesothelioma, With the best standard of care (chemotherapy)survival mean is increased to 12 months. months on average. Amphera is activelylooking for investors to finance the pivotal phase Advice, Scientific After a first round of EMA II/III study for therapy. our dendritic cell MANAGEMENT CEO Ilona Enninga, CCO Rob Meijer, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED December 2012 EMAIL [email protected] TELEPHONE +31 73 627 4520 ADDRESS Onderwijsboulevard 225 5223 DE ’s-Hertogenbosch The Netherlands CONTACTS Ilona Enninga CEO Rob Meijer CCO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Anaptys Bio Anaptys www.anaptysbio.com Vice President, Target and Translational Biology Translational and Target Vice President, McKnight, Dr. AnaptysBio in 2012 and has since led target selection and translational studies across our proprietary McKnight joined Dr. Biotherapeutics R&D initiative in Sandwich, McKnight was key member of Pfizer’s Dr. AnaptysBio, Prior to pipeline programs. McKnight was a Group and Project Leader at UCB Celltech U.K., Dr. Before joining Pfizer, Massachusetts. and Cambridge, U.K. (Hons.) in Immunology from the McKnight received his B.Sc. Dr. College London. and a Senior Lecturer in Immunology at King’s He completed post-doctoral training in Molecular Immunology from the University of Oxford. University of Glasgow and a D.Phil. and at the University of Oxford where he directed efforts T cell immunoregulation, studying Boston, at Harvard Medical School, to better understand molecular profiling of macrophage populations. Dr. King, Chief Scientific Officer Dr. where he was involved in the King was at Medarex, Dr. AnaptysBio, Prior to AnaptysBio in November 2008. King joined Dr. King is Dr. and led the development of a new class of antibody-drug conjugates. design and selection of therapeutic antibodies, an established expert in antibody engineering and antibody therapeutics has been involved in the design and development and he worked where At Celltech in the UK, of three FDA-approved antibody products and several other clinical stage antibodies. a PEGylated antibody fragment for therapy of autoimmune diseases and he was the lead inventor of Cimzia®, for 14 years, an antibody-drug conjugate for therapy of acute myeloid leukemia. was involved in the design and development of Mylotarg®, where he was part of the team later acquired by Corixa, King was at Coulter Pharmaceuticals, Dr. Prior to joining Medarex, King Dr. lymphoma. a radiolabelled antibody for therapy of non-Hodgkin’s which successfully refiled the BLA for Bexxar®, and was a Glaxo Group from the University of Surrey in the U.K., and his Ph.D. Warwick from the University of received his B.S. D.Phil. McKnight, Andrew J. Research postdoctoral fellow. Mr. Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus AnaptysBio’s Suria was appointed since led CEO in 2011 and has Mr. Suria was Mr. AnaptysBio, Prior to across keyto the development of a robust antibody product pipeline therapeutic areas. he was responsible for where partnering and alliance management of next-generation protein therapeutics in at Maxygen, Astellas. Bayer and Sanofi-Aventis, including partnerships with Roche, hematology and autoimmunity, oncology supportive care, Ontario Western in immunology from the University of an M.S. in biochemistry from Kalamazoo College, Suria holds a B.Sc. Mr. M.D. Marco Londei, and an Executive MBA from the Richard Ivey School of Business. Chief Development Officer Londei, Dr. Immunosciences and Area Head, Therapeutic AnaptysBiofrom Bristol-Myers Squibb (BMS) where he was Londei joined Dr. Londei Dr. Prior to BMS, responsible for early clinical and translational research for a portfolio of immune-related therapeutics. Science Officer for the Genomics Translational and Medicine at Novartis, Translational Autoimmunity was Global Head of He led the design and execution of more than 70 early stage clinical studies at Institute of the Novartis Research Foundation. canakinumab and several other biologic therapies for immune- of secukinumab, including the development Novartis and BMS, from the Faculty of Medicine of Bologna and has at University Londei received his M.D. Dr. mediated inflammatory diseases. He was a key member of the team which pioneered UK. London, Immunology Unit, Tumor conducted post-doctoral studies at the development of anti-TNF therapies while at the Kennedy Institute of Rheumatology of Medicine Imperial (KIR) Faculty Londei was Professor at the Faculty of Medicine Dr. London with Professors Ravinder Maini and Marc Feldmann. College, Autoimmunity and Gastroenterology Consultant at University College London of and then Professor Imperial College London, and has published over 160 peer- He is a widely in inflammation, recognized world-class contributor prior to joining Novartis. Ph.D. King, David J. self-recognition and immune modulatory checkpoints. reviewed papers in the fields of autoimmunity, COMPANY PROFILE COMPANY AnaptysBio is a privately-heldcompany focused on the generation of antibody therapeutics and is the leader a pipeline of novel are developing We in the use of somatic hypermutation (SHM) for antibody generation. inflammation and including differentiated programs in cancer immunotherapy, therapeutic antibody candidates, fibrosis. applicable to a ANB020, pipeline is led byOur internal pipeline antibody a novel anti-IL-33 therapeutic antibody, atopic dermatitis and food allergies. including asthma, Th2 diseases, variety of which couples fully libraries with in vitro somatic human antibody proprietary platform, SHM-XEL™ AnaptysBio’s replicates key features of the human hypermutation in mammalian cells to generate highly antibodies, functional immune system and overcomes limitations technologies. of prior antibody Momenta, Gilead, Celgene, Novartis, Roche, The Company has previouslywith Merck, announced partnerships and DTRA. DARPA Tesaro, MANAGEMENT President & CEO Hamza Suria, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2005 EMAIL [email protected] TELEPHONE +1 858 362-6295 ADDRESS 10421 Pacific Center Court Suite 200 CA 92121 San Diego, CONTACT Hamza Suria President & CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u AB Biotechnologies Athera www.athera.se COMPANY PROFILE COMPANY the in-depth understanding of the immunologicalAthera has a unique and components in atherosclerosis, the fully human lead product candidate, The inflammatory leading to cardiovascular disease (CVD). process has developed a biomarker and companion Athera In addition, clinical development. is in antibody PC-mAb, linked to increased risk is for cardiovascular disease and anti-PC, The biomarker, diagnostic CVDefine® kit. therapeutics. novel Athera’s forcould in the future be used identification of patients that benefit from PRODUCT PIPELINE PC-mAb MANAGEMENT CEO Carina Schmidt, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL [email protected] TELEPHONE +46 76 1938 190 ADDRESS Athera Biotechnologies AB 4th floor Sankt Eriksgatan 117, 113 43 Stockholm, Sweden CONTACT Carina Schmidt CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Diagnostics Atomo www.atomodiagnostics.com FINANCIAL SUMMARY Please speak with company directly PROFILE COMPANY Atomo is an award company winning commercialising disruptive user focued diagnostic for solutions both health markets professional use and consumer to use complex rapid products replace the need test kits with a convenient reliable user friendly solution Atomo’s Atomo enabling Atomo tests are ideal for and consumer applications POC ease of use, due to their simplicity and ‘bits in a box’ test kits. to target large market opportunities largely unserviced by existing AtomoRapid platform is easily re-validated for existing diagnostic assays and typically delivers improved The diagnostics products. preference when compared to existing perofrmance and overwhelming user PRODUCT PIPELINE device / Generation I commercially launched AtomoRapid / Rapid test companion diagnostics AtomoRapid is an integrated ehealth compatible disposablerapid test device that can deliver at home diagnostic programs.support of Phase III trilas and subsequent drug launch materially reducing trial costs and It enables at home and primiary physician monitoirng of trial performance, significnalty improving patient compliance and convenience. AtomoRapid supports a wide range of clinical applications has already been commercialised for and a range of commercial diagnostic markers. MANAGEMENT Chief Executive Officer Mr John Kelly, Director of Operations Mr Ricky Sadler, Director of Business Development Mr Byron Darroch, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2010 ADDRESS 701-703 Paramatta Road, Level 2, EMAIL [email protected] CONTACT Mr John Kelly Chief Executive Officer TELEPHONE +61 (0)2 9099 4750 NSW 2040 Leichhardt, Australia. WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Azanta A/S Azanta www.azanta.com FINANCIAL SUMMARY DKK 39 mill Sales 2013: PROFILE COMPANY women´s health A/S is a privately owned specialty pharma company primarily operating oncology, within Azanta an internationalA/S is to become market leader within specialty Azanta The vision of and addiction medicine. currentlyA/S markets or makes available a Azanta pharma products and innovative pharmaceutical products. a hypoxic radiosensitizer for the treatment of head including Nimoral, products, string of specialty pharmaceutical Azanta addition, In Angusta for labour induction. and neck cancer patients undergoing primary radiotherapy and A/S has a portfolio for of low risk development projects commercialization within the near future. MANAGEMENT CEO Mølle, Claus J. CFO Bo Kruse, Hanne Damgaard Jensen, CDP/COO 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +45 70 25 95 45 ADDRESS 20 Tranegaardsvej 2900 Hellerup CONTACT Claus Moller President and CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u BerGenBio AS BerGenBio www.bergenbio.com FINANCIAL SUMMARY $10m grant) of rounds from 2009 to date. funding through a series (plus ca. $30m equity Rasied Ca. private and instituational investors. VC, From Norweagin earlyConsidering an IPO end 2015/ 2016 PROFILE COMPANY BerGenBio is a clinical stage company biopharmaceutical focused on developing innovative drugs for aggressive, drug resistant cancers. which is The Company (EMT) biology, transition is a world leader in understanding epithelial-mesenchymal this original Building on widely recognised as a key pathway drug-resistance and metastasis. in acquired cancer biological pipeline of novel EMT inhibitors. insight BerGenBio is developing a promising BerGenBio intends to develop its product candidates of concept stage; to proof further clinical development and subsequently commercialisation will be through strategic and partnerships with experienced global alliances bio-pharma oncology businesses. PRODUCT PIPELINE Phase Ib / IIa BGB324: trials are on going Multiple Phase Ib clinical AXL. orally bio-available small molecule inhibitor of Highly selective, and selected Phase II trials planned for unique clinical opportunities. Preclinical BGB001 : one program has in late stage preclinical development: AXL, This is three monoclonal antibody programs against already been licensed to a specialist biopharma company for forward development and commercialisation. Preclinical BGB002 : it is in late stage lead optimisation This is a small molecule development program against EMT target, a novel including very aggressive negative triple Substantial preclinical data suggests multiple clinical positions, phase. breast cancer and other drug resistant cancers that to treat. are difficult MANAGEMENT He is also a Professor at the Department of is the co-founder of BerGenBio. Professor James Lorens On completing his postdoctoral research studies at Stanford University Biomedicine at the University of Bergen. as a founding scientist and research a San Francisco based biotechnology company, he joined Rigel Inc., Lorens has managed several large scientific collaborations in cancer research and development Prof. director. he leads a large In addition to BerGenBio, with major pharmaceutical and biotechnology companies. angiogenesis His group internationally is active in EMT, active research laboratory 22 researchers. comprising articles and patents. Lorens is an author of more than 70 peer-reviewed Prof. and cancer research. He Officer in 2013. joined BerGenBio in 2011 as a consultant and became Chief Medical Yule Murray Dr. began his career in the pharmaceutical industry1998 after completing his medical training in oncology in National Service, Health Whilst working in the United Kingdom’s Cambridge. Addenbrookes Hospital, at Murray supervised multiple early of novel anticancer products and completed a PhD in phase clinical studies whilst working in several top-ten pharmaceutical companies, In the last ten years, experimental pharmacology. which has led to he has planned and executed global development strategies for several anticancer drugs, licensing approvals for novel tubulin binders in solid tumors and epigenetic therapies in acute leukemia. an R&D Previously he held the position of CFO at GexCon, Petter Nielsen joined BerGenBio in 2015 as CFO. company that developed into an international group of companies focusing on commercial products and valuation and IFRS from IPOs, Nielsen has extensive experience related to mergers and acquisitions, services. Auditing Advisory He obtained an MSc in Services group. Transaction where he has worked in the Young Ernst & both from the Norwegian School of Economics. Administration, and an MSc in Economics and Business 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] TELEPHONE +47 535 01 564 ADDRESS BerGenBio AS Jonas Lies vei 91 Bergen, 5009, Norway CONTACT Mr Richard Godfrey Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Compositions and methods enabling detection and characterization of O-GlcNAc BioCrypton, Inc. Inc. BioCrypton, www.biocrypton.com FINANCIAL SUMMARY A funding. BioCrypton is privately funded and raising Series PROFILE COMPANY US). BioCrypton is a private biotech company specializing in a high-impact ultra BioCrypton (San Francisco, clinical diagnostic sensors and comprehensive multiplexed molecular sensitive protein BioChip tests to improve financial benefits provide healthcare costs. for insurance companies and lower patient outcomes, BioChip and immunochemistry Multiplex protein assay/diagnostic supported by test proprietaryProduct: biopsy. urine, saliva, serum, BioChip assay is compatible with a range of patient samples (blood, algorithms. and cloud encrypted data, web, HIPAA-compliant Product is integrated with Health-IT module (novel algorithms, database). Platform Technology: Our technology is applicable for robust diagnostics and glycosylated sites and O-GlcNAc glycosylated proteins. cardiovascular diseases, CNC, Alzheimer, including cancer, drug development in a number of clinical applications, PNAS. Science, originated at Caltech and we have publications in Nature, Our are well validated, and diabetes. Strong portfolio of issued patents. IP: BioChip and multiplexed clincial diagnostic test for Pancreatic Cancer and Product Applications: 1st focus: 2nd focus BioChip and diagnostic test for (“all- Gastrointestinal (GI) cancers and GI chronic diseases Pancreatitis. BioCrypton R&D can be easily expanded and applicable to Arthritis. 3rd BioChip and diagnostic test for in-one”). other complex human diseases. Our workflow BioCrypton has on-going R&D and laboratoriesBioCrypton in San Francisco. R&D capabilities: The directly integrated with global biobank which has operations at 90 clinical sites in 15 countries around. biobank has significant biorepository (about 100,000 samples from ~7,000 individual cases) and brings study design, to BioCrypton 12 years of expertise in tissue research projects including tissue procurement, processing and analysis. specimen collection, clinical network management, regulatory affairs, we are integrating advanced and sustainable R&D model: profitable, leveraging are a proven, We R&D Model: It will our R&D with outsourcing to validated partners with whom we have CROs and business worked before. expedite our timelines and reduce the cost of R&D. Opportunity Market Clinical Need and Large Population of PC patients Pancreatic cancer (PC) is one of the most aggressive and deadliest GI cancers. PC can be deaths by 2020. is growing and PC is anticipated to be the 2nd leading cause of cancer-related “too late-to-treat” PC is asymptomatic in early stages and usually detected at a treatable if diagnosed early. to the lack of pain) due organ failure, stage when patients already have significant clinical symptoms (metastasis, Pancreatitis is a disease which can result specific and sensitive diagnostic tests to detect cancer at early stage. Chronic and chronic pain. cyst formation, infection, serious tissue damage, bleeding, in serious complications: Severe pancreatitis can harm heart, pancreatitis can get worse over time and can lead to permanent damage. Statistics - prevalence: monitoried and treated appropriately. and kidneys if pancreatitis is not detected, lungs, 766,000. 553,000; prescriptions: 881,000; hospitalizations: 1.1 million cases per year; ambulatory care visits: robust and cost efficient blood test for non-invasive, sensitive, there is a critical need for a comprehensive, Thus, Who will prescribe: especially at early stages. diagnostic and monitoring of pancreatic cancer and pancreatitis, surgeons and pathologists. general medicine physicians, Oncologists, opportunity for see the our product to be the 1st in class and the best-in- We is about $1 billion per year. Market class. PRODUCT PIPELINE BioChip and diagnostic test : Discovery R&D Cancer and Pancreatitis clinical Pancreatic Multiplex protein BioChip and immunochemistry assay/diagnostic test supported by proprietary algorithms. BioCrypton biopsy. urine, saliva, serum, BioChip assay is compatible with a range of patient samples (blood, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition
YEAR FOUNDED 2012 EMAIL [email protected] ADDRESS BioCrypton Inc., 300, Ste Ave., 290 Utah CA 94080 South San Francisco, CONTACT Ph.D. Ossovskaya, Valeria CSO CEO, BioCrypton WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued...... continued and encrypted data, web, HIPAA-compliant product will be integrated Health-IT module (novel algorithms, with cloud database). test : Early stage R&D Arthritis BioChip and diagnostic Arthritis. and blood based clinical diagnosticMultiplex protein BioChip test for and test : Early stage R&D Gastrointestinal BioChip diagnosticMultiplex protein BioChip and blood based clinical for test Colon cancer and other colon diseases blood based diagnostic test. “All-in-one” IBS). (Ulcerative colitis, OPPORTUNITES BioChip Diagnostic product R&D and pipeline BioCrypton Multiplex protein BioChip is lookig for Series A funding ($4million with milestones) Product: and immunochemistry BioChip assay is compatible assay/diagnostic test supported by proprietary algorithms. Product is integratedwith Health-IT module biopsy. urine, saliva, serum, with a range of patient samples (blood, IP: Strong portfolio of issued and cloud database). encrypted data, web, HIPAA-compliant (novel algorithms, (2) Gastrointestinal (GI) cancers and GI Product Pipeline: (1) Pancreatic Cancer and Pancreatitis. patents. Arthritis. (3) biochip assay). chronic diseases (“all-in-one” methods (Collaboration or co-licensing opportunity): Compositions and Platform Technology glycosylated glycosylated sites and O-GlcNAc enabling detection and characterization of O-GlcNAc proteins. Compositions and methods enabling detection and characterization of O-GlcNAc Platform Technology: Our technology is validated and applicable for robust glycosylated sites and O-GlcNAc glycosylated proteins. CNC, Alzheimer, including cancer, diagnostics clinical applications, and drug development in a number of originated at published in Caltech and methods are well validated, Our and diabetes. cardiovascular diseases, PNAS. Science, Nature, BioMarker Discovery program Our Biomarker program is comprehensive combination of discovery and characterization of biomarkers of In our biomarker program we are also offering a glycobiomarkers and histopathology services. diseases, blood etc) or we can collect biospecimens for your R&D significant collection of human biospecimens (tissue, clinical implementationaccording your specific goals with custom study design and precision medicine prohram. Our workflow directly integrated with global biobank which has operations at 90 clinical sites in 15 countries Our biobank has significant biorepository (about cases). 100,000 samples from ~7,000 individual around. translational medicine and diagnostics Biobank has 12 years of track record working with pharma in discovery, are providing an We CPTAC). network management Government (US) contracts and clinical (TCGA, areas, clinical regulatory affairs, study design, expertise in tissue research projects including tissue procurement, processing and analysis. specimen collection, network management, MANAGEMENT was Director Dr.Ossovskaya Prior , CSO and co- founder of BioCrypton. is CEO, Ph.D., Ossovskaya, Valeria From 2003 to 2009 of Sanofi Innovation Center and served as Director of R&D at Sanofi Global Oncology. served as a co-founder and Director of R&D at BiPar Sciences (acquired by Sanofi in 2009), Dr.Ossovskaya Prior to joining BiPar, where she established preclinical development and translational medicine programs. Her experience includes Assistant Research Professor at UCSF and Scientist at Rigel. served as Dr.Ossovskaya a number of collaborations and strategic alliance management with biotech and pharmaceutical companies, holds a B.S. Dr.Ossovskaya Technologies. and Oxford Gene Novartis, Janssen, including Johnson & Johnson, completed UICC molecular genetics fellowship at in Molecular Biology, a Ph.D. Virology and Biochemistry, in the University of Illinois at Chicago and postdoctoral training at departments of Pathology and Surgery at UCSF. BioCrypton, Inc. Inc. BioCrypton, www.biocrypton.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition
YEAR FOUNDED 2012 EMAIL [email protected] ADDRESS BioCrypton Inc., 300, Ste Ave., 290 Utah CA 94080 South San Francisco, CONTACT Ph.D. Ossovskaya, Valeria CSO CEO, BioCrypton WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ...continued journals and holds more than 35 published a number of scientific papers has in peer-reviewed Dr.Ossovskaya patents and patent applications. is Since 2003 Dr.Potapova is the President and co-founding partner of BioCrypton. Ph.D., Olga Potapova, a companies specializing in group of biotech and Scientific Director of Cureline Inc., Chief Executive Officer collaborating with major clinical centers in histopathology and translational medicine, human tissue research, (TCGA) NCI/NIH Atlas The Cancer Genome investigator is a principal at Dr.Potapova and the USA. Asia, Europe, Sugen/Pharmacia/ held various scientific positions at NIH, Dr.Potapova Prior to Cureline, program since 2010. She has been involved in multiple successful research programsof cancer including the development Pfizer. and multiple human biospecimen procurement, human prenatal diagnostic tests, therapy sunitinib (Sutent), is an international expert in strategic management alliance Dr.Potapova preclinical drug development programs. has Dr.Potapova in Biochemistry. degree in Physics and a Ph.D. She holds an M.S. and business collaborations. NIH and NATO. AACR/AFLAC, received multiple awards and fellowships from of Product Development Vice President joined BioCrypton team as Executive Ph.D., Mikhail Gishizky, broad experience in biotech and pharmaceutical expert and executive with is an Dr.Gishizky Advisor. and biopharmaceutical R&D and technologies that have drug therapies led to breakthrough and diagnostics. VP of was a co-founderhe served of Sugen where for 18 years in various positions including Dr.Gishizky served Dr.Gishizky After Sugen, Discovery the acquisitions by through Pharmacia and Pfizer. Target Research and Dr.Gishizky extensive leading in silico pathway analysis R&D programs. as Chief Scientific Officer at Entelos, translational research clinical bioinformatics, technology implementation, expertise includes drug development, IPO, business experiences also includes Dr.Gishizky at biotech startups and big pharmaceutical companies. from Gishizky received a B.A. Dr. pharmaceutical organizations. non-profit and FDA, liaison with government, San Francisco, in Endocrinology from the University of California, holds a Ph.D. University of California Berkeley, Angeles. Los and completed postdoctoral training at the University of California, servicesMacauley Johnson LLC provides comprehensive Chief Financial Officer to BioCrypton since October Macauleya biotech industry Johnson LLC has twenty-five years of finance and accounting experience in 2012. Private Committed Equity Financing, accounting and administrative functions, including start-up operations, BiPar Sciences, Previous biotech projects include VC funding. venture debt and IPOs, Investment in Public Equity, Chiron and Gilead among others. Athena Neurosciences, Therapeutics; Elan, Pain BioCrypton, Inc. Inc. BioCrypton, www.biocrypton.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition
YEAR FOUNDED 2012 EMAIL [email protected] ADDRESS BioCrypton Inc., 300, Ste Ave., 290 Utah CA 94080 South San Francisco, CONTACT Ph.D. Ossovskaya, Valeria CSO CEO, BioCrypton WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CEO Biophytis www.biophytis.com PROFILE COMPANY Its candidates therapeuticsBIOPHYTIS develops new derived from phytonutrients involved in ageing processes. AMD. with a focusand dry on Sarcopenic Obesity products, are both drug and nutraceutical PRODUCT PIPELINE regulatory PC drug candidate : : sarcopenia BIO103 : clinical nutraceutical candidate : obesity : sarcopenic BIO101 : regulatory PC drug candidate : geographic atrophy : BIO203 : clinical candidate nutraceutical : AMD : dry BIO201 : OPPORTUNITIES 15M€ round C investment in 2015 MANAGEMENT Stanislas Veillet, CSO René Lafont, COO Dioh, Waly CFO Montigny, J.C. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2006 EMAIL [email protected] TELEPHONE +33 14 183 6610 ADDRESS de l’OPERA 1 av. 75001 PARIS France CONTACT Stanislas Veillet CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Calypso Biotech SA Biotech Calypso www.calypsobiotech.com FINANCIAL SUMMARY ans is currently raising a 8.4 Mi Calypso initilal 2.5 Mi EUR funding from MS-Ventures Biotech SA has received of concept in patients to proof by 2018. CALY-002, one of its programs, A to bring EUR series PROFILE COMPANY discovers and develops spin-off a from Merck-Serono incorporated in Switzerland, Calypso Biotech SA, two best-in-class antibodies Our pipeline includes therapeutic antibodies for gastro-intestinal diseases. severe respectively. neutralizing matrix and Interleukin-15, metalloproteinase-9 PRODUCT PIPELINE : Preclinical CALY-001 Clearly differentiated from competitor GS-5745 (in Fully antibody. human selective and neutralizing anti-MMP-9 oncology of action. and fibrotic diseases) based on unique mode early clinical trials in IBD, IBD and immuno-oncology (combination with PD-1/PDL-1 blockade) Calypso Biotech indications: : Preclinical CALY-002 AMG-714 clinical Clearly superior to discontinued Humanized selective and neutralizing anti-IL-15 antibody. program. life threatening refractoryundisclosed niche celiac disease and other ultra-rare, Calypso Biotech indications: indications. OPPORTUNITIES Clearly differentiated from competitor Fully antibody. human selective and neutralizing anti-MMP-9 CALY-001 oncology and fibrotic diseases) based on unique mode of action. GS-5745 (in early clinical trials in IBD, IBD and immuno-oncology (combination with PD-1/PDL-1 blockade) Calypso Biotech indications: AMG-714 Clearly superior to discontinued Humanized selective and neutralizing anti-IL-15 antibody. CALY-002 clinical program. life threatening refractoryundisclosed niche celiac disease and other ultra-rare, Calypso Biotech indications: indications. MANAGEMENT PhD, Chief Executive Officer DVM, Vicari, Alain PhD, Chief Scientific Officer Chvatchko, Yolande 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2013 EMAIL [email protected] TELEPHONE +41-22-552-3307 ADDRESS 14 Aulx, Chemin des Plan-les-Ouates CH-1228 Geneva Switzerland CONTACT PhD DVM, Vicari, Alain CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
CTL’s completed and submitted PII results provide evidence of safety and efficacy. Average PII licensing deal and submitted PII results provide evidence of safety and efficacy. completed CTL’s Publication of PII results will drive M&A and upfront. value1 in 2013 was ~$643M total including ~$131M licensing interest. in-house to capture to optimise value CTL should complete the next clinical trial (Phase III) PIII a However, sale or IPO leading to a Big Pharma trade Total licensing deal1 which averaged ~1.7B ~$355M Upfront and in London. CTL seeks to diversify its shareholder base with sophisticated investors ahead of an IPO or In 2014, transaction in 2015. CTL offers a rare opportunity for UK Biotechnology investment in a world-class company with the innovation and management to captureoffering significant upside while near term commercialisation and EIS2 risk mitigation. Ltd. Cell Therapy www.celltherapyltd.com PROFILE COMPANY Therapy Ltd (CTL) is a Bio-Pharmaceutical company developing novel Objective: Founded in 2009 Cell CTL has discovered and developed four that in-house products are undergoing clinical Regenerative Medicines. Heartcel™w having late completed PIIa clinical trial in stage Heart failure. trials with lead product, innovation in-house has produced 2 platform technologies and fourproducts CTL’s Results: In just 5 years, (Clinical Professors American Society) and clinicians President of scientists (Nobel laureate, World-class Team: led by experienced pharmaceutical Toronto) Therapy from top universities Oxford and of Cardiac surgery Cell and active Board and Scientific advisory of global experts. committee management (ex-Roche), IP portfolio extensive was discovered and developed in-house with retention of commercial Approach: CTL’s IP and Close academic collaborations allow completion of trials in a fraction of normal time and cost. rights. Good results from Heartcel™ trial in 2014, clinical data carefully packaged for efficiency. transaction and tax three Skincel™ trials in 2015 and Orphan drug authorisation and marketing approval sought for 2016. optimise To product portfolio compares favourably with most listed stem cell companies. Opportunity: CTL’s CTL should complete final trials of Heartcel™ to gain Orphan drug approval. value creation from this portfolio, averageThe completed Heartcel™ trial might garner 2013 PII licensing deal value of ~$643M total including approval~$131M upfront1 but completing PIII and gaining may drives average valuation to over $1 Billion1. OPPORTUNITIES • • • • MANAGEMENT Chairman & Chief Scientific Officer CTL Sir Martin Evans, Prof. Ajan Reginald, Executive Director CTL Mr. Director CTL Lord Jones of Birmingham. Digby, CTL Audit and Governance Committee Director and Head of Rhodri Morgan, Mr. Director CTL Mubasher Sheikh, Dr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2009 EMAIL [email protected] ADDRESS Cardiff Gate Business Park Malthouse Avenue Pontprennau CF23 8RU Cardiff, UK Wales, CONTACT Ajan Reginald Mr. Executive Director CTL WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ellular Biomedicine Group, Inc. Group, Biomedicine Cellular www.cellbiomedgroup.com COMPANY PROFILE COMPANY Group is a biomedicine Cellular Biomedicine largest population, needs of the world’s Addressing unmet medical firm engaged of effective in the development cellular therapies for degenerative and airway joint diseases biomedical and cellular technical as well as providing immuno-oncology drugs for various cancers, diseases, Led by a seasoned management team and board with more than 150 services facilities in China. to healthcare it is the only pure-play NASDAQ-listed China market- and the USA, Europe, in China, years of relevant experience focused company. biomedicine developmental MANAGEMENT Chief Executive Officer Cao, William (Wei) Dr. Chairmain Liu, Steve (Wentao) Dr. Chief Financial Officer (Bizuo) Liu, Tony 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2009 EMAIL Investor Relations [email protected] TELEPHONE +1 650 566 5064 Vivian Chen +1 (646) 284-9427 ADDRESS 530 University Avenue Suite 17 Palo Alto, CA USA 94301, CONTACT Cao (Wei) William Dr. Chief Executive Officer Grayling Vivian Chen, USA) (New York, Investor Relations WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CFO Biotech DanDrit www.dandrit.com FINANCIAL SUMMARY Raised $12 million. Cash reserve for of operations 3 years PROFILE COMPANY an immunotherapy of colorectal cancer in to prevent recurrence MCV, develops DanDrit Biotech (OTCQB:DDRT) is a dendritic cell MCV patients Evidence of Disease (NED) after resection and chemotherapy. who reached No vaccine stimulates system to kill remaining or metastatic the immune cancer cells that could grow and lead to trial will start enrollment in March 2015. Phase III clinical ‘VIVA’ The relapse. PRODUCT PIPELINE Phase III CRC MCV, MANAGEMENT CEO MBA, MD, Eric Leire, Bob Wolfe, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2001 EMAIL [email protected] TELEPHONE +1 (646) 460 4077 ADDRESS PO Box 189 VT Randolph, 05060 United States CONTACT MBA MD, Eric Leire, CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CEO/CFO Senior Vice President Finance, Accounting & Controlling Vice President Finance, Senior AG Epigenomics www.epigenomics.com FINANCIAL SUMMARY ISIN DE000A1K0516) and (ECX, Prime Standard: Epigenomics is publiclyat listed the Frankfurt Stock Exchange, EPGNY). (OTCQX: ADR program in the U.S.A. has established a Level 1 website. For financial information refer to the Investor Relations please section of the Company’s PROFILE COMPANY diagnosticsEpigenomics is a molecular company developing and commercializing innovative products for cancer. to improved leading products enable to diagnose doctors cancer earlier and more accurately, The Company’s is a blood-based test forthe early detection Epi proColon®, Epigenomics’ lead product, outcomes for patients. has received approval by the Chinese Food and which is currently marketed in Europe, of colorectal cancer, Administration (FDA). Food and Drug Administration for China and is under regulatory review by the U.S. Drug in Europe. Epi proLung®, the Company markets its tissue assay for use in lung cancer diagnosis, Additionally, technology and products have been validated multiple partnerships with leading global through The Company’s Epigenomics is an international company with operations in diagnostic companies and testing laboratories. Europe and the U.S.A. PIPELINE PRODUCT Epi proColon® test which is currently marketed in is a blood-based test for the early detection of colorectal cancer, Epi proColon®, Administration for China and is under regulatory has received approval by the Chinese Food and Drug Europe, Administration (FDA). Food and Drug review by the U.S. Epi proLung® Epi proLung® is a tissue assay for use in lung cancer diagnosis in Europe. MANAGEMENT Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the and Europe. U.S. & Company) Burrill and Venture, Deutsche Therapies, (formerly Biotie Taapken Thomas The team is headed by Dr. Digene and Qiagen). Abbott Diagnostics, Uwe Staub (formerly Dr. Thomas Taapken, Dr. COO Uwe Staub, Dr. Epigenomics Inc. Noel Doheny, Albert Weber, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1998 EMAIL [email protected] TELEPHONE +49 30 24345-0 ADDRESS Geneststraße 5 10829 Berlin Germany CONTACT Thomas Taapken Dr. CEO/CFO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Head Modeling and Software Development Exploris Health AG Health Exploris www.exploris.info COMPANY PROFILE COMPANY in eDiagnostic solutions Exploris Health – A pioneer eDiagnosticCardioexplorer is a non-invasive test that timely detects patients with coronary artery disease. An been validatedCardioexplorer has already in a prospective clinical study at Hospital Basel. the University So far no other eDiagnostic approach has been able such reliable to produce additional study is underway. results. The convergence of biology computer engineering and information is turning healthcare into an based industry payers. physicians and bringing huge benefits to patients, that will be disruptive, Exploris Health provides physicians with an innovative platform of non-invasive eDiagnostic tests for detection of using easily available patient data and a routine blood test. life-threatening diseases, Exploris The aim is to establish gold standard CAD triage the Cardioexplorer test as the tool in primary care. health insurance company Helsana, including, institutions, Health has several partnerships with leading Swiss Additionally we are in advanced discussions with diagnostic companies. telecom provider Swisscom and others. increasing the efficiency of treating diseases at the earliest stage, Growing demand for better clinical outcomes, that are some of the major drivers the healthcare process and reducing healthcare costs are stated to propel this market. such The healthcare analytics market showcases a lucrative growth potential due to its several advantages, prevention of prediction and readmissions and hospitals stays, reduction of hospital as regulatory compliance, and prevention. claims processing quality care, chronic diseases, PRODUCT PIPELINE study : Successfully completed prospective clinical Test Cardioexplorer setting and in hospital invasive status - costly, Accurate diagnosis of CAD Coronary Reliable and early detection artery cause of death disease (CAD) is the leading in the developed world. diagnosis there is no non-invasive available, Until now, costs. of CAD is crucial to improve outcomes and reduce which directly assesses a life threatening the heart arteries (stenosis). narrowing of – A new gold standard eDiagnostic test for coronaryCardioexplorer heart disease the new gold standard stratification test for primary care physicians Exploris has developed Cardioexplorer, Cardioexplorer test The to timely detect patients with a high risk of developing coronary artery disease (CAD). Y/N). assesses the actual hemodynamic situation in the artery (stenosis Reduction in unnecessary yields substantial cost savings Cardioexplorer referrals and angiographies where pursuant to a avoids unnecessary referrals to a cardiologist for a costly and invasive angiography, recently patients published study in the New England Journal of Medicine in >30% of the no stenosis is which was published Exploris successfully completed a prospective clinical study with Cardioexplorer, detected. next to robust and reliable CAD diagnosis, Importantly, in the International Journal of Cardiology in 2014. Cardioexplorer shows low false positive and false negative rates. MANAGEMENT Founder / CEO Peter Ruff, Clinician / Cardiologist Michael Zellweger, Prof. Head Business Development Michael Failer, Dr. Andrew Tsirkin, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition TELEPHONE +41 44 283 29 21 ADDRESS Exploris AG 52 Toedistrasse 8002 Zurich Switzerland CONTACT Peter Ruff Founder / CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
Galecto Biotech AG Biotech Galecto www.galecto.com PROFILE COMPANY inflammation and other Galecto Biotech is focusedon developing novel drugs for the treatment of fibrosis, which are a binding lectins, products target galectins or galactoside The company’s serious human diseases. potency Galectin high Galecto Biotech’s groupto be involved in many of proteins shown disease processes. The company is led by top-level scientists Modulators maytreatment open new possibilities for many patients. Sunstone Capital and SEED Ventures*, MS Galecto Biotech is funded by Novo Seeds, and biotech executives. close proximity to the founders’ with research Denmark, is located Galecto Biotech in Copenhagen, Capital. groups. announced that Galecto Biotech it has entered into an option agreement with Bristol-Myers 2014, In November, Squibb for a total potential payment of $444 million. PRODUCT PIPELINE TD139 Inhalable for small molecule Galectin-3 inhibitor in development the treatment of idiopathic pulmonary fibrosis MANAGEMENT CEO Schambye, T. Hans Dr. COO Anders Pedersen, CMO Paul Ford, Dr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE +45 70 70 52 10 ADDRESS Cobis Science Park 3 Vej Ole Maaloes DK-2200 Copenhagen Denmark CONTACT Schambye T. Hans Dr. CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued...
3C23K, a humanized mAb in pre-IND stage which binds to AMHRII, an unaddressed target specifically AMHRII, mAb in pre-IND stage a humanized which binds to 3C23K, 3C23K increases dramatically complete responses in pertinent in vivo expressed in gynecological cancers. ovarian cancer models, including granulosa cells tumors and AMHRII program, Ovary and other gynecologic cancers (endometrium) for registrationmucinous ovarian cancer with potential fast-track An expansion cohort with 3C23K in combination with chemotherapy in resistant gynecological tumors (n=25-30) SA Pharma GamaMabs www.gamamabs.com FINANCIAL SUMMARY France). GamaMabs raised a €3.6m series-A led by(Bpifrance, Innobio PROFILE COMPANY GamaMabs is a private biopharmaceutical company French dedicated of original to the development optimized in cancer. monoclonal antibodies (mAbs) from 3 sources: originates GamaMabs’ innovation • Access to glyco-engineering Emabling® technology which enhances antibodies’ efficacy • HER3 fully-human optimized mAbs. potential: “best-in-class” • Follow-on program with needs indications: high therapeutic GamaMabs addresses • Breast cancer and pancreatic cancer for HER3 program Triple-Negative • GamaMabs’ experienced management track record in Biotech / Pharma. has a successful PRODUCT PIPELINE 3C23K : Pre-IND 3C23K is a first-in-class monoclonal antibody directed the receptor of the anti-Müllerian hormone against including target widelyAMHRII is a pertinent unaddressed expressed in gynecologic cancers, (AMHRII / MISIIR). cervix and endometrial cancer patients’ adenocarcinoma samples. ovarian cancer, increasing their ability immune cells, 3C23K is a glyco-engineered mAb which leverages tumor-associated as these effector cells are Ovarian cancer is a clinical setting well-suited for 3C23K, to destroy tumor cells. dominant in patients’ samples. This efficacy is also shown to 3C23K displayspatho-mimetic a high efficacy in multiple relevant in vivo models. translating into the first lines chemotherapeutic agents, be synergistic with carboplatin (CT) and paclitaxel (PT), outstanding improvement in Complete Response (CR) and survival. 3C23K has Application being scheduled in Q3 2015. Trial its Clinical 3C23K is in the pre-IND stage, demonstrated a particularly safe profile in regulatory preclinical studies. H4B-121: Preclinical H4B-121 leverages immune H4B-121 is a glyco-engineered fully human monoclonal antibody targeting HER3. cells and displays outstanding in vitro and in vivo efficacy. OPPORTUNITIES Investment in series-B financing GamaMabs is looking to raise €9m+ to finance 3C23K early clinical trials up to initial proof of concept. will be completed for all preclinical activities 3C23K (financed by previous At targeted closing (2Q2015), financing round). including: 2017, This series-B proceeds will finance the company up to year-end A dose escalation phase Ia with 3C23K in gynecological cancers – – agentAn expansion cohort with 3C23K as a single in granulosa tumors (n=15) – scenario amounts to €9m. “3C23K-only” The financing needs for a 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2013 TELEPHONE +33 (0)5 31 61 60 69 ADDRESS Centre Pierre Potier 1 place Pierre Potier ONCOPOLE entrée B Toulouse BP 50624 - 31106 Cedex 1 FRANCE CONTACT Stéphane Degove, CEO (co-founder) WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
...continued SA Pharma GamaMabs www.gamamabs.com VP R&D and Strategy (co-founder) MD, Jean-François PROST, developed and/or He discovered, UCB pharma and LFB). Pierre Fabre, Leads the R&D of several European Pharmas (Servier, LFB he contributed to develop the At Wilfact. Keppra and Ixel, Valdoxan, Artex, Procoralan, registered in Europe/US Protelos, roledumabublituximab (anti-D) and (CD20). Emabling® technology and two Emabling® mAbs up to phase II: Senior Advisor MD, Oncology Anne Bousseau, chain, She developed expertise all along the value industryHas more than 25 years’ experience in the pharmaceutical R&D. In having served Oncology early and late development in global R&D at successively Sanofi. as Discovery program head (AIDS), Anne was heading the Oncology early development teams. her last position, ADC/T cell engager partnering on AMHRII ADC/T cell engager partnering ADC through collaborationsAMHR2 on Gamamabsleverage is looking to its know-how and antibodies targeting AMHR2. T cell engager programs targeting or engagerT cell technologies and interested in ADC or biotech or pharma with validatedThe targeted partners are a target specific of gynecological cancers. MANAGEMENT Stéphane Degove, CEO (co-founder) He was a co-founder & CFO of Strategy Consulting (OC&C) and in biotech. Has 18 years’ experience in Pharma (Sanofi), Endotis Pharma where he raised €37m. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2013 TELEPHONE +33 (0)5 31 61 60 69 ADDRESS Centre Pierre Potier 1 place Pierre Potier ONCOPOLE entrée B Toulouse BP 50624 - 31106 Cedex 1 FRANCE CONTACT Stéphane Degove, CEO (co-founder) WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u 1 Size Market Market $2bn $2bn $200m $525m $2bn $4bn Continued... 2015 2015 H1 2015 H1 H1 H2 2015 H2 Results expected H2 2015 H2 2015 H1 DevelopingDeveloping patient patientdiagnosticsdiagnostics&& centric centricdevices devices technologies.com - readout Status studies brown@glide - bioequivalence bioequivalence 2015 trial
Preclinical equivalence Preclinical Awaiting clinical Awaiting Clinical Preclinical studies Feasibility studies Feasibility Development mark.carnegie vaccine* vaccine* * anthrax vaccine * anthrax flu octreotide Pfenex Partner programmes © Glide Pharma 2015 Pharma Glide © SDI® parathyroid hormone SDI® parathyroid Prostate cancer diagnostic cancer Prostate SDI® SDI® SDI® GLP1 agonist Seasonal Pipeline * Technologies Glide www.glide-technologies.com Glide octreotide : Clinical bioequivalence trial 2015 Glide octreotide : Clinical bioequivalence octreotide solid dose formulation results in a pre-clinical proof-of- achieved successful In mid-2014 Glide’s Glide recently announced concept study comparing it with the currently product (Sandostatin®). marketed liquid Albany Molecular Research Inc for manufacture forplace in a clinical study targeted to take the appointment of the second half of 2015. readout clinical ‘PROSPECT’ prostate cancer diagnostic : Awaiting Glide In July worldwide licence to an innovative 2014 Glide announced it had taken an exclusive non-invasive prostate ‘Prospect’ the technology is being developed initially Renamed cancer diagnostic technology from FScan Ltd. as a ‘Prospect’ longer term the company In the intends to develop as an analyte-specific reagent in the USA. diagnostic test and to pursue regulatory approvals in the US and in Europe. equivalence Glide parathyroid hormone (PTH) : Preclinical Biomedical Catalyst for the development of a novel In November 2012 Glide was awarded £2.3m by the UK’s targeted A preclinical PK study is solid dose formulation of teriparatide (PTH) for the treatment of osteoporosis. for completion in Q2 2015. studies : Preclinical Glide Anthrax Vaccine April 2013 Glide was awarded a development contract by Pfenex Inc to develop a solid dose formulation In in whole with The Pfenex projectis funded antigen (‘rPA’). Anthrax bacillus recombinant protective containing the Precinical studies will Allergy and Infectious Diseases (’NIAID’). Federal Funds from the US National Institute of continue during 2015. studies Glide GLP1 agonist : Feasibility Glide is continuing its exploration of the solid dose formulation platform for the delivery of therapeutics currently The field of GLP-1 agonists is attracting a great deal of commercial and attention self-administered by patients. proof-of-principle formulation data with exenatide are being generated throughout 2015. FINANCIAL SUMMARY in 5 rounds £14m Invesco Perpetual Feb 2013. £11m invested pre 2013 PROFILE COMPANY octreotide solid dose Glide’s is a clinical stage device and diagnosticbusiness. development Technologies Glide injection generatesdata clinical Q4 2015 and its prostate cancer diagnostic generates initial clinical read out Q1 intends to complete a £15m funding 2015 Glide pipeline includes peptides and vaccines. The preclinical 2015. enabling trials and partnering. three clinical POC PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European Portfolio
1 Size Market Market $2bn $4bn $200m $2bn $2bn $525m
8th Annual European Life Science CEO Forum & Exhibition
YEAR FOUNDED 2001 EMAIL mark.carnegie-brown @glide-technologies.com CONTACT Dr Mark Carnegie-Brown Chief Executive Officer 2015 2015
H1 2015 H1 H2 2015 H2 H2 H1 2015 H1 H1 H2 2015 H2 Results expected DevelopingDeveloping patient patientdiagnosticsdiagnostics&& centric centric devicesdevices technologies.com - readout Status studies brown@glide - bioequivalence bioequivalence 2015 trial Feasibility studies Feasibility Development Clinical clinical Awaiting equivalence Preclinical Preclinical studies Feasibility mark.carnegie vaccine* vaccine* * anthrax vaccine * anthrax flu octreotide Pfenex Partner programmes © Glide Pharma 2015 Pharma Glide © Pipeline SDI® diagnostic cancer Prostate hormone SDI® parathyroid SDI® SDI® GLP1 agonist Seasonal * Portfolio WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Business Development Director ...continued Glide Technologies Technologies Glide www.glide-technologies.com OPPORTUNITIES • £15m Fundraising 2015 • octreotide SDI® beyond Licensing – Partner to advance clinical PoC • parathyroid Licensing – Partner to co-develop hormone SDI® after preclinical result< MANAGEMENT Chairman Mr Bryan Morton, Chief Executive Officer Dr Mark Carnegie-Brown, Chief Financial Officer Mr Richard Bungay, Development & Operations Director Dr Genevieve Motte, Mills, Dr Tony 8th ANNUAL & Exhibition Forum CEO Science Life European 1 Size Market Market $2bn $4bn $200m $2bn $2bn $525m
8th Annual European Life Science CEO Forum & Exhibition
YEAR FOUNDED 2001 EMAIL mark.carnegie-brown @glide-technologies.com CONTACT Dr Mark Carnegie-Brown Chief Executive Officer 2015 2015
H1 2015 H1 H2 2015 H2 H2 H1 2015 H1 H1 H2 2015 H2 Results expected DevelopingDeveloping patient patient centric centric devices devices & & diagnostics diagnostics technologies.com - readout Status studies brown@glide - bioequivalence bioequivalence 2015 trial Feasibility studies Feasibility Development Clinical clinical Awaiting equivalence Preclinical Preclinical studies Feasibility mark.carnegie vaccine* * anthrax vaccine * anthrax flu octreotide Pfenex Partner programmes © Glide Pharma 2015 Pharma Glide © Pipeline SDI® diagnostic cancer Prostate hormone SDI® parathyroid SDI® SDI® GLP1 agonist Seasonal * Portfolio WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
Hansa Medical AB Medical Hansa www.hansamedical.com FINANCIAL SUMMARY TSEK -17,629 2013 TSEK -24,709, Operatiing profit 2014 PROFILE COMPANY Lead project companyHansa Medical is a biopharmaceutical focused on novel immunomodulatory enzymes. in transplantation with potential use and rare IdeS is an antibody-degrading enzyme in clinical development, share (HMED) is listed on Hansa Medical’s Sweden. The company is based in Lund, autoimmune diseases. Adviser. AB as Certified with Remium Nordic Nasdaq First North in Stockholm PRODUCT PIPELINE IdeS : Clinical phase II is a a unique molecule with a novel mechanism, IdeS, IdeS bacterial enzyme that cleaves human IgG antibodies. IdeS swiftly and efficiently. degrades all IgG specifically, has been tested for in vitro safety and efficacy in numerous clinical trial on a Phase I During 2013, and in vivo models. demonstrating IdeS as 29 healthy subjects was conducted, efficacious and well tolerated with a favorable safety profile. a Phase II clinical trial in sensitized During 2014 and 2015, patients awaiting kidney transplantation has been conducted. Preliminary data shows that IdeS has very efficacy in good The highly sensitized patients on the kidney transplant waitlist. study shows that IdeS has the capacity patients to make sensitized eligible for transplantation by decreasing HLA IdeS has potential indications In addition to transplantation, antibodies to levels acceptable for transplantation. IdeS is protected by several patents anti-GBM disease. within a variety of rare autoimmune diseases including journals. and has been published in numerous peer review MANAGEMENT President and CEO Fredrik Lindgren, Corporate Development Director DR. Emanuel Björne, Christian Kjellman, Chief Scientific Officer Dr Lena WIndstedt, Clinical Research Director 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 TELEPHONE +46 46 16 56 70 ADDRESS Hansa Medical AB Box 785 P.O. SE-220 07 Lund Sweden CONTACT Fredrik Lindgren President and CEO HansaMedical WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Helsinn Healthcare SA Healthcare Helsinn www.helsinn.com PROFILE COMPANY privately owned pharmaceutical group focused quality cancer care with on building Helsinn is a family run, Helsinn also has Switzerland, Founded in 1976 with headquarters in Lugano, a large portfolio of products. business model is Helsinn’s the USA and a representative office in China. operatingIreland, subsidiaries in supplement products in the medical devices and nutritional focusedof pharmaceuticals, on the licensing therapeutic care. area of cancer development by completing their performing early-to-lateHelsinn Group in-licenses stage new chemical entities, then prepares necessary Helsinn as well as associatedpre-clinical/clinical studies manufacturing activities. products are out-licensed to its Helsinn’s regulatory filings in order to achieve marketing approvals worldwide. thatglobal network of marketing and commercial partners have been selected for their local market knowledge. Helsinn supports these partners by of product and scientific management providing a full range services, Helsinn has built a large product portfolio of and medical marketing advice. regulatory, including commercial, Helsinn established a new In March 2013, global partners. cancer care products with the alliance of over 65 conduct direct sales in order to Inc., Therapeutics (U.S.), Helsinn commercial organization within its subsidiary, products are manufactured according to the highest Helsinn’s market. and marketing activities within the U.S. in Switzerland and Ireland from where GMP facilities and environmental standards at Helsinn’s safety, quality, Further information on Helsinn Group is available at www. they are then supplied worldwide to customers. helsinn.com OPPORTUNITIES strategy/collaborations Partnering Purpose of our participation identification to the meeting is the of in licensing opportunities in the fields of Cancer Pain & Inflammation. G.I., Oncology, Supportive Care, In addition we are also looking for late stagebe commercialized directly products to in the US. MANAGEMENT Group CEO Riccardo Braglia, Group General Manager and COO Giorgio Calderari, Head of Corporate Business Development Roberto De Ponti, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1976 EMAIL [email protected] TELEPHONE +41 (0) 91 985.21.21 ADDRESS Helsinn Healthcare SA Via Pian Scairolo 9 6912 Lugano/Pazzallo Switzerland CONTACT Roberto De Ponti Head of Corporate Business Development WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Therapeutics Heptares www.heptares.com FINANCIAL SUMMARY A and Series B venture financing rounds. Series USD60m raised in seed, PROFILE COMPANY a superfamily of drug Heptares creates transformative (GPCRs), medicines targeting G protein-coupled receptors Our proprietary drug design technology structure-based range of human diseases. receptors linked to a wide Using this GPCRs. yet historically undruggable or challenging, enables us to engineer for drugs highly validated, we havepotential to transform an exciting pipeline of new medicines with the built the treatment of approach, Our pharmaceutical partners and other diseases. migraine, schizophrenia, diabetes, ADHD, disease, Alzheimer’s MVM Ventures, and we are backed by Clarus AstraZeneca and MedImmune, Takeda, MorphoSys, include Cubist, Ventures. Takeda the Stanley Family Foundation and Fund, Venture Novartis Life Science Partners, PRODUCT PIPELINE Selective muscarinic M1 receptor agonist (Phase 1) Schizophrenia disease, Alzheimer’s disease and other disorders of Alzheimer’s First selective muscarinic M1 receptor agonist for treatment of cognitive impairment. M4 and Dual M1/M4 receptor agonists (preclinical) diseases and other Alzheimer’s Psychosis in Schizophrenia, First-in-class selective M4 agonists for the treatment and related of psychosis behavioural & psychiatric Dual M1/M4 agonists for patients with co-morbid psychosis and cognitive impairment. symptoms. A2A receptor antagonists (late preclinical) Adenosine Attention ADD, disorders ADHD, Novel small molecule antagonists that selectively enhance dopaminergic transmission in key regions of the effective with superior safety and non-stimulant fast-acting, profile is once daily, Target ADHD. brain linked to current agents. tolerability vs. CGRP antagonists (preclinical) & Prophylaxis Treatment Migraine a Novel oral/intra-nasal small molecule antagonists of the calcitonin gene-related peptide (CGRP) receptor, clinically validated mechanism for treating & preventing migraine attacks. GPR39 agonists (preclinical) 2 Diabetes Type a novel and biologically validated mechanism for improving glycaemic First oral small molecule GPR39 agonist, control and preventing disease progression via preservation of islet cell function. GLP-1 agonists (preclinical) 2 Diabetes Type mechanism for GLP-1 is a breakthrough controlling glycaemia and reducing First oral once-daily GLP-1 agonist. weight in patients with type 2 diabetes. Orexin 1 antagonists (preclinical/discovery) Addiction Nicotine Binge Eating, First selective Orexin 1 subtype receptor antagonist for treatment of addiction and compulsive disorders. mGlu5 receptor modulator (preclinical/discovery) Dyskinesia Depression, Autism, pharmacokinetics Novel mGluR5 receptor negative allosteric modulator with potential best-in-class selectivity, and safety. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] ADDRESS BioPark Broadwater Road Garden City Welwyn AL7 3AX TELEPHONE +44 (0)1707 358 628 CONTACT Malcolm Weir CEO UK WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
CEO and co-founder CMO & VP Development CMO & ...continued Therapeutics Heptares www.heptares.com OPPORTUNITIES receptor agonistSelective muscarinic M1 agonistsM4 and Dual M1/M4 receptor antagonistsA2A receptor Adenosine CGRP antagonists GPR39 agonists MANAGEMENT Malcolm Weir, CSO and co-founder Fiona Marshall, President Daniel Grau, Tasker, Tim CBO Barry Kenny, VP Chemistry MIles Congreve, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] ADDRESS BioPark Broadwater Road Garden City Welwyn AL7 3AX TELEPHONE +44 (0)1707 358 628 CONTACT Malcolm Weir CEO UK WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Histide AG Histide www.histide.com COMPANY PROFILE COMPANY a novel therapy using non-mutagenic extracellular Therapeutics™, Histide™ is pioneering Recoding technologies to direct cell fate. HistideTM of the mechanisms underlyingBased on the universal understanding behavior, mammalian cell has created an innovative platform of complex microenvironments with the capacitydictate to the precise These include cells from different origins tissue and at contrasted types. commitment of various cell ranging from stem cells to specialized mature cells. differentiation stages, a broad and disruptive intellectual property portfolioHistide™ has developed Molecules™, including Recoding Therapeutical Development being a technological break-through with vast Micro-environmental Design and medical devices and medical cosmetics. indication spectra of pharmaceuticals, Histide™ has developed strong international collaborations with leading Universities and Based in Europe, and technologyInstitutes around the globe in order to make its expertise known and promote the Recoding Therapeutics™. PRODUCT PIPELINE Cell Recoding Molecule - Oncology : Discovery extracellular recoding of neoplastic cells into healthy cells. Non-mutagenic, Regeneration : DiscoveryCell Recoding Molecule - Tissue extracellular regeneration of any type of human tissue. Non-mutagenic, OPPORTUNITIES Oncology Out-Licensing Specific targeted CRP molecules to heal differentof cancer. types Regeneration Out-Licensing Tissue Specific targeted CRP molecules to regenerate combinations) tissue (drug-device MANAGEMENT Chairman; Exec. Romain Julia, CEO Florian Kemmerich, CSO Zouani, Omar F. Dr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2014 EMAIL [email protected] ADDRESS HISTIDE AG Chaltenbodenstrasse 8 8834 Schindellegi Switzerland CONTACTS Romain Julia Chairman Exec. Florian Kemmerich CEO Zouani Omar F. Dr. CSO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ImmunID www.immunid.com FINANCIAL SUMMARY $ millions in grants. several $5m investments, PROFILE COMPANY immune molecular diagnosticsImmunID is a pioneer of diagnostics aiming to set the global immune standard. The company atT cell repertoire diversity the genomic level. evaluates the Its clinical product ImmunTraCkeR and blue-chip clinical centers and provides testing worldwide to leading is ISO9001/ISO13485 accredited pharmaceutical companies. and ImmunIg are proprietary immune molecular diagnostics test analysing and quantifying ImmunTraCkeR repertoire diversity and ImmunIg measures B-Cell T-Cell measures ImmunTraCkeR immune competence. DNA. repertoire diversity using multi-N-plex qPCR on genomic Current clinical research and confidential cooperations. Sanofi-Pasteur, Current industrial customers are Roche, Asia. US and customers in Europe, MANAGEMENT Chairman and CEO PhD, Bernhard Sixt, Kurt Schmidt, Chief Financial Officer 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2005 EMAIL [email protected] TELEPHONE +33 0 438 785 770 ADDRESS ImmunID parvis Néel Louis 7, BP50 38040 Grenoble France CONTACTS PhD Bernhard Sixt, Chairman and CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Dir Marketing & Strategy VP Operations CEO VP R&D Immunomic Therapeutics, Inc. Therapeutics, Immunomic www.immunomix.com Dr. Tim Tim Coleman, Dr. Heiland, Teri Dr. Ms. Sia Anagnostou, Dir Business Development Colin Magowan, Mr. Acting CFO Bernie Rudnick, Mr. FINANCIAL SUMMARY A Preferred Therapeutics has raised over $17 million in private equities most recently with a Series Immunomic Astellas Pharma with The Company recently transaction with closed on a licensing round of $7 million (2014). payment$15 million as an upfront and CMC support. clinical pllus and an additional $55 million in milestones The Companyto open a Series B round in 2015. is expecting PROFILE COMPANY Therapeutics is developing next generation focus vaccines with a particular on allergy using our Immunomic has been shown in the clinic Technology Our LAMP-vax Platform. Technology patented and proprietary LAMP Our current lead products are for responses to targets in allergy and oncology. T-cell to induce potent helper in Japan JRC-LAMP-vax) which is being advanced through the clinic Japanese red cedar pollen (ASP4070, Therapy is a unique approach to Vaccine Allergy Our Allergy. and forAstellas Pharma Peanut with our partner, In addition to our treating allergy in allergy and represents the first true advance therapy in over 100 years. Immunomics also has a relationship in animal health for Astellas, recent licensing and collaborative deal with Therapeutics Immunomic Asterias (formerly with Geron). canine atopic dermatitis and for a cancer vaccine with is currently a privately held company options for but is exploring funding 2015 and beyond. PRODUCT PIPELINE : Phase I/II / Allergy Vaccine JRC-LAMP-vax The JRC-LAMP-vax (ASP4070 in Japan) formulated is a DNA vaccine to treat allergy caused by red cedar pollen. The first Company plans to apply the vaccine to also treat cedar and juniper & cypress tree species. mountain clinical studies showed that 4 bi-weekly skin treatments in 100% of the subjects converting from skin resulted product will be entering the clinic in JapanThe in 2015 under the test positive to skin test negative by month 8. for mountain cedar. Astellas Pharma and in the U.S. guidance of : Phase I ARA-LAMP-vax The Company plans to ARA-LAMP-vax is a DNA vaccine formulated to treat food allergy caused by peanuts. The product is begin subjects then in moderately Phase I clinical studies in 2015 first in healthy allergic adults. The Company has a pre- formulated as an allergy vaccine therapeuticsgiven and will be as four doses biweekly. will be filing the complete IND IND meeting on the proposed study in March and by the end of Q3. OPPORTUNITIES Platform LAMP-Vax T-cells. LAMP-vax can be widely applied to stimulate the immune system via MHC-II presentation and helper The CD4+ mediated has had success in allergy response has been documented in multiple clinical studies and it has been shown to be effective in animal health applications for In addition, and oncological applications. The technology is supported by a substantial literature portfolio. allergy and for infectious diseases. MANAGEMENT William Hearl, Dr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2006 EMAIL [email protected] TELEPHONE +1 717 327 1919 ADDRESS 1214 Research Blvd, Hershey, Suite 2016, 17036 PA CONTACT William Hearl Dr. CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... ISA101 : Phase II the E6 and E7 oncogenic amino acids long) derived from ISA101 consists of 13 synthetic long peptides (25-35 forThis strain is responsible 50% of human cervical cervical cancers and intra- proteins of the HPV 16 virus. anal cancers and premalignant head and neck cancers, epithelial neoplasias and more than 85% of HPV-positive It is administered either subcutaneously AIN). or anal lesions (termed anal intra-epthelial neoplasia, HPV-induced or intradermally. establishing clinical proof-of-concept. ISA101 has completed a Phase II trial in vulvar intra-epithelial neoplasia, development in clinical ISA101 has completed a Phase I/II trial and has entered into further In cervical cancer, a Phase I/II trial in patients in 2013. with anal intra-epithelial neoplasia (AIN) has started In addition, 2013. ISA203 : Preclinical Antigen in MElanoma) and is useful ISA203 is derived from the human antigen PRAME (PReferentially expressed ISA203 consists of synthetic long peptides (SLP®) conjugated to for the treatment of different type of cancers. AMPLIVANT®. proprietary adjuvant ISA’s expression and association with proliferation makes PRAME attractive to develop an The tumor-specific cancer cells would not be able PRAME-expressing to escape from immunotherapy for multiple indications. which in turn unless the cells would down-regulate PRAME expression, PRAME-directed cell-mediated immunity, would decrease their aggressiveness. ISA204 : Preclinical ISA204 is a combination conserved of selected Synthetic Long Peptides (SLP®s) derived from regions of It is designed as an effective immunotherapy adjuvant technology. AMPLIVANT® hepatitis B antigens with ISA’s T cell response againstmultiple and avoids virus escape mutants by inducing a for the entire patient population, conserved viral antigens. ISA204 is capable of inducing an effective immune response against hepatitis B virus (HBV)-infected cells by and It can be easily combined with the current standard of care, avoiding immune tolerance and viral resistance. aims to induce sterilizing immunity against HBV. ISA Pharmaceuticals www.isa-pharma.com PROFILE COMPANY fully synthetic is an immunotherapy company developing rationally designed, ISA Pharmaceuticals B.V. The company has built a proprietary immunotherapeutics against and persistent viral infections. cancer technology, AMPLIVANT® immunotherapy platform and on the Synthetic Long Peptide (SLP®) concept based Synthetic long which enable the generation safe and effective of of action. drugs with a known mechanism components as essential peptides are broadly applicable to multiple targets and ideally suited for monotherapy, SLP® immunotherapies and as novel immunomodulators. in combination cancer treatments, with conventional are capable of fully disease. the fighting and directing the body‘s own defenses towards harnessing PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2004 EMAIL [email protected] TELEPHONE +31 71 33 22 310 ADDRESS Oortweg 19 J.H. NL-2333 CH Leiden The Netherlands CONTACTS Ronald Loggers CEO Cornelis (Kees) Melief CSO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Combine with Check point control blockers, preclinical work demonstrates synergy in established HPV-tumor preclinical work demonstrates synergy in established HPV-tumor Combine with Check point control blockers, models preclinical and clinical data demonstrate the synergy in established HPV-tumor Combine with Chemotherapies, models ...continued Conjugates : Phase I SLP®-AMPLIVANT® They are system. of the immune (TLRL) are among the most powerful stimulants receptor ligands Toll-like inflammation, including infections, byinvolved in all diseases caused a deregulation of the immune system, in a much more chemicallyTLRs act defined way than atherosclerosis and cancer. autoimmune diseases, adjuvants. Alum and (incomplete) Freund’s conventionally like used adjuvants TLR ligand (TLR1/2 ligand) by by changes guided crystallographic ISA has substantially a known improved structure modeling of the ligand receptor interaction. TLR ligands to its SLP® ISA Pharmaceuticals has conjugated this newly developed proprietary class of Moreover, conjugates have to 1000-fold been shown to be 100- more These SLP®-AMPLIVANT® immunotherapeutics. to unconjugatedpotent in inducing an immune response compared SLP®s in preclinical and mouse tumor models. OPPORTUNITIES ISA101 partnering Actively pipeline. seeking partners to expand current clinical • New indications • • licensing SLP® Technology 50 Between 20 to synthetic peptides. off-the-shelf, SLP® immunotherapeutics are rationally designed, ISA’s and hence are optimal for they are longer than conventional peptide immunotherapeutics, amino acids in length, the greater length of SLP®s Furthermore, an efficient and prolonged presentation cells. by antigen-presenting thereby enabling an SLP® immunotherapeutic allows the full array to be used, of HLA alleles (no HLA-restriction) typical SLP® product A irrespective of individual HLA types. to activate the immune system of all human beings, It thereby covers the most immunogenic contains between 4 and 13 different carefully peptides. selected long T cell regions of a therapeutic target and contains epitopes for the efficient induction of both CD4 and CD8 responses. No ex vivo manipulation of dendritic off-the-shelf compounds. SLP® immunotherapeutics are fully synthetic, is achieved directly because efficient DC-targeting in vivo. cells (DC) is required, licensing Technology MPLIVANT® TLR1/2 ligand with technology comprises a proprietary and synthetic small molecule AMPLIVANT® ISA’s enhanced immunostimulatory activity that chemically has been coupled to the peptide in the standard SLP® conjugates allow lower dosing at higher efficacy through better SLP®-AMPLIVANT® manufacturing process. T cell priming. dendritic cell antigen processing and presentation as well as enhanced but also to any other type of targeted This technology is not only applicable to all SLP® immunotherapeutics, technology improves the AMPLIVANT® ISA Pharmaceuticals´ significantly enhancing its efficacy. immunotherapy, immuno-stimulatory potency of SLP® based immunotherapeutics 100- to 1000-fold. TLR ligand-coupled antigen and conjugates mediate cell targeting with the direct dendritic AMPLIVANT® T cell response effective antigen presentation and leading to long-term, activation of these dendritic cells, induction. Strategic partnering/investment opportunity MANAGEMENT CEO Ronald Loggers, CSO Cornelis (Kees) Melief, acting CMO Richard (Rick) Stead, ISA Pharmaceuticals www.isa-pharma.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2004 EMAIL [email protected] TELEPHONE +31 71 33 22 310 ADDRESS Oortweg 19 J.H. NL-2333 CH Leiden The Netherlands CONTACTS Ronald Loggers CEO Cornelis (Kees) Melief CSO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Head of Chemistry Therapeutics Karus www.karustherapeutics.com FINANCIAL SUMMARY Wyvern IP Group, 2005 Seed Round (£0.75m): others Angels, Esperante, IP Group, (£4m): investments Various 2007 - 2011 A/S Novo Partners, Venture New Leaf SV Life Sciences, (£ND): VC investment 2012 Series B PROFILE COMPANY Therapeuticsis a leader in the development of innovative medicines that have breakthrough potential in Karus treating inflammatory disease and cancer. from scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, The Company’s which innovative have clinical and commercial potential small molecule drugs with significant been developed. The UK-based Company is privately-held financial track record and experienced investors including with a strong A/S and IP Group. Novo Ventures, New Leaf SV Life Sciences, developing Therapeutics is led by a strong management team with considerable experience of building, Karus America. and partnering therapeutic assets in Europe and North PRODUCT PIPELINE complete KA2237 : Preclinical Dual-selective PI3K-p110bd inhibitor for the treatment tumors (immuo-oncology) of solid and hematological including DLBCL. tumors, KA1463 : Preclinical PV, EBA, incuding RA, Dual-selective PI3K-p110bd inhibitor for the treatment complex disorders, of immune etc. MG, NMO, KAR3000 inflammation : Candidate Nomination Potent and selective HDAC6 inhibitor for the treatment a broad range of inflammatory of disorders and transplantation rejection. KAR3000 cancer Potent and selective HDAC6 inhibitor for the treatment a broad range of hematological of malignancises with a focus on Multiple Myeloma ad GvHD MANAGEMENT Chief Executive Officer Dr Simon Kerry, Prof Stephen J Shuttleworth, Chief Scientific Officer Dr Chief Medical Officer Penny Ward, Finance Director Mr Simon Jones, Head of Development Dr Simon Roitt, Head of Biology Dr Peter Finan, Coulter, Dr Tom Head of Preclinical Dr Elisabeth Bone, and Safety Pharmacology Toxicology Head of Dr Kemal Haque, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2006 EMAIL [email protected] TELEPHONE +44 (0)1235 829140 ADDRESS 93 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ CONTACT Dr Simon Kerry Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... – $5.4 million revenue for 2014 – $9.6 million net loss for (unaudited) 2014 2014 / 13.7 M fully– 11.8M shares undiluted diluted & outstanding December 31, – Series D Offering – Estimated close Q2 2015 KineMed www.kinemed.com FINANCIAL SUMMARY 2014 cash equivalents at• $5.1 million cash and December 31, • $12.5M • $58.5M pre PROFILE COMPANY revenue-generatinga is KineMed technologyhealth company thatproprietarya developed has proteomics kinetic Our efficiency and cost-effectiveness of drug development. biomarker platform that can improve the quality, making clinical outcomes, biomarkers capture the underlying are predictive of longer-term causes of disease and Our predictive biomarker tests them particularly valuable trials in humans. in FDA Phase 2 proof-of-concept what are are designed to rapidly establish pathway, working as intended on a targeted whether a drug lead is what the best dose and regimen the most responsive disease indications and patient populations for the lead, and whether a companion diagnostic test would how the candidate compares to competitive therapies, is, our biomarker platform also are designed to enable more For approved drugs, help the drug to gain approval. personalized medical care PRODUCT PIPELINE Noscapine ALS : IND – New therapeutic use for the microtubule-modulating agent noscapine DM neuropathy PD, ALS, – US Patent allowed for Rx – Based on pre-clinical biomarkers of neuronal transport ALS small and rapid biomarker studies – Phase 1B/2A 7-week trial • 30 patients, • H2 2015 Preclinical FX-5A Cardiovascular: ApoA1 by maximizing FX-5A is a 37 amino acid peptide designed to mimic the anti-atherosclerotic activities of FX-5A the major transporter of cholesterol. ABCA1, the mobilization of cholesterol from macrophages via By substituting five non-polaramino acids on ApoA1. peptide is bi-helical peptide based on the sequence of 5A) the lipid affinity of the second helix is its name, (hence the hydrophobic face of one helix with alanine, ABCA1. specificity reducing cytotoxicity and increasing for removing cholesterol from cells via diminished, Extensive pre-clinical and clinical trial data exists demonstrating reductions in atheroma volume after 5 Efficacy: ApoA1 mimetic activity of FX-5A has been extensively characterized The ApoA1 and HDL mimetics. treatments of FX-5A reduces atherosclerosis and vascular in preclinical studies performed by leading academic researchers. inflammation in animal models. the major protein ApoA1, Therapy have utilized normal and modified full length Acute HDL Clinical trials of showing that a short course can significantly reduce atherosclerotic plaque size and volume. component of HDL, based on recombinant and CSL-112, Cer-001 There are currently two HDL mimetics in clinical development, respectively. ApoA1, and human plasma derived full length activates multiple pathways which have cardiovascular in vivo, Preclinical studies confirm that FX-5A peptide, been shown to increase reverse cholesterol transport (RCT) FX-5A has benefits normally associated with HDL. two indicators of cholesterol mobilization from plaques and reversal and macrophage specific cholesterol efflux, 5A increases RCT in a dose-dependent manner indistinguishable from the In rat studies, of atherosclerosis. HDL). ApoA1 (reconstituted result obtained using human ApoE-KO mice to Intravenous administration of the 5A peptide complexed with phospholipid was found in indicating that 5A shares many of the same beneficial antiatherogenic and reduce atherosclerosis, promote RCT, ApoA-I in HDL therapy. ApoA-I and may be a suitable substitute for features of 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2001 TELEPHONE +1 510 655 6525 ADDRESS 5980 Horton Street Suite 470 Emeryville CA 94608 USA CONTACT Doyle Patrick J. Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Executive Vice President, Research & Development Vice President, Executive ...continued OPPORTUNITIES FX-5A Out ApoA1 by maximizing peptide designed to mimic the anti-atheroscleroticFX-5A is a 37 amino acid activities of FX-5A transporter of cholesterol. the major ABCA1, the mobilization from macrophages of cholesterol via five non-polaramino acids on By substituting ApoA1. based on the sequence of peptide is bi-helical peptide affinity of the second helix is 5A) the lipid (hence its name, helix with alanine, the hydrophobic face of one ABCA1. reducing cytotoxicity and increasing specificity for removing cholesterol from cells via diminished, Extensive pre-clinical and clinical trial data exists demonstrating reductions in atheroma volume after 5 Efficacy ApoA1 mimetic activity of FX-5A has been extensively characterized The ApoA1 and HDL mimetics. treatments of FX-5A reduces atherosclerosis and vascular in preclinical studies performed by leading academic researchers. inflammation in animal models. the major protein ApoA1, Therapy have normal and modified full length utilized Acute HDL Clinical trials of showing that a short course can significantly reduce volume. atherosclerotic plaque size and component of HDL, on recombinant based and CSL-112, Cer-001 There are currently two HDL mimetics in clinical development, respectively. ApoA1, and human plasma derived full length activates multiple pathways which have cardiovascular in vivo, Preclinical studies confirm that FX-5A peptide, (RCT) FX-5A has been shown to increase reverse cholesterol transport benefits normally associated with HDL. two indicators of cholesterol mobilizationreversal from plaques and and macrophage specific cholesterol efflux, RCT in a dose-dependent manner indistinguishable 5A increases from the In rat studies, of atherosclerosis. ApoA1 (reconstituted HDL). result obtained using human ApoE-KO mice to Intravenous administration with phospholipid was found of the 5A peptide complexed in indicating that 5A shares manyantiatherogenic of the same beneficial and reduce atherosclerosis, promote RCT, ApoA-I in HDL therapy. ApoA-I and may be a suitable substitute for features of Noscapine ALS Out noscapine New therapeutic use for the microtubule-modulating agent: DM neuropathy PD, ALS, – US Patent allowed for Rx – Based on pre-clinical biomarkers of neuronal transport ALS small and rapid biomarker studies – Phase 1B/2A 7-week trial • 30 patients, • H2 2015 Liver Fibrosis NASH Biomarkers of fatty in contemporary liver disease and NASH has become one of the highest priorities drug Treatment capture blood test has the potential to the rate of disease activity in liver fibrosis non- KineMed’s development. invasively and can potentially of drug candidates answer the two central questions holding back testing in fatty 1) which patients are at for risk progression (who to treat) and 2) whether a treatment is liver disease and NASH: working (identifying early whether a drug is working). are presently liver disease with key conducting several clinical studies in fibrotic opinion leaders from We The aim of these studies is to clinically validate our blood test of liver fibrosis in different academic medicine. sets of patients. have initiated clinical studies with three academic leaders in fatty liver disease and fibrosis that serveWe 1) to demonstrate early response of The goal of these studies is: several purposes with regard to validation. our biomarker to therapeutic interventions that fibrosis; 2) to show that reduce our tests identify who are the who needs anti-fibrotic treatment); and 3) to show the technical rapid progressors with fatty liver disease (i.e., we have several Additionally, reproducibility and analytic robustness of our non-invasive biomarker tests. including scleroderma. submitted publications from our work in liver disease and other fibrotic conditions, MANAGEMENT and Director Chief Executive Officer Chairman of the Board, Fineman, David M. Chief Scientific Officer and Director President, Hellerstein, Marc K. Chief Business Officer Doyle, Patrick J. Chief Financial Officer Loar, Matthew M. President of Muscle and Health Division Evans, William J. Scott Turner, KineMed www.kinemed.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2001 TELEPHONE +1 510 655 6525 ADDRESS 5980 Horton Street Suite 470 Emeryville CA 94608 USA CONTACT Doyle Patrick J. Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... al v o ppr A US r o f DA d F e r i u w/ q e ed ng eted eted ope e 2 i R l l r s p p u a plet E eet m m h m P Trial in M eted Co Co o r l l 2 n C o a p f l al al o n e i m a t n o i Tri Tri o a o Tri C has ti tr b a dit P s a 2 2 2 1 i d r f e e e e A a o s s s s eg e a a a a R ep n h h r h h nd n O P P P I P P E Kuros Biosurgery AG Biosurgery Kuros www.kuros.ch KUR-023 : Registration KUR-023 is a synthetic sealant for application to the dura during cranial and spinal surgeries. KUR-023 has successful completed a 41 patient clinical study in Europe and is being prepared for CE- For US registration a US pivotal study. Kuros intends to complete marking. Kuros has extensive granted patents and patent applications covering KUR-023 and its synthetic sealant technologies. KUR-111 : Phase III KUR-111 is an orthobiologic being developed for bone regeneration in trauma. KUR-111 will compete in the $3bn per annum bone graft substitute market of which >$1.5bn is US. It is currently being prepared KUR-111 has completed a Phase IIb study in which it met its primary endpoints. for entry into a Phase III study. Kuros has extensive patents and patent applications covering KUR-115 and its related fibrin technologies. KUR-113 : Phase III KUR-113 is a bone growth a currently promoter design to improve fracture healing and addresses under- developed market that Kuros estimates has the potential to be greater than $2bn worldwide. A Phase IIB study involving approximately 200 patients has demonstrated superiority to standard of care in The product would need to complete Phase III prior to market authorization. open tibial shaft fracture healing. Kuros has extensive patents and patent applications covering KUR-113 and its related fibrin technologies. COMPANY PROFILE COMPANY AG is dedicated to the development of innovative biologicand biomaterial-based product Kuros Biosurgery The company sealants and surgical wounds. candidates for localized therapy in the fields of orthobiologics, (ETH) and University of Technology was founded is a spin-off in 2002 and from the Swiss Federal Institute of Zurich. Kuros Biosurgerya broad pipeline of clinical stage has products based on its biomaterial and biologic Kuros’ priority programs are: technology platforms. sealant which has successfullyA synthetic clinical study and is being completed a European KUR-023 – prepared for CE Mark. KUR-111 – an orthobiologic that has demonstrated to autograft non-inferiority in a large Phase IIb study. KUR-115 – an orthobiologic that testing and is designed to have has completed preclinical equivalent efficacy, than gold standard and other leading products. but be safer, NeoMed Management and CDC Innovation. Incubator, Venture investors include: The company’s Regeneration. Tissue Areas of activity:Biomaterials and PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 TELEPHONE +41 (0)44 200 56 00 ADDRESS Kuros Biosurgery AG 1 Technoparkstrasse CH-8005 Zurich Switzerland CONTACT Didier Cowling Mr. Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Chief Business Officer Kuros Biosurgery AG Biosurgery Kuros www.kuros.ch Chief Technology Officer Technology Jason Schense, Chief Dr. ...continued KUR-115 : Phase II (peak sales ~$800M) in InFuse™ and improve on, KUR-115 is an orthobiologic to compete with, designed spinal fusion. meeting has been held with the A pre-IND forKUR-115 is being prepared entry into a Phase II clinical study. FDA. Kuros has extensive patents patent and applications covering KUR-115 and its related fibrin technologies KUR-212 : Phase II KUR-212 is designed to be the first product for surgical that wounds both adheres skin grafts (avoiding the use of sutures or staples) closure which in turn (reducing the time to wound and improves wound healing reduces infection and potentially reduces hospital stay). patientsKUR-212 has completed a Phase IIa study in burns with a Phase IIb dosing study being the next development stage. MANAGEMENT Didier Cowling, Chief Executive Officer Mr. Alistair Irvine, Dr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 TELEPHONE +41 (0)44 200 56 00 ADDRESS Kuros Biosurgery AG 1 Technoparkstrasse CH-8005 Zurich Switzerland CONTACT Didier Cowling Mr. Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u VP Research and Development Pharma Lanthio www.lanthiopharma.com FINANCIAL SUMMARY 2012 4.8M Eur A November Series PROFILE COMPANY companyLanthio Pharma is a biopharmaceutical focusing on the discovery of therapeutic and development proprietary Based on its LanthioPep technology the company a pipeline of constrained is building peptides. lanthionines not only Introduction of with improved drug-like properties. lanthionine containing peptides improves the proteolytic stability specificity and activity. of peptides but also leads to enhanced receptor for in preclinical development is a selective angiotensin II type 2 receptor agonist, LP2, lead product, Lanthio’s lung and kidney fibrosis OPPORTUNITIES receptor agonist LP2 – Selective AT2 receptor of the renin-angiotensin system. AT-2 LP-2 is a lanthionine-stabilized highly specific agonist of the anti-inflammatory activity. and anti-fibrotic receptor is associated with tissue protection, AT2 Activation of the In-vivo studies haves and kidney shown promising results in lung fibrosis models and LP2 is currently in First-in-man studies are scheduled to commence in 2015. preclinical development for organ fibrosis. – Selective MAS receptor agonist PanCyte using Angiotensin-(1-7) is an agonistic peptide that was discovered by Lanthio Pharma, Lanthionine-stabilized The compound is stable and resistant to angiotensin-convertingenzyme. its proprietary LanthioPep technology. Pancyte has high specificity shows increased intrinsic activity compared to wild-type for the MAS receptor and Angiotensin-(1-7). diabetic ischemia and stroke. PanCyte has therapeuticdiseases, potential in cardiovascular agonist lanthipeptide apelin – Selective APJ receptor Based on the natural apelin proteolytically ligand Lanthio Pharma is developing stabilized lanthipeptide apelin Several analogs have been selected for in-vivo testing in myocardial infarction and heart failure analogs. models. MANAGEMENT CEO MBA, PhD, Heinz Schwer, CSO PhD, Gert Moll, CMO PhD, MD, Jessica Mann, PhD, Sjoerd Wadman, VP Business Development PhD, Michiel Lodder, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2012 EMAIL [email protected] TELEPHONE +31 50 30 50 240 ADDRESS AS Groningen 9700 PO Box 719, 9727 DL Rozenburglaan 13 B, Groningen The Netherlands CONTACTS MBA PhD, Heinz Schwer, CEO PhD MD, Jessica Mann, CMO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Pioneer in the photonic integration of optical coherence tomography (8+ yr. experience) and with a strong background in Pioneer in the photonic integration of optical coherence tomography (8+ yr. business administration and management. S.L. MedLumics www.medlumics.com COMPANY PROFILE COMPANY providing of execution in RF ablationMedLumics solves the problem for atrial fibrillation arrhythmias, and other companyThe is developing a therapeutic accurate local navigation real-time assessment of lesion formation. and clear showing reached pre-clinical validation, The design has Tomography. catheter guided by Optical Coherence direct visualizationnecrosis and size prediction in thick of detection of lesion borders, contact quantification, ventricle walls. a clinical version of its catheterMedLumics is now developing for in 2016. first-in-human work MANAGEMENT PhD, President & CEO Eduardo Margallo, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2011 ADDRESS Medlumics S.L. TELEPHONE +34 91 803 39 25 EMAIL [email protected] [email protected] CONTACT Eduardo Margallo 1E Ronda de Poniente 16 – Cantos 28760 Tres SPAIN WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... 967 EBITDA (ke) 3200 -1567 7156 -1953 26512 7210 Revenue (ke) 2018 PROFILE COMPANY Business Description: working to bringing top-endocrinologist Mendor is a next generation diabetes technology company, & solution in real time. hands, & provider’s decision making into patient’s and from Mendor & strips, blood glucose meter revenue comes from the sales of Mendor Discreet® Mendor’s A Service). As ONE service solution (Software & Devices Menarini 1st product (BGM) is currently & China through partners: being sold in 16 EU countries Mendor’s Tagene. Mediq and Diagnostics, individual and outcome driven. vision is a world where diabetes care is integrated, Mendor’s Products/Solutions: Mendor ONE™ - new game changing digital & wireless glucose monitoring & diabetes management solution, 1. patient smartphone app and strips/lancets with home cloud software, consisting of a cellular glucose meter, paid by the payers and used by diabetes clinics & patients. all with a fixed monthly fee, delivery, enabling meter on the market, first true all-in-one blood glucose Mendor Discreet blood glucose meter – the 2. daily blood glucose. measurements of discreet and user-friendly Markets: Target and 1 & 2 diabetics on injectable drugs needing frequent monitoring & management, Type segment is Target glucose monitoring (€9b) and an emerging markets are: Target being a major cost & risk segment in diabetes. diabetes management for outcome driven care (€6b) Barriers to Entry: as well as Barriers to entry technologies include slow adoption of new & solution offerings by payers & providers, Sanofi etc. Roche, major players such as J&J. Customer Pipeline: Mediq (Baltics) and Tampere (major payer in Finland), City of Menarini Diagnostics, Sanofi, Current customers: Medical (China), Tagene Competition/Substitution: There are currently only two competing companies offering a holistic glucose monitoring & diabetes (US) & Telcare in the market: management solution with wireless connectivity and individual data driven care, Livongo (US). Mendor www.mendor.com FINANCIAL SUMMARY 2Me€ revenue: 12 mo. Trailing e <300k€ Monthly Net Burn: 2017 Breakeven Date: e€17 M Capital Raised to Date: 3,5M government soft-debt / e venture debt) 6,5Me€ (3Me Debt: Life Science Finnvera, Biothom, pension fund, Ilmarinen Industry Investment, Siilasmaa, Risto Current Investors: Partners Angels (LSP), Financials 2015 2016 2017 14272 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2006 EMAIL [email protected] TELEPHONE +358 45 345 1970 ADDRESS 25, Munkkiniemen puistotie 00330 Helsinki, Finland CONTACT Kristian Ranta CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u VP Q&R – ex GE ...continued Business Model: glucose monitors and strips as a service Mendor sells with a fixed A Service (SDAAS). As Software and Devices Each patient gets a personal meter for with a subscription of unlimited 2-3 years monthly fee directly to payers. cloud software & smartphone app.test strips & licenses to use for R&D): Future Products (Pipeline insulin pump & CGM adding eg. Software development, 2nd generation integrated glucose meter. wireless compatibility & support for clinics & patients. cities Distribution/Sales Model: Sales through distributors and sales directly to payers companies, (insurance and pharma). Global FTO patents More filed and pending. USA & China. Key patents granted in EU, Technologies/IP: validated by several research reports. PRODUCT PIPELINE Mendor ONE™ : On the market a consisting of New game changing digital & diabetes & wireless glucose monitoring management solution, all with a patient smartphone app and strips/lancets with home delivery, cloud software, cellular glucose meter, paid by the payers and used by diabetes clinics & patients. fixed monthly fee, market Mendor Discreet blood glucose meter : On the daily enabling discreet and user-friendly market, The first true all-in-one blood glucose meter on the measurements of blood glucose. MANAGEMENT CRF Health CEO – ex. Kristian Ranta, CTO – ex LifeScan head of R&D Oliver Davies, Minna Isotalus, CFO – ex PwC & E&Y VP Production – ex Flextronics Jukka Lehtinen, Niina Vilkas, Mendor www.mendor.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2006 EMAIL [email protected] TELEPHONE +358 45 345 1970 ADDRESS 25, Munkkiniemen puistotie 00330 Helsinki, Finland CONTACT Kristian Ranta CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Pharmaceuticals Metys www.metys-pharma.ch FINANCIAL SUMMARY repayable valued at in shares 20% totalling CHF 1.2 million as convertible loan, Seed investment rounds A closing. discount to pre-money valuation agreed at Series to raise CHF 18 million. A round intends Series A investment. as tradesale or IPO foreseenA investor exit of Series 2.5 to 3 years after signing Series PROFILE COMPANY developing dimiracetam forMetys Pharmaceuticals is the prevention and treatmentchemotherapy-induced of neuropathic pain. PRODUCT PIPELINE Dimiracetam a Dimiracetam is an orally than 180 subjects’ safety and tolerability active small molecule with more data, and an open IND. more than 75 kg of GMP drug substance, complete preclinical safety package, including drug-induced neuropathy models. neuropathicDimiracetam is active in multiple animal models of pain, the effect becomes more Dimiracetam is effective repeated after a single oral dose; with twice-daily dosing, effect not does dimriacetam’s and unlike pregabalin, Dimiracetam is more effective than pregabalin, persistent. there is no evidence of tachyphylaxis. wane with prolonged use: This is believed to prevent and to reverse Dimiracetam acts by blocking glutamate-induced glutamate release. glutamate-dependent long term potentiation at only the first and anatomical site where a peripheral axon connects to spinal neurons in the spinal dorsal horn. for trial of dimiracetam the prevention of oxaliplatin-induced Metys Pharmaceuticals is preparing the DISTALL dose-ranging study of three multi-center, placebo-controlled, is a randomized, DISTALL peripheral neuropathy. different dose levels of dimiracetam in 184 patients treated twice-daily for three months at the outset of their The primaryweekly endpoint is the change from baseline in the average score of oxaliplatin-treatment regimen. a patient-reported numeric rating scale of oxaliplatin-induced neuropathy symptoms. OPPORTUNITIES prevention of oxaliplatin-induced peripheral neuropathy Dimiracetam, MANAGEMENT CEO & Founder Michael Scherz, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2013 TELEPHONE Michael Scherz +41 79 408 79 82 EMAIL [email protected] ADDRESS Steinenring 8, CH-4051 Basel CONTACT Michael Scherz Officer Founder & Chief Executive WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Chief Business Officer Midatech Pharma PLC Pharma Midatech www.midatechpharma.com Dr Daniel Palmer, Chief Scientific Officer Dr Daniel Palmer, Head of Manufacturing Mr Justin Barry, COMPANY PROFILE COMPANY high- Midatech company is a nanomedicine focused on the development and commercialisation of multiple, targeted therapies for major diseases with unmet medical need. value, Midatechcandiatespipeline of novel clinical and pre-clinical product is advancing a its proprietary based on drug conjugate release delivery and sustained platforms with a clear focus key on the therapeutic areas of strategy to develop its products in-house in is Midatech’s and neuroscience/opthalmology. cancer, diabetes, and to accelerate growth business through strategic of its in other indications, rare cancers and with partners acquisition of complementary products and technologies. MANAGEMENT Chief Executive Officer Dr Jim Phillips, Chief Medical Officer and Chief Operating Officer Dr Craig Cook, Finance Director Mr Nick Robbins-Cherry, Dr Tim Sparey, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition EMAIL [email protected] TELEPHONE 44 (0)1235 841 575 ADDRESS Milton Park Innovation Centre 99 Park Drive Milton Park Abingdon Oxfordshire OX14 4RY United Kingdom CONTACT Dr Jim Phillips Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Therapeutics Mirna www.mirnarx.com COMPANY PROFILE COMPANY Inc. (Mirna) is a clinical-stage company biopharmaceutical developing a broad pipeline of Mirna Therapeutics, oncologyleading microRNA-based therapeutics. Replacement Therapy that has is the first microRNA MRX34, candidate, lead product Mirna’s deliver a mimic of the naturally MRX34 was designed to patients. testing in cancer into clinical advanced MRX34 a wide variety of cancers. which is under expressed in suppressor miR-34, occurring microRNA tumor open-label Phase 1 trial in 2013 and is currentlyentered clinical testing in being studied in a multicenter, The Phase 1 clinical patients with unresectable primaryinvolvement. liver cancer or solid cancers with liver trial is expected to enroll approximately 120 patientsalso includes a separate and cohort of patients with Results of the Phase 1 clinical trial are expected in late 2015. hematological malignancies. natural ability to fight cancer on multiple levels, body’s microRNA Replacement Therapy restores the by replacing cancer stem cells and metastasis, tumor growth, including repression of tumor immune evasion, naturally occurring tumor suppressor microRNAs that under expressed in cancer cells with microRNA are Controlling these multiple cancer pathways may also reduce the risk of the development of drug mimics. one of the more prevalent problems of modern cancer therapies. resistance, suppressor microRNA mimics have great potential as cancer therapeutics capacity due to their to Tumor to other as compared regulate many different oncogenes across multiple pathways as well as to repress PD-L1, targeted cancer therapies that affect only or oncogenic pathways. one or two oncogenes patent portfolio relating to its proprietary microRNA mimics technology consists of ten issued U.S. Mirna’s patents that include cancer and non-cancer therapeutic claims related use to 15 tumor suppressor microRNAs and foreign pending patent applications that it either owns or in-licenses from third and more than 100 U.S. significant funding from New has received TX, Austin, founded in 2007 and located in The company, parties. Mirna is also Ventures and other private investors. Sofinnova Venture Investments, Pfizer Associates, Enterprise and from CPRIT. Fund, Technology Emerging the State’s both through Texas, funded by the State of MANAGEMENT Chief Business Officer Casi DeYoung, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] TELEPHONE +1 512 901 0900 ADDRESS 100 Suite St., Woodward 2150 TX Austin, 78744 USA CONTACT Casi DeYoung Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Ltd. Therapeutics Misson www.missiontherapeutics.com Chief Executive Officer of MISSION Therapeutics. He has extensive experience from business and corporate He development Therapeutics. Chief Executive Officer of MISSION He has a comprehensive diabetes and anti-infectives. as well as R&D in several key therapeutic areas including oncology, and has been responsible for and acquisitions within biotech, successful mergers international experience and network, as well as an big pharma, large biotech and His background includes biotech startups, venture investments and licensing. initial career in academia. Chief Executive Officer of Prosidion 2015, ASA from 2013 to Pharma He was Chief Executive Officer and President of Bionor of Prosidion in the US and President Inc. Vice President OSI Pharmaceuticals Executive Limited in the UK from 2003 to 2005, from OSI Pharmaceuticals Inc., Vice President Corporate & Business Development, He was Executive Ltd from 2005 to 2009. He has previously held positions as Managing Director at acquisition of OSI in 2010. Astellas Pharmaceutical Inc’s 2009 until Anker Denmark. Director at and as Business Development Novo Nordisk, Switzerland, OSI Pharmaceuticals venture arm in Zug, PhD and DMSc qualifications in medical microbiology. has MD, COMPANY PROFILE COMPANY Therapeutics is a specialist biopharmaceutical company aim is to translate (SME) whose new molecular MISSION cell biologyunderstandings of human into drugs that will markedly improve the management of life-threatening particularly cancer. diseases, Therapeutics is developing a broad platform of technologies for the discovery and further development MISSION The company will predominantly of first-in-class modulators enzymes involved in cancer and other diseases. of the deubiquitylating in particular research emergingexploit the new and exciting on ubiquitin pathways, Therapeutics’ scientists MISSION thatcontrol many cellular responses including DNA damage. enzymes (DUBs), building on their experience in exploiting the are developing drugs to inhibit the proliferation of tumour cells, now an established and powerful mechanism to selectively kill genetically defined concepts of synthetic lethality, Moreover MISSION is exploiting is DUB drug discovery platform (Ubi-SphereTM) and expertise in order cancers. including neurodegeneration out with cancer, for DUBs across several therapeutic areas, to identify chemistry’s and muscle wasting. MANAGEMENT Anker Lundemose, CEO 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE +44 (0)1223 497 454 ADDRESS Babraham Research Campus Moneta (Building 280) Cambridge CB22 3AT United Kingdom CONTACT Anker Lundemose CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Roche. That I clinical trials in 2013. compound completed Phase Roche. / Novimmune SA Novimmune www.novimmune.com FINANCIAL SUMMARY financial information is confidential. development stage company, As Novimmune is a privately owned, PROFILE COMPANY Novimmune is a drug discovery and development company focused on the creation of antibody-based drugs for and cancer. immune-related disorders, the targeted treatment of inflammatory diseases, has generated Novimmune several therapeutic to treat antibodies designed immune-related disorders date, To the immune-oncologyand is now poised to enter space with new products that cancer. aim to fight specific for clinically validated and novel targets. compounds, The pipeline is a balance of preclinical and clinical Each of these portfolio becoming a medicine for products has the potential of multiple medical conditions due to the intrinsic mechanism of action. Five of these compounds are currently in early with the three most advanced in clinical clinical development Acute bispecific antibody programs against Novimmune has initiatedtwo internal, In addition, Phase II. as well as other oncology targets to yet be announced. Lymphoma, Leukemia and Non-Hodgkin’s Lymphocytic hope with the express The company has also been purposefully of orphan drug indications, targeting a number of eventually providing safe and effective treatment to some of the often neglected populations options suffering from rare diseases. indicatesWhere the mechanism of action of a discovered antibody broader applications or multiple indications, In 2010, companies. compound with larger pharmaceutical Novimmune has partnered the development of the the company signed an exclusive partnering agreement with to co-develop its NI-1401 compound for example, Genentech Novimmune has developed two unique and proprietary antibody generation In addition to these compounds, platforms — a monoclonal antibody platform antibody platform and a bispecific — designed to streamline the technology Novimmune makes these and characterization of fully-human antibodies. production, identification, platforms available to create unique antibodies for pharmaceutical companies. outside in recognition of being the European Award Novimmune received the European Biotechnica In 2009, “the greatest future potential.” biotechnology company with and maintains strong ties to a Switzerland, The company is based in the Plan-les-Ouates suburb of Geneva, the University of Geneva. including number of academic research institutions, PRODUCT PIPELINE NI-0501 : Phase II Pilot NI-0501 is a fully human monoclonal antibody discovered and developed by Novimmune as a potent inhibitor in which the drug candidate was well I clinical trials, Novimmune advanced NI-0501 through Phase of IFNy. tolerated at therapeutically relevant doses. A Phase II clinical trial of NI-0501 in patients with hemophagocytic lymphohistiocytosis is currently recruiting study participants. NI-0101 : Phase I TLR4 NI-0101 monoclonal antibody potently suppresses inflammatory reactions by blocking Novimmune’s signaling driven by the previously mentioned ligands. Tumor Necrosis Factor- TLR4 leads to release of many of inflammatory types modulators including Activation of through the These responses help to isolate and clear bacteria and, alpha (TNF-a) and Interleukin-6 (IL-6). adaptive immune system heighten resistance of the host in the event of re-infection. and including sepsis, TLR4 signaling can provoke various acute inflammatory conditions, abnormal However, atherosclerosis, arthritis, among others, has been implicated in various chronic inflammatorydiseases including, II diabetes have Type Even obesity and and contact dermatitis. transplant rejection, osteoporosis, lupus, asthma, TLR4 signaling. been linked to excessive forNI-0101 has completed as successful phase I trial in healthy volunteers and an IND phase II will be submitted in Q1 2015 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1998 EMAIL [email protected] TELEPHONE +41 22 839 71 41 ADDRESS Aulx 14 Chemin des 1228 Plan-Les-Ouates Geneva Switzerland CONTACT Adrian Mills Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ENA- / Continued... MIP-2a, CXCL5 MIP-2a, / Gro-a, CXCL2 Gro-a, / II open-label study in renal allograft / IL-8, TNF, IL-1, IL-6, G-CSF, GM-CSF, antimicrobial peptides, and matrix metalloproteinases. antimicrobial peptides, GM-CSF, G-CSF, IL-6, IL-1, TNF, IL-8, / ...continued Novimmune SA Novimmune www.novimmune.com NI-1701 : Pre-clinical A bispecific antibody that may enhance tumor killing without collateral damage cancer NI-1701 is intended to fight tumor cells using antibody by luring our immune system to seek and destroy mediated immunotherapy. acting therapeutic antibodies have been injected into patients in order to attach to the cancer cells, For decades, the targets in a process “eat” kill and such as macrophages or neutrophils, so that immune cells, “flags” as attachingThis process involves the antibody through its two Fab arms to the tumor cells and called phagocytosis. tail (the Fc portion). bridging to the immune cell via the antibody’s One method is by overexpressing the cancer cells often adapt and trick the immune system to back off. However, the Indeed, macrophages to leave them alone. “tell” hijacking the means by healthy cells which CD47, protein, the worse the prognosis for the patient across a variety of cancers. more CD47 expressed by a tumor, signal is an excellent therapeutic strategy except for fact that the “don’t eat me” blocking the CD47 Thus, healthy cells also express this protein. The bispecific nature of the kappa-lambda body offers solution to overcoming tumor resistance to a three-armed antibody therapies. foralumab : Phase II NI-0401, responses by T-cell to alter auto-aggressive NI-0401 monoclonal antibody (mAb) is intended Novimmune’s receptor complex through binding with the CD3 epsilon receptor. T-cell targeting the and a Phase I disease, A Phase I and Phase IIa clinical trial in Crohn’s transplantation have been completed. NI-1401 : Phase I NI-1401 is an anti-IL17 monclonal antibody. in which they induce the release Interleukin-17 affects non-immune target cells, a broad range of immune and such as CXCL1 of neutrophil-attracting chemokines and other mediators, 78, CXCL8 78, including rheumatoid IL-17 has been linked to a wide variety of autoimmune and inflammatory diseases, They may also play a role and allograft rejection. lupus, psoriasis, inflammatory diseases, bowel asthma, arthritis, in anti-tumor immunity. OPPORTUNITIES NI-0101 TLR4 NI-0101 monoclonal antibody potently suppresses inflammatory reactions by blocking Novimmune’s signaling driven by the previously mentioned ligands. Tumor Necrosis Factor- TLR4 leads to release of many of inflammatory types modulators including Activation of through the These responses help to isolate and clear bacteria and, alpha (TNF-y) and Interleukin-6 (IL-6). adaptive immune system heighten resistance of the host in the event of re-infection. and including sepsis, TLR4 signaling can provoke various acute inflammatory conditions, abnormal However, atherosclerosis, arthritis, among others, has been implicated in various chronic inflammatorydiseases including, II diabetes have Type Even obesity and and contact dermatitis. transplant rejection, osteoporosis, lupus, asthma, TLR4 signaling. been linked to excessive forNI-0101 has completed as successful phase I trial in healthy volunteers and an IND phase II will be submitted in Q1 2015 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1998 EMAIL [email protected] TELEPHONE +41 22 839 71 41 ADDRESS Aulx 14 Chemin des 1228 Plan-Les-Ouates Geneva Switzerland CONTACT Adrian Mills Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ...continued Novimmune SA Novimmune www.novimmune.com Director of Legal Affairs, Admininstration, & Intellectual Property Admininstration, Affairs, Director of Legal Nathalie Muller, Prior to joining including legal affairs and intellectual property. Administration, Director Nathalie Muller is Novimmune’s She previously worked for the Affairs for Medabiotech. Administration and Legal Nathalie was Head of Novimmune in 2000, administrative and HR issues for the United and handled legal, Legal and Intellectual Property Department of Debiopharm, Nations and the International Labour Organization. Cristina de Min, Chief Medical Officer Cristina de Min, expereince and has been the Chief Medical Officer Cristina de Min has over 15 years of drug development at Novimmune also responsible for where she was the global Cristina held various leadership positions at Roche, Previously, since May 2010. development of a series of compounds primarily endocrine diseases. targeting autoimmune and Chief Scientific Officer Marie Kosco-Vilbois, With over 25 years of experience, joining the company in 2002. Chief Scientific Officer, Marie Kosco-Vilbois is Novimmune’s she was previously Head of Immunology and preclinical pharmacology at the Serono Pharmaceutical Research Institute, of the Basel Institute and a Scientific Member for Research Institute in Geneva, Wellcome Head of Immunology at the Glaxo Immunology. Chief Business Officer Adrian Mills, Most recently he was the EU Commercial Adrian Mills joined Novimmune in July 2014 after an extensive career with GSK. Adrian has over 20 years of experience in life sciences leading Director in the Rare & Critical Diseases Business Unit. Adrian worked in consulting Prior to GSK, strategy development and commercial operations. commercial functions in both R&D, (Booz & Co) and investment banking (Schroders) advising life sciences companies. Jack Barbut has been Chief Executive Officer at Novimmune since 2000. With more than 30 years of professional experience With more than 30 years of professional Jack Barbut has been Chief Executive Officer at Novimmune since 2000. and the former Jack is Executive Officer of Synarc, President and Chief in clinical trials management and drug development, Vice-Chairman and President of Clinical Services of Chrysalis International. was the founder, NI-1701 A bispecific antibody that may enhance tumor killing without collateral damage cancer NI-1701 is intended to fight tumor cells using antibody by luring our immune system to seek and destroy mediated immunotherapy. acting therapeutic antibodies have been injected into patients in order to attach to the cancer cells, For decades, the targets in a process “eat” kill and such as macrophages or neutrophils, so that immune cells, “flags” as attachingThis process involves the antibody through its two Fab arms to the tumor cells and called phagocytosis. tail (the Fc portion). bridging to the immune cell via the antibody’s One method is by overexpressing the cancer cells often adapt and trick the immune system to back off. However, the Indeed, macrophages to leave them alone. “tell” hijacking the means by healthy cells which CD47, protein, the worse the prognosis for the patient across a variety of cancers. more CD47 expressed by a tumor, signal is an excellent therapeutic strategy except for fact that the “don’t eat me” blocking the CD47 Thus, healthy cells also express this protein. The bispecific nature of the kappa-lambda body offers solution to overcoming tumor resistance to a three-armed antibody therapies. MANAGEMENT Chief Executive Officer Jack Barbut, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1998 EMAIL [email protected] TELEPHONE +41 22 839 71 41 ADDRESS Aulx 14 Chemin des 1228 Plan-Les-Ouates Geneva Switzerland CONTACT Adrian Mills Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u OCT www.oct-clinicaltrials.com PROFILE COMPANY With the team of more Russia and the US. OCT is a leading CRO operating in Central and Eastern Europe, OCT provides a full range of high-quality services Phase I to IV including the within than 120 professionals, organization BE studies. and conduct of approachOCT believes in a partnering risk-share and co- exploring in to clinical development and is interested with products in earlydevelopment opportunities stage clinical development. OCT ensures that your product countries of operationsWith local expertise in our and a focus on quality, experienced team Our development and approvaladvances through clinical efficiently and and effectivley. needs from standalone CRO servicesdelivers quality results to fulfill your development such as medical writing, datamanagement / statistics to the management and conduct of project management/monitoring, consultancy, full clinical programs. 150 full-serviceSince 2005 OCT has been involved in more than and functional service projects in a wide range but with a focus on oncology. of therapeutic areas, MANAGEMENT President Dmitry Sharov, Clinical Operations Director Irina Petrova, Business Development Regional Head, Graham Birrell, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2005 EMAIL [email protected] TELEPHONE +7 (812) 449 86 34 ADDRESS 8/2 Bolshaya Moskovskaya, suite 4-1, let-A, 191002 Saint Petersburg, Russia CONTACT Graham Birrell Business Regional Head, Development WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Oncopeptides AB Oncopeptides www.oncopeptides.se FINANCIAL SUMMARY Fullymultiple in Phase II studies with the lead compound melflufen financed to complete in US and myeloma Europe. Western PROFILE COMPANY by creating of existing basic cytotoxic cytosuperiors to enhance oncologyOncopeptides is working therapies, cytosuperior of the chemotherapeutic is a alkylator named melflufen, lead compound, Oncopeptides compounds. Western European patients with is currently Melflufen US and undergoing Phase II efficacy studies in melphalan. A family of enzymes that is expressed at very high levels in cancer relapsed and/or refractory multiple myeloma. melflufen and its metabolites causes to accumulate in the diseased cells. such as multiple myeloma cells, cells, and thereby This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, better treatment of the disease. PRODUCT PIPELINE Melflufen Oncopeptides is currently in relapsed- combined with dexamethasone running a Phase II study of melflufen Western 2 in US and 4 in refractory multiple myelome (median of 4-5 previous lines of therapy) at six centers, Based on preliminary data we have efficacy data achieved with Overall Response Rates and Clinical Europe. This Benefit Rates that are roughly double compared to recent in this lateapprovals stage patient population. will be completed The clinical trial difference seems to translate well into Progression Free Survival rates as well. in first half of 2015. ASH meeting in December 2014 we presented results from the first six (6) patients evaluated Recently at the (http:// are able to review the full poster here: You at at MTD (40 mg/m2) with an ORR of 60% and CBR 100%. www.oncopeptides.se/wp-content/uploads/2015/02/Oncopeptides-poster-presented-at-ASH-20141.pdf) AB will be made with Phase II data available as well as meeting notes from An investment in Oncopeptides western regulatory agencies in the second half of 2015. Melphalan flufenamide (abbreviated melflufen and previously called J1) is a potent and highly lipophilic alkylator the In contrast to other alkylating agents that are hydrophilic, designed for efficient targeting of tumor cells. melflufen can Inside cells, lipophilicity of melflufen leads to rapid into tissues and cells. and extensive distribution directly bind DNA or is readily metabolized by intracellular peptidases into the well-known antitumor compound Due to the high activity which also has alkylating properties. melphalan or by esterases into des-ethylmelflufen, metabolites is rapid in these cells formation the of melflufen’s of peptidases and esterases in human tumor cells, melphalan is hydrophilic and des-ethylmelflufen is hydrophobic, Since with subsequent inflow of more melflufen. In multiple myeloma cells melflufen gives there is a possibility for intracellular trapping of these alkylators. AUC) of alkylating agents compared to that seen after an at least a 20-fold higher intracellular exposure (as an This can be explained by these cells, a more efficient transport of melflufen into equimolar dose of melphalan. efficient conversion into other alkylating molecules inside the cells and a less rapid disappearance from the cells. OPPORTUNITIES Melflufen Oncopeptides is currently in relapsed- running a Phase II study of melflufen combined with dexamethasone Western 2 in US and 4 in refractory multiple myelome (median of 4-5 previous lines of therapy) at six centers, Based on preliminary data we have achieved efficacy data with Overall Response Rates and Clinical Europe. This Benefit Rates that are roughly double compared to recent approvals in this late stage patient population. The clinical trial will be completed difference seems to translate well into Progression Free Survival rates as well. in first half of 2015. with Phase II dataAB will be made available as well as meeting notes from An investment in Oncopeptides western regulatory agencies of 2015. in the second half Melphalan flufenamide (abbreviated melflufen and previously called J1) is a potent and highly lipophilic alkylator 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2001 EMAIL [email protected] TELEPHONE +46 (0) 705 695 471 ADDRESS 15 Västra Trädgårdsgatan 111 53 Stockholm Sweden CONTACTS Jakob Lindberg Mr. CEO Bjorn Hammarberg Dr. Business Development WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ...continued Oncopeptides AB Oncopeptides www.oncopeptides.se designed for efficient targeting of tumor cells. In contrast to other alkylating agents that are hydrophilic, the In contrast to other alkylating thatagents are hydrophilic, designed for of tumor cells. efficient targeting melflufen can Inside cells, leads to rapidlipophilicity of melflufen cells. and extensive distribution into tissues and directly bind DNA or is readilymetabolized by antitumor compound intracellular peptidases into the well-known Due to the high activity which also has alkylating properties. melphalan or by des-ethylmelflufen, esterases into metabolites is rapid in these cells the formation of melflufen’s in human tumor cells, of peptidases and esterases and des-ethylmelflufen is hydrophobic, Since melphalan is hydrophilic of more melflufen. with subsequent inflow In multiple myeloma cells melflufen gives there is a possibility for intracellular trapping of these alkylators. AUC) of alkylating agents compared to that seen after an at least a 20-fold higher intracellular exposure (as an byThis can be explained a more efficient transport of melflufen into these cells, equimolar dose of melphalan. efficient conversion into other alkylating the cells and a less rapid molecules inside disappearance from the cells. MANAGEMENT Bjorn Hammarberg, Business Development Dr. Eva Nordstrom, Head of Clinical Ms. Fredrik Lehmann, Director CMC Dr. Jakob Lindberg, CEO Mr. Johan Harmenberg, CMO Dr. Alan Hulme, Chairman of the Board Mr. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2001 EMAIL [email protected] TELEPHONE +46 (0) 705 695 471 ADDRESS 15 Västra Trädgårdsgatan 111 53 Stockholm Sweden CONTACTS Jakob Lindberg Mr. CEO Bjorn Hammarberg Dr. Business Development WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u COO President & CEO Oncos Therapeutics Therapeutics Oncos www.oncos.com PROFILE COMPANY The Therapeutics is a clinical stage company developing off-the-shelf immunotherapeutics. cancer Oncos lead product has been elucidatedmechanism of action of its highly in Ph I and is thought to be complementary It will soon enter into combinationcancer (immuno)therapies. with other studies to that of checkpoint modulators. look forward to clinical collaborations with other companies developing complementaryWe therapies. PRODUCT PIPELINE ONCOS-102 : Ph Ib Off-the shelf immunotherapy adenovirus with a GM-CSF transgene (Ad5/3D24- based on an immunogenic immune response that has been clinically T-cell) GMCSF) inducing a strong systemic cellular (CD8+ demonstrated to target tumor antigens upon local administration. ONCOS-402 : Ready for Ph I Off-the shelf immunotherapy adenovirus with a CD40L transgene (Ad5/3D24- based on an immunogenic CD40L). OPPORTUNITIES ONCOS-102 Collaboration opportunities for combining ONCOS-102 with mechanistically proof-of-concept studies complementary cancer therapy in man. ONCOS-402 Collaboration opportunities for ONCOS-402 with mechanistically (non-)clinical studies combining complementary cancer therapy. Pipeline Preclinical collaborationagents opportunities to build novel (including immunomodulators) as transgenes into response can tumor targeted immune The advantage this is that of a systemic, Oncos platform constructs. be generated simultaneously avoiding events by systemic adverse delivering the agents locally via transgene Simultaneously Oncos products have expression in cancer cells rather systemically. than administering them been clinically demonstrated targeted activation to cause a powerful and tumor of the cellular immune system. MANAGEMENT Frans Wuite, Antti Vuolanto, CMO Magnus Jaderberg, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2009 EMAIL [email protected] TELEPHONE +358 10 279 4000 ADDRESS Saukonpaadenranta 2 FI-00180 Helsinki FINLAND CONTACT Frans Wuite President & CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Medicine Translational Oryx www.oryx-medicine.com FINANCIAL SUMMARY € raised since 2007. 25 Mio. Oryx ist backed by private investors / UHNWs, PROFILE COMPANY Center Cancer Research projects from research institutions like the German picks up promising cancer ORYX clinical proof of until clinical phases and develops them through preclinical and (DKFZ) or German Universities ORYX a product portfolio oversees of 3 projects currently trials. in phase I/IIa clinical ORYX concept/efficacy. licenses for world-wide all its development projects. holds exclusive, PRODUCT PIPELINE ParvOryx : Phase I/IIa ParvovirusParvOryx: (H-1PV) against H1 a variety of human tumors Oncolytic parvovirus H1 is a wild type rat virus that readily infects and lyses cancer cells from a wide variety as breast and lung cancer, pancreatic, glioblastoma multiforme, These tumor types include of human tumors. prostate cancer and pediatric (neuroblastoma and medulloblastoma), tumors lymphoma, well as melanoma, Unlike other natural or modified oncolytic viruses currently under investigation H-1PV is wild-type renal cancer. a unique safety property to the clinical investigation.This adds completely apathogenic for humans. Mode of action predominantly The virus exerts a cytotoxic/oncolytic effect, H-1PV acts at relatively low multiplicities of infection. shut cell cycle arrest, mediated by in dysregulation the non-structural protein (NS1) resulting of transcription, oncolysis viral In addition, activation of cellular stress response and induction of cell death. off of replication, Through the selective lysis and the of tumor cells appears to trigger a marked immunostimulatory effect. subsequent stimulation of the adaptive residual disease (MRD) will be recognized and immune system minimal Since the virus is able tumor cells eliminated by immune cells (bystander the selective action of primed effect). to cross the blood brain barrier glioblastoma multiforme was chosen as the tumor entity for (GBM) the present clinical Phase I/IIa study. Highly convincing preclinical data show that treatmentH-1PV results in complete tumor remissions in with animal models bearing human GBM. MicOryx : Phase I/IIa Therapeutic FSP vaccine against microsatellite instable (MSI-H) cancers High level MSI-H is characterized by a lack of DNA mismatch repair (MMR) and observed in about 15% of Virtually all tumors occurring in the frame of hereditary non-polyposis colorectal cancer colorectal cancers. are characterized the most common hereditary cancer predisposition syndrome, syndrome, (HNPCC) or Lynch which lead to the MSI tumorigenesis is mainly driven by mutations occurring at coding microsatellites, by MSI-H. frame shift-derived inactivation of the corresponding protein products and to the translation of tumor-specific These FSPs are both foreign and tumor specific antigens. neopeptides (FSPs). Mode of action gastric and small endometrial, These tumors include colorectal, FSPs are strongly expressed. In MSI-H tumors, In patients with MSI-H colorectal bowel cancer as well as tumors of the urinaryand other solid tumors. tract which demonstrates that FSPs are humoral and cellular immune responses against FSPs are observed, cancer, This observation is taken up by the first recognized by the immune system and can trigger an immune response. in class vaccination approach to prime the adaptive immune system against FSPs using a cocktail of three FSPs to prevent outgrowth or destroy MSI-H tumors. TAF1B(-1)] HT001(-1) and [AIM2(-1), The FSP vaccination concept represents also a prime candidate for a preventive cancer vaccine for Lynch syndrome mutation carriers. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] TELEPHONE +49 8106 21 311 0 ADDRESS Marktplatz 1 85598 Baldham Germany CONTACT Dr Bernard Huber CEO and Founder WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u ...continued Medicine Translational Oryx www.oryx-medicine.com VicOryx : Phase I/IIa VicOryx Therapeutic against p16INKa vaccine high-risk human papilloma cancer virus (HR-HPV) induced are associatedAbout 5% of all cancers with high-risk human papilloma virtually virus including all cervical 20-40% of vaginal penile cancers and 30-60% of head and neck and and vulvar cancers, 85-95% anal cancers, prophylactic vaccines are approved two for infection causing high grade prevention of HPV Currently, cancers. have specific protective immunity but do not a HPV-type which induce cervical intraepithelial neoplasia (CIN), therapeutic effect on HPV infections. Mode of action strongly expressed tumor antigen in is a non-viral, The human cyclin dependent kinase inhibitor p16INKa HR-HPV associated cancers and precursor lesions independently of the viral subtype once cells achieve a p16INK4a prevents the progression of When expressed, transformed and possibly malignant phenotype. HR-HPV transformed In leads to an irreversible cell cycle arrest. which cells through the G1 phase, “normal” Under physiological the p16INK4a pathway is blocked thus promoting unlimited cell division. cells however, In patients with HPV associated cancers humoral conditions p16INKa is only cells. expressed in senescent/dying which demonstrates that p16INKa and cellular immune responses againstspontaneously, p16INK4a occur This observation up by is taken is recognized by the immune system and can trigger response. an immune the vaccination approach to prime the adaptive against immune system p16INKa using a synthetic p16INK4a peptide to prevent outgrowth or cure of HR-HPV associated cancers. immune responses against In healthy individuals, No signs of autoimmunity have been detected in any patients. antigen overexpression in the cell is an early Since p16INKa consequence of p16INK4a have not been observed. transformation in all HR-HPV associated cancers this vaccination approach represents also a prime candidate for a preventive cancer vaccine. OPPORTUNITIES for out-licensing Available ParvOryx : MicOryx for out-licensing : Available for out-licensing : Available VicOryx MANAGEMENT CEO and Founder Dr Bernard Huber, CMO Dr Dr Michael Dahm, CFO Mr Klaus Kirschenhofer, COO Dr Ottheinz Krebs, CBDO Dr Sven Rohmann, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] TELEPHONE +49 8106 21 311 0 ADDRESS Marktplatz 1 85598 Baldham Germany CONTACT Dr Bernard Huber CEO and Founder WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued...
Otic Pharma Otic www.oticpharma.com FINANCIAL SUMMARY Company is raising now USD 10 M. inception. USD 6 M were raised since PROFILE COMPANY Throat (ENT) disorders. Nose, OticPharma develops differentiated therapeutic products for the treatment of Ear, which is currently for being prepared a Phase III clinical trial, FoamOtic Externa, leading product, The company’s Ciprofloxacin. antibiotic, non-ototoxic most commonly-used, is a novel dosage form on the industry’s based FoamOtic Externa enables sustained drug exposure, proprietary FoamOtic platform, Based on the company’s This steroid- ear”). “swimmer’s Acute Otitis Externa (AOE, fewer administrations and lower doses for treatment of to tilt the with no need free product offers a more convenient administration of self-applied medication to the ear, This makes administration much easier head or lie on the side to ensure that the medication in the ear. remains thus can improve compliance and safety. and especially for children, and more convenient, Other products targeted for unique indications on the FoamOtic platform and based in development include for Externa in dogs and FoamOtic Media for Otitis the Foam-O-Vet FoamOtic Sinus for Chronic Sinusitis, treatment of Otitis Media. the OticPharma was established in 2008, The company has a strong IP portfolio for applications. a wide range of company is privately held with headquarters in Israel. PRODUCT PIPELINE FoamOtic Externa : ready for Phase 3 single agent (Ciprofloxacin) investigational foam product for the potential FoamOtic Externa is a steroid-free, The product successfully study in 220 completed a proof-of-concept clinical Acute Otitis Externa. treatment of The foam is -based Phase 3 clinical study. Currently it is being prepared for a U.S. minor and adults patients. given once a day for 7 successive days. : ready for Phase 2 Foam-O-Vet fungal) designated steroid and anti for the treatment of Canine is a combination drug (antibiotic, Foam-O-Vet once byThe product will be administered the veterinarian (one and done) instead of the current Otitis Externa. The product was teasted in standard of care which is twice daily administration by of ear drops the pet owner. The product is ready for POC study in sick dogs. practicability and residence time. dogs for acceptability, FoamOtic Sinus : research The FoamOtic Sinus is designated for the treatment of Chronic Sinusitis in patients undergoing Sinus surgery. product is based on FoamOtic technology and will minimize the risks related to multiple administrations of antibiotics and steroids. FoamOtic Media : research FoamOtic Media is designated for the treatment of patients undergoing tympanostomy tube insertion surgery. The product is based on FoamOtic technology. OPPORTUNITIES FoamOtic Externa will strat Study in the summer of 2015. Investment is required to complete the pivotal study. FoamOtic Sinus Investment is required to conduct a clinical trial. Foam-O-Vet Investment is required to conduct the field study in dogs. Ear disorders Otic Pharma is willing to license-in products for ENT disorders. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +972 73 2903831 ADDRESS 7 Oppenheimer St., Science Park, Rehovot 7670107, Israel CONTACT PhD Orna Palgi, Executive VP R&D WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
Galit Itzhaki, B. Pharm, Clinical Director B. Galit Itzhaki, Itzhaki is an experienced manager trials both in international of Phase II and pivotal clinical CRO companies and with Ms. industry-sponsored companies. ...continued MANAGEMENT VP R&D PhD, Executive Orna Palgi, Teva and held senior positions at Palgi pharmaceutical and biotechnology is a seasoned drug development executive, Dr. Proneuron and Pharmos Corporation (NASDAQ:PARS). (NYSE:TEVA), PhD, Chief Operating Officer Rodrigo Yelin, and served as a project was Project Manager and Director of Computational Genomics at Evogene (NYSE:EVGN), Yelin Dr. He has extensive experience leading biotechnology projects from inception to licensing. leader at Compugen (NYSE:CGEN). Chief Financial Officer CPA, Anat Nursella, Ltd and Elutex and brings over a decade of experience in financial management and Nursella is the former CFO of NasVax Ms. operations in a wide range of industries. Otic Pharma Otic www.oticpharma.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +972 73 2903831 ADDRESS 7 Oppenheimer St., Science Park, Rehovot 7670107, Israel CONTACT PhD Orna Palgi, Executive VP R&D WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Pre Diagnostics AS Diagnostics Pre www.pre-diagnostics.com COMPANY PROFILE COMPANY with high accuracy in the earlyA new blood-based test disease stages is warranted for effective drug space. Alzheimer’s development within the MANAGEMENT CEO Håkon Sæterøy, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition EMAIL [email protected] TELEPHONE +47 926 95 175 ADDRESS 1413 Vika P.O.Box N-0115 Oslo Norway CONTACT Håkon Sæterøy CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Probiodrug www.probiodrug.de PROFILE COMPANY PBD) biopharmaceutical company dedicated to the research and AG is a publicly traded (Euronext, Probiodrug disease (“AD”). Alzheimer’s development of new therapeutic products for the treatment of company the successfully developed a novel therapeutic for concept diabetes – the DP4 Founded in 1997, the basis forinhibitors – which provided a novel class of antidiabetics – the gliptins. Disease treatments Alzheimer’s become a leading company aim is to in the development of Probiodrug’s Today a new therapeutic It has identified concept Disease patients. Alzheimer’s and to thereby life for provide a better The development approaches targeting pyroglutamate- are linked to disease initiation progression. and The Company use has medical Disease. Alzheimer’s Abeta (pGlu-Abeta) as a therapeutic strategy to fight and composition of matter patents related of QC and anti-pGlu-Abeta- specific monoclonal to the inhibition with a leading position in this field of research. view, in the Company’s providing it, antibodies, PRODUCT PIPELINE IIb IIa, PQ912 : Phase II, PQ912 is a small currently entering into a Phase 2a study. PQ912 is the lead product candidate of the Company, molecule that was discovered and profiled and was nominatedby Probiodrug by the Company for regulatory Alzheimer PQ912 is a specific inhibitor of QC which has shown therapeutic benefit in development in 2010. PQ912 has shown to be safe and well tolerated in a and revealed a high level of QC-inhibition animal models. The preparation of the Phase 2a study started in Phase 1 study with 200 healthy young and elderly volunteers. The first patient is expected to be August 2014. filing started in Application (“CTA”) Trial The Clinical March 2014. treatedwith the first with PQ912 in the first quarter of 2015 data expected to be available in mid 2016. PBD-C06 : Preclinical aiming to PBD-C06 targets pGlu-Abeta, currently in preclinical research. PBD-C06 is a monoclonal antibody, The Company Abeta untouched. selectively clear the brain from pGlu-Abeta while leaving forms non-toxic of the amount of antibody reaching the brain due to the high specificity of PBD-C06 for pGlu-Abeta, believes that, will be sufficient to neutralize the toxic peptides. PQ1565 : Preclinical candidateThe product has shown attractive drug- currently in late preclinical research. PQ1565 is a QC-inhibitor, like properties in preclinical studies. MANAGEMENT CEO Dr Konrad Glund, CFO Hendrik Liebers, CDO Dr Inge Lues, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1997 EMAIL [email protected] TELEPHONE +49 345 5559900 ADDRESS 22 Weinbergweg D-06120 Halle (Saale) Germany CONTACT Dr Konrad Glund CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CEO Director, Board of Directors Director, Prokarium Ltd. Prokarium www.prokarium.com FINANCIAL SUMMARY $5.5 million which enabledSeed funding in 2012 of BioSolutions as well acquisition of vector IP from Emergent as working capital for R&D on two vaccines. preclinical Currently and Chlamydia B of $20 million to cover ETEC-diarrhoea challenge raising a Series phase 1 study 2016 and onwards. PROFILE COMPANY UK Clinical-stage company vaccine development (travellers’ with three products under development and Chlamydia vaccines) C.difficile, diarrhea&typhoid, is based on a Salmonella which forms the basis of all our vaccines, Vaxonella, The oral vaccine delivery platform, It was safe phase 2 challenge). strain that (up to and incl. has been in 8 clinical trials as a typhoid vaccine Typhi and very well tolerated in almost 500 volunteers including 101 children. backed by one Prokarium is a limited company with full FTO (10 patents or under exclusive license), owned Oxford and Birmingham universities on various R&D have partnerships with Cambridge, We angel investor. projects as well as with a big pharma company difficile. on Clostridium Our strategy is to partner and eventually to some indications out-license/sell rights to pursue the development of a small number of our own vaccines. First company to show immunogenicity against all ETEC strains in Our anticipated highlight for end of 2015: resulting in 45% of all causes of travellers diarrhea covered by vaccine (current Dukoral human clinical trial, vaccine covers <10% of all causes and is primarily vaccine) a cholera MANAGEMENT Fjallman, Ted Dr. CFO Peter Coleman, Mr. CSO Rocky Cranenburgh, Dr. Head of Clinical Development Mike Darsley, Dr. Clinical Project Manager Alireza Shamaei-Tousi, Dr. Chairman Board of Directors Steven Chatfield, Dr. Board of Directors Director, Carl-Johan Spak, Dr. Allan Jarvis, Dr. Advisory Board Member Scientific David Sherratt, Prof. Advisory Board Member Scientific Elisabeth Lindner, Dr. Advisory Board Member Scientific Ian Henderson, Prof. Advisory Board Member Scientific Nigel Slater, Prof. 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2012 EMAIL [email protected] TELEPHONE +44 (0)781 1367729 CONTACTS Fjallman Ted Dr. CEO Steven Chatfield Dr. Chairman Board of Directors WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Protagonist, Inc. Protagonist, www.protagonist-inc.com FINANCIAL SUMMARY 9 M (2003-2009) US $ A: Series (2013-14) US $ 18 M Series B: Main Investors 1) Lilly ventures Development Corporation)2) JJDC (Johnson & Johnson 3) Ventures Starfish 4) PharmStandard PROFILE COMPANY Protagonist is a peptide therapeutics company with a validated technology platform that is discovering & It envisions a game ‘oral peptide drugs’ as a targeted therapy for GI (gastro-intestinal) diseases. developing changing treatment paradigm shift in the treatment through its targeted therapy of IBD approach on those autoimmune targets that offer and which are currently multibillion dollar opportunities addressed only by Entyvio). Remicade, Humira, injectable antibodies (eg. Our current financing plans call raise in 1H 2015 thatfor a $ 35 M Series C/Mezzanine should enable us to and achieve phase 2A clinical POC with alfa4beta7 progress three different assets in the clinic in 2015-16, integrin oral peptide antagonist PTG-100 by end of 2016. PRODUCT PIPELINE Development PTG-100 : Preclinical as its an alpha-4-beta-7 integrin-specific oral peptide antagonist, The company recently nominated PTG-100, PTG-100 will enter specifically for Ulcerative Colitis. first development candidate for oral targeted therapy of IBD, human clinical trails in October 2015 with the anticipation Ph 2A clinical POC completion by of end of 2016. Research Oral IL-23r Antagonist : Preclinical Preclinical proof-of-concept has been established oral peptide in its second program with an aimed at A development candidate nomination is anticipated in 2015. intervention of the IL-23 pathway. OPPORTUNITIES oral integrin antagonist PTG-100, as its an alpha-4-beta-7 integrin-specific oral peptide antagonist, The company recently nominated PTG-100, will enter PTG-100 specifically for Ulcerative Colitis. first development candidate for oral targeted therapy of IBD, human clinical trails in October 2015 with the anticipation of Ph 2A clinical POC completion by end of 2016. The company is interested in creative partnerships and/or co-development scenarios . Oral Il23r Antagonist The company is interested in creative partnerships and/or co-development scenarios around this preclinical stage asset. MANAGEMENT President and CEO Dinesh Patel, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2003 EMAIL [email protected] TELEPHONE +1 408 649 7370 ADDRESS Suite 100 521 Cottonwood Drive, CA 95035-7404 Milpitas, USA CONTACT Dinesh Patel President and CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Inc. Biopharmaceuticals, Provectus www.pvct.com COMPANY PROFILE COMPANY its PV-10, specializes in developing oncologydermatology and therapies. Inc., Provectus Biopharmaceuticals, is designed for tumors (intralesional administration), injection into solid novel investigational drug for cancer, cancers of the liver, Its oncology focus is on melanoma, thereby for reducing potential systemic side effects. The Companydesignations has received orphan drug from the FDA for its melanoma and and breast cancer. is undergoing its topical investigational for drug dermatology, PH-10, hepatocellular indications. carcinoma as a therapy 2 trials of PV-10 Provectus has completed phase clinical testing for and atopic psoriasis dermatitis. and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. for metastatic melanoma, PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL [email protected] TELEPHONE +1 866 594-5999 ADDRESS 7327 Oak Ridge Highway TN Knoxville, 37931 USA CONTACT MBA CPA, Peter Culpepper, Chief Financial Officer/Chief Operating Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Chief Technology Officer Chief Technology PV-10 is a platform technology for solid cancers and has shown preclinical or clinical activity in manyPV-10 types of solid tumors ...continued Inc. Biopharmaceuticals, Provectus www.pvct.com PV-10 and breast cancers of the liver, melanoma, including but not limited to to treatRose Bengal based drugs cancer, cancer. PH-10 psoriasis and including atopic dermatitis to treatRose Bengal based drugs inflammatory dermatoses, OPPORTUNITIES • Utilize great global potential of PV-10 • • Build partnerships in selected geographies • Control supply chain Actively participate in the development to commercialization • MANAGEMENT Chief Executive Office and Chairman PhD, Craig Dees, President and Board Member PhD, Scott, Timothy PhD, Eric Wahter, Chief Financial Officer/Chief Operating Officer MBA, CPA, Peter Culpepper, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL [email protected] TELEPHONE +1 866 594-5999 ADDRESS 7327 Oak Ridge Highway TN Knoxville, 37931 USA CONTACT MBA CPA, Peter Culpepper, Chief Financial Officer/Chief Operating Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u
Saphetor www.saphector.com PROFILE COMPANY empower the To Saphetor provides big-data analysis for next generation DNA sequencing in clinical diagnostics. leading we have seamlessly integrated the world’s the best choice formedical professional to make the patient, genetic databases into our proprietary systems in order to accurately genomic alterations identify causal for a using our web platform to provide timely reports based thus enable diagnostic labs, We large range of diseases. patients and connect to treatments on the most up-to-date information from academic and clinical research, and are looking to are now testing our platform diagnostic in partnership with leading labs, We and clinical trials. validate and pharmaceutical and biotech industries to help find expand our reach to the therapeutic new targets. MANAGEMENT CEO Andreas Massouras PhD, Business Development Chris Maggos, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2014 TELEPHONE +41 22 548 0009 ADDRESS EPFL Innovation C, Park – Bâtiment 1015 Lausanne Switzerland CONTACTS Andreas Massouras PhD CEO Chris Maggos Business Development WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u rhage). With a high commercial With a rhage).
Serendex Pharmaceuticals A/S Pharmaceuticals Serendex www.serendex.com PROFILE COMPANY Serendex we believe thatAt patients need better treatment. with severe lung diseases Serendex at Glance BE Alveolar Proteinosis), (PulmonaryWith our GM-CSF we focus on respiratory conditions such as PAP For our Factor ARDS (Acute Respiratory Distress Syndrome). Fibrosis infections) and CF (Cystic (Bronchiectasis), Alveolar Haemor VIIa (FVlla) we focus on inhalation treatment of DAH (Diffuse we have to develop inhalation a vision products for the treatment lung diseases by of these developing focus, We will succeed through a worldwide FVlla) into inhalation drugs. drugs (GM-CSF, specific existing systemic fordistribution of our drugs inhalation based on an extensive outsourcing strategy and international strategic Serendex’ development strategy is focusing on development of OUR DEVELOPMENT STRATEGY alliances. These indications have GM-CSF and FVlla to be used for inhalation for several different pulmonary indications. been chosen based on published documentation and patient showing the potential for cases our products used API (Active Product Ingredient) for both GM-CSF Serendex has worldwide exclusive rights to the for inhalation. By using Serendex has submitted or obtained IPR (Intellectual Property Rights) for all its indications. and FVlla. we are able to lower API of well know systemic drugs as the active ingredient for our inhalation products, the This allows Serendex to efficiently develop as well as reducing time to market. development risks and costs, part of our focusThe main indications have an Orphan Drug Designation drugs to meet high medical needs. of the Serendex pipeline is treatmentThe potential of more than 700.000 (ODD) due to their relative rareness. have planned for a pivotal study phase II/III with We Our Pipeline persons annually in the EU and US alone. In Q3 2015 phase II trials will be initiated starting in Q4 2015 in Europe and Japan. GM-CSF (Molgradex) in PAP If you wish to know more Pre-clinical trials will commence in Q3 2015 for FVIIa. ARDS in Europe. BE and for CF, www.serendex.com. please refer to our website: about our products and focus indications, MANAGEMENT CEO Arvid Nielsen, Dr Kim 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2008 TELEPHONE +45 7930 1414 ADDRESS tv 2. Slotsmarken 17, 2970 Hørsholm Denmark CONTACT Arvid Nielsen Dr Kim CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Cash (£m) (2.1) 8.9 (20.3) 15.9 (23.7) 21.5 Adj. EPS (p)
(7.1) (10.6) EBITDA (£m) 0.2 (4.9) 0.1 0.0 Sales (£m) Therapeutics Silence www.silence-therapeutics.com FINANCIAL SUMMARY 2014. £22m cash as at 30, November Financial Summary Atu027 phase 2a metastatic pancreatic cancer, Atu027, MANAGEMENT CEO Ali Mortazavi, Finance Director Freeborn, Tim Head of R&D Dr Lars Karlsson, Medicine Translational Head of Dr Mike Khan, 2012A 2013A 2014E PROFILE COMPANY It has developed proprietary modifications to Therapeutics is a leading RNA therapeutics company. Silence to enhance the with advanced liposomal chemistries improve the robustness of RNA sequences together Its technology selectively can silence or replace the expression of any gene in the delivery of its therapeutics. This allows the in vivo. modulating expression up as well as down in a variety of organs and cell types, genome, technology is currently in the Silence’s development of therapeutics for clinical need. diseases with high unmet clinic in a Phase 2a pancreatic cancer trial. PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2005 EMAIL [email protected] TELEPHONE +44 (0)20 3700 9711 ADDRESS Square 1 Lyric London W6 0NB United Kingdom CONTACT Dr Mike Khan Medicine Translational Head of WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Synthena AG Synthena www.synthena.com PROFILE COMPANY Swiss biopharmaceutical company focused on the development of new AG is a privately held, Synthena Its lead product drugs fortricycloDNA based oligonucleotide the treatmentdiseases. of severe neuromuscular unprecedented where it has shown forSYN01 is in preclinical development Duchenne muscular dystrophy, functions in different cardiac and cognitive animal models. respiratory, muscle, efficacy in restoring skeletal and Pompe disease. disease, Steinert’s Atrophy, Further research programsare ongoing in Spinal Muscular MANAGEMENT Chief Executive Officer Renner PhD, Wolfgang 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2012 EMAIL [email protected] TELEPHONE +41 (0) 31 631-4265 ADDRESS Freiestrasse 3 3012 Bern Switzerland CONTACT Dr Wolfgang Renner Chief Executive Office WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Tonix Pharmaceuticals Pharmaceuticals Tonix www.tonixpharma.com TNX-102 SL : Entering Phase 3 Completed Phase 2B in 2014 and entering Phase 3 in TNX-102 SL for the treatment of fibromyalgia. Developing Q2 2015. TNX-102 SL : Phase 2 Initiated Phase 2 trial in TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). Developing January 2015. TNX-201 : Entering Phase 2 Completed Phase 1 study and TNX-201 for the treatment tension-type headache (ETTH). of episodic Developing entering Phase 2 in Q2 2015. MANAGEMENT CEO & Chairman Co-Founder, MD, Seth Lederman, Chief Financial Officer PhD, MD, Gershell, Leland J. Chief Scientific Officer MBA, PhD, Daugherty, Bruce L. Chief Medical Officer MD, Gregory Sullivan, Commercial Planning and Development Vice-President, Senior MBA, PhD, Ronald Notvest, Vice President of Finance Senior Jessica Edgar, FINANCIAL SUMMARY Pre-revenue PROFILE COMPANY develops first-in-class medicines Pharmaceuticals of the central nervousfor common disorders system, Tonix These disorders tension-type headache. and episodic post-traumatic stress disorder, including fibromyalgia, and high utilization of healthcare services, inadequate treatment options, are characterized by disability, chronic significant economic burden. be a is designed to (cyclobenzaprineTNX-102 SL HCl sublingual tablet), lead product candidate, Tonix’s fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post- TNX-201 ((R)-isometheptene mucate) is in development for Product candidate traumatic stress disorder (PTSD). the most common form of headache. episodic tension-type headache, TNX-102 SL as Phase 2b BESTFIT trial (BEdtime Sublingual has announced top-line results from the Tonix and plans to initiate a Phase 3 program in fibromyalgia second quarter in the Therapy), Fibromyalgia Intervention A Phase 1 TNX-102 SL in PTSD was initiated in January 2015. of A Phase 2 trial of 2015 to support registration. plans to begin study in episodic a Phase 2 clinical Tonix and TNX-201 has been successfully completed, study of tension-type headache in the second quarter of 2015. PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 [email protected] EMAIL TELEPHONE +1 212 980-9155 ADDRESS 509 Madison Avenue Suite 306 NY 10022 York, New CONTACTS MD Seth Lederman, & Chairman CEO Co-Founder, Jessica Edgar of Finance Vice President Senior WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Vaxart, Inc. Vaxart, www.vaxart.com COMPANY PROFILE COMPANY Tablet Stable Platform – Room Temperature Vaccine Recombinant Tablet is a privately held company recombinant antigen vaccines that developing by are administered Vaxart tablet The tablets are temperature stable held at and can be room temperature for up to one rather than by injection. year. of Indications Suitable for Wide Range tablet based on a modular vector based platform vaccines are that is suitableVaxart for any recombinant The human papilloma virus that including those are contained in licensed vaccines for seasonal influenza, antigen, vaccine New as well as any recombinant antigens currently in the industry pipeline. (HPV) and hepatitis B, a significant advantage in addressing indicationssuch as constructs are routinely assembled in a matter of days, seasonal influenza or newly emerging pathogens. Vaccines Vaccine Comparable to Injectable Tablet Product Profile of tablet H1N1 seasonal influenza Vaxart’s phase I studies, placebo controlled double blind, In recent randomized, After a single dose, vaccine generated comparable safety and immunogenicity results to marketed vaccines. 90% of subjects generated as measured by robust systemic antibody responses heamagglutinin inhibition (HAI) the industry correlate for protection. 75% of subjects seroconverted by HAI, and microneutralization (MN) assay. a unique and differentiating were generated and mucosal responses in 90% of subjects, T-cell robust In addition, and were Only mild adverse events (AEs) occurred in the study, feature when compared to injectable vaccines. evenly distributed between placebo and vaccine recipients. Rates Vaccination to Significantly Increase have the Potential Vaccines Tablet tablet vaccine can be shipped and stored without refrigeration and can be self-administered or Vaxart opening up opportunities to administer vaccine in the work place, administered under administrative supervision, at school or even at home. Pipeline Vaxart or advancing into the clinic in 2015: Three high value vaccine candidates are currently in the clinic, • Seasonal Influenza • Norovirus • RSV Impact only 45% of the largest market, In the US, Seasonal influenza is currently a $3 Billion Market worldwide. In adults age 18 – 64 all those for who vaccine is recommended are actually vaccinated in any given year. A tablet vaccine could dramatically impact vaccination rates, just over 30%. vaccination rates are much lower, the largest segment of the population. particularly in the 18 – 64 age group, Annually some 150,000 – RSV causes significant morbidity and mortality in children as well as in elderly. 200,000 adults and elderly are hospitalized due to RSV infection. affecting some 20 million people annually in the US Norovirus is a highly prevalent viral intestinal infection, among the population. but is causing significant morbidity bug, “cruise-ship” It is best known as the alone. military food and first responders would all industrygreatly benefit from workers, health care workers, Travelers, particularly by convenient tablet that can be self-administered. vaccination, A portfolio All three indications will likely require annual vaccination campaigns offering significant synergies. will be ideal to address these high volume – high value RSV and norovirus consisting of tablet vaccines for flu, and offer a formidable competitive advantage vis a vis other products currently in development markets, MANAGEMENT Chief Executive Officer and Director MBA, MD, Latour, Wouter Chief Scientific Officer and Director PhD., Founder, Sean Tucker, Vice President Development Chief Operating Officer and MBA, John Cornwell, Chief Medical Officer PhD, MD, David Liebowitz, Chief Financial Officer MBA. John Harland, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2004 EMAIL [email protected] TELEPHONE +1 650 550 3500 ADDRESS Suite 9A 385 Oyster Point Blvd., South San Francisco, CA 94080 CONTACT Latour Wouter CEO WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CBDO CTO Development & commercialization of industrial protein production processes by application of exclusive and Development & commercialization production processes by of industrial protein application of exclusive and proprietary technologies and know-how VTU has already entered into commercial technology license and partnership agreements with key industry players Experienced business manager and highly skilled entrepreneur, 5 companies founded since 1990, PhD in Process 5 companies founded since 1990, Experienced business manager and highly skilled entrepreneur, Engineering Thomas Purkarthofer, Dr. PhD in Chemistry responsible for new business development, Business Development Manager, Roland Weis, Dr. PhD in Molecular Biotechnology Head of expression strain development and engineering, Iskandar Dib Dr. PhD in Biotechnology and Biochemical Engineering Principal R&D manager fermentation and downstream processing, COMPANY PROFILE COMPANY providing time-saving development is a leading contract research and development company, Technology VTU protein production processes of cost-efficient recombinant for manufacturing of biologics and other proteins. proprietary technologiestogether with a strong IP portfolio and know-how are the basis exclusive, Cutting-edge, for most versatile the broadest toolbox and technology platform available for recombinant protein Pichia pastoris expression / production enabling being processes highest productivities ever reported with production – economically viable – robust and readily scalable – safe with negligible risk of contamination – environmentally friendly – accompanied by simplified protein purification procedures Excellence: pastoris Protein Expression VTU Pichia – High speed expression strain development – Upstream process development and optimization – Downstream and analytical process development – Small-scale production of purified non-GMP material – Sound technology & data transfer to our customers – Outlicensing / co-development opportunities for proteins. several recombinant Business model: – – Granting commercial technology milestone and royalty payment licenses furnishing incomes – Production and distribution of high-margin proteins – MANAGEMENT CEO Michael Koncar, Dr. VTU Technology www.vtu-technology.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +43 (316) 4009-4017 ADDRESS GmbH VTU Technology A-8074 Grambach Parkring 18 CONTACT Thomas Purkarthofer Head of Business Development WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u CSO and Founder FINANCIAL SUMMARY grant income only no revenues, i.e. Biotech company, lead product PD- of II clinical trial equity financing needed to complete Phase Additional EUR 2.0-3.0 million protec PROFILE COMPANY drugs using a novel therapeuticZytoprotec is developing approach – cytoprotection. survival is being developed to improve the of patients on peritoneal PD-protec®, lead product, Zytoprotec’s a treatment for kidney failure. dialysis, blinded, A randomized, effectsPD-protec® has shown safety and promising efficacy in a Phase I/II trial. multicenter Phase II trial has commenced at 2014. the end of Q2 About 10 percent of these patients are 2.3 million patients annually receive dialysis treatment. Worldwide, treated with peritoneal dialysis (PD). Cytoprotective PD solutions have the potential to significantly improve the outcomes of PD treatment and consequently overall dialysis to increase the share of PD within the market. PRODUCT PIPELINE phase II PD-protec : clinical PD-protec is targeted to improve side effects dialysis of peritoneal significantly such as peritonitis and membrane failure. OMNI-protec : pre-clinical OMNI-protec is targeted to all peritoneal dialysis patients do not receive glucose solutions. who MANAGEMENT CEO Michael Hoffmann, Prof. Christoph Aufricht, Prof. Uwe Schlokat, Chairman Uwe Schlokat, Prof. Board member (investor relations) Bernd Seibel, GmbH Zytoprotec www.zytoprotec.com 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2007 EMAIL [email protected] TELEPHONE +43 1 406 20 02 ADDRESS Mariannengasse 28/2 1090 Wien CONTACT Bernd Seibel relations)Board member (investor WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Non-Executive Director Scientific Team Leader Scientific development of an antisense technology platform for suppressing unwanted gene expression, and applying the technologydevelopment of an antisense platform for suppressing unwanted gene expression, platform for finding cures several medical indications;against Ltd. GeneCode www.genecode.com COMPANY PROFILE COMPANY companyGenecode Ltd is an R&D focussing on the discovery of innovative and development preclinical drug candidates and the commercialization of novel technologies mostly biomedicine and gene in the field of technology. business fields linked together Genecode has two main by the competence in computational chemistry: • factor mimetics as drug candidates• development of neurotrophic against neurological diseases. MANAGEMENT Managing Director Katrin Idla, Executive Director Paavo Pilv, Executive Director Kaupo Karelson, Team Leader Scientific Andres Merits, Tõnis Timmusk, Scientific Team Leader Scientific Mart Saarma, Non-Executive Chairman Mati Karelson, Non-Executive Director Mehis Pilv, Thomas Björn Waldin, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 1993 EMAIL [email protected] ADDRESS Ahtri 8, 10151 Tallinn Estonia WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Continued... Inc. Biopharmaceuticals, Provectus www.pvct.com COMPANY PROFILE COMPANY its PV-10, specializes in developing oncologydermatology and therapies. Inc., Provectus Biopharmaceuticals, is designed for tumors (intralesional administration), injection into solid novel investigational drug for cancer, cancers of the liver, Its oncology focus is on melanoma, thereby for reducing potential systemic side effects. The Companydesignations has received orphan drug from the FDA for its melanoma and and breast cancer. is undergoing its topical investigational for drug dermatology, PH-10, hepatocellular indications. carcinoma as a therapy 2 trials of PV-10 Provectus has completed phase clinical testing for and atopic psoriasis dermatitis. and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. for metastatic melanoma, PRODUCT PIPELINE 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL [email protected] TELEPHONE +1 866 594-5999 ADDRESS 7327 Oak Ridge Highway TN Knoxville, 37931 USA CONTACT MBA CPA, Peter Culpepper, Chief Financial Officer/Chief Operating Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Chief Technology Officer Chief Technology PV-10 is a platform technology for solid cancers and has shown preclinical or clinical activity in manyPV-10 types of solid tumors ...continued Inc. Biopharmaceuticals, Provectus www.pvct.com PV-10 and breast cancers of the liver, melanoma, including but not limited to to treatRose Bengal based drugs cancer, cancer. PH-10 psoriasis and including atopic dermatitis to treatRose Bengal based drugs inflammatory dermatoses, OPPORTUNITIES • Utilize great global potential of PV-10 • • Build partnerships in selected geographies • Control supply chain Actively participate in the development to commercialization • MANAGEMENT Chief Executive Office and Chairman PhD, Craig Dees, President and Board Member PhD, Scott, Timothy PhD, Eric Wahter, Chief Financial Officer/Chief Operating Officer MBA, CPA, Peter Culpepper, 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition YEAR FOUNDED 2002 EMAIL [email protected] TELEPHONE +1 866 594-5999 ADDRESS 7327 Oak Ridge Highway TN Knoxville, 37931 USA CONTACT MBA CPA, Peter Culpepper, Chief Financial Officer/Chief Operating Officer WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
t back :: next u Die Standortagentur Tirol ist eine Einrichtung des Landes Tirol mit dem gesetzlichen Auftrag, den Wirtschafts- den Auftrag, mit dem gesetzlichen Tirol Einrichtung des Landes ist eine Tirol Die Standortagentur Arbeitsplätze zu sichern und um dadurch bestehende nachhaltig zu stärken, Tirol Wissenschaftsstandort und neue zu schaffen. Zukunfsstiftung Tiroler www.standort-tirol.at 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition EMAIL [email protected] TELEPHONE +43 512 576262 ADDRESS Zukunftsstiftung Tiroler Ing.-Etzel-Straße 17 6020 Innsbruck Österreich WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u
Advancing a New Front in the War against Cancer against War a New Front in the Advancing is developing advanced therapiesProvectus Biopharmaceuticals designed to target - while minimizing side liver and breast cancers - melanoma, and destroy the deadliest effects. specializes in developing oncology and dermatology Inc., Provectus Biopharmaceuticals, is designed for injection into its novel investigational drug for cancer, PV-10, therapies. thereby reducing potential for systemic side solid tumors (intralesional administration), and breast cancer. cancers of the liver, Its oncology focus is on melanoma, effects. The Company has received orphan drug designations from the FDA for its melanoma its topical investigational drug for PH-10, and hepatocellular carcinoma indications. Provectus clinical testing for is undergoing psoriasis and atopic dermatitis. dermatology, and of PH- as a therapy for metastatic melanoma, has completed phase 2 trials of PV-10 10 as a topical treatment for atopic dermatitis and psoriasis. Provectus Biopharmaceuticals, Inc. Biopharmaceuticals, Provectus SILVER SPONSORS SILVER
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u
www.torreyapartners.com Torreya Partners LLC is a leading boutique advisory LLC is provides firm that Partners strategic Torreya Financings and Partnering with Mergers & Acquisitions, advice and assistance worldwide. to life science companies required forthe long-term thinking and objective advice Partners provides life Torreya take great pride in handling complex We science companies to create lasting value. financial and strategic matters most sophisticatedfor some of the private and public reputation Our advice, has been built on quality life science companies in the world. bring the caliber of We forexcellence in deal execution and good outcomes our clients. people and quality of relationships found banks along in some of the largest investment Torreya detailed serviceyou expect from a boutique advisory with the attentive, firm. Philadelphia and San Francisco. York, Partners has offices located in New Torreya Partners LLC Partners Torreya SILVER SPONSORS SILVER 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.berlinpartner.de First choice: Berlin Partner for Business and Technology for Business First choice: Berlin Partner investors and scientific institutions in Business and technology support for companies, With GmbH mission. Technologie Wirtschaft und Partner für Berlin – this is the Berlin our many experts customized services and research network, and an excellent science expand innovate, provide an outstanding range of programs to help companies launch, and secure their economic future in Berlin. Technology Berlin Partner for Business and A unique public-private partnership, collaborates with the Berlin State Senateover 200 companies dedicated and to promoting responsible for Berlin Partner is also marketing the German capital to the world, their city. campaign. “be Berlin” for example with the successful Berlin Partner Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.biodeutschland.org As the sector association of the biotechnology industry, BIO Deutschland has of the biotechnologyAs the sector association industry, development of an of supporting and promoting the set itself the objective on modern biosciences. economic sector based innovative It is run by a board of ten The Berlin-based association currently 300 members. has over as well members consisting of CEOs and managing directors of biotechnology companies, This committee comprehensively various fields represents the as directors of BioRegions. in the sector. are organised in working groupsThe member companies and their experts that deal with finance and taxation; licences and technical contracts; regulatory the following topics: matters; innovation German-US cooperation; and entrepreneurship; HR; policy; health Using a wide range of competition and regulatory policy; technology transfer; and PR. BIO Deutschland lobbies for legal parameters for improvements to the political initiatives, innovative small and medium-sized enterprises. biotechnology sector representative at the European BIO Deutschland is Germany’s BIO Deutschland also works closely with other biotech in Brussels. EuropaBio, association, organisations in Europe and the USA in order to lobby for of the sector in the interests The association is also very active in a broad range an internationally coordinated way. of events with the aim of providing biotechnology with a platform forand discussion interaction. BIO Deutschland Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.biotechgate.com Your source for life science companies and licensing information. for life science companies source Your If you are about to negotiate company. deal between a Biotech and a Pharma a licensing Or Or you are looking for Pharma company a big to out-license your Biotech product. medical technologyyou are active in the sector and just want to identify (Medtech) for Or you are an investor looking investment potential cooperation partners or customers. aboutopportunities - or you just want to know historical financing rounds and valuations in This portal can solve all of these Pharam and medical device field. Biotech, the life sciences, problems – and even more. Biotech Gate Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.citigatedr.co.uk Citigate Dewe Rogerson is the leading international consultancy specialising is the leading international consultancy Citigate Dewe Rogerson Europe, UK, corporate communications across the in financial and exclusively Asia. North America and Citigate has a dedicated 60 years combined Pharma & Biotech team with more than corporate and financial PR and investor of skills: experience in the sector and a unique mix The team provides sector expertise and journalism and academic science. finance, relations, overall benefiting from the company’s forms an integrated part of Citigate Dewe Rogerson, strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established in working with track record As well as core skills in financial biotechnology companies at all stages in development. the team has financial PR and media relations, transactions support, calendar work, Recent clients include and new media consultancy. design extensive experience in branding, and numerous emerging companies in the UK and Europe, listed global top-five biotechs, Scandinavia. and the Netherlands, Germany, France, businesses in the UK, team has been involved in major corporate Pharma & Biotech transactions such Citigate’s have advised on a number We and M&As. other public and private fundraisings, as IPOs, Paris - €52 EXplorer (Euronext METabolic of IPO transactions across Europe including; Santhera Pharmaceuticals (SWX Algeta (Oslo Stock Exchange - €30 million), million), Hutchison China ThromboGenics (Euronext Brussels - €35 million), – CH88.5 million), Arpida (SWX - €63 $211 million), Zentiva (LSE and PSE – US (AIM - £40 million), MediTech BioFusion (AIM - £8.2 (CSE - €30 million), TopoTarget Inion (LSE - £35 million), million), million) and ExonHit (Alternext - 7.3 million). Citigate Dewe Rogerson Buildings Wall 3 London London Wall London EC2M 5SY +44 (0)-207-638-9571 Tel: Citigate Dewe Rogerson Citigate Dewe Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.edisongroup.com Edison is a UK-based investment intelligence firm.Edison is a UK-based York, New 70 equity analystsIt employs more than operating in London, from offices and Frankfurt that coverage provides research on more than 700 Wellington Sydney, the largest dedicated making it one of and mid-cap small publicly traded companies, Healthcare is the largest industry group within Edison with 12 research providers worldwide. Continental analysts covering some 150 biotech/medical device companies located in UK, Europe, North America and Australia. Edison Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.freemindconsultants.com Tel: (617) 648-0340 (617) 648-0340 Tel: (617) 904-1767 Fax: [email protected] Email: Boston FreeMind Group #124 Ave. 423 Brookline MA 02215 Boston, DC Washington FreeMind Consultants 4094 Majestic lane # 269 VA 22033 Fairfax, Jerusalem FreeMind Group Center Tech Hi - Hebrew University Jerusalem 95702 Israel FreeMind is a consulting group whose goal is to assist its clients in maximizing in its clients group whose goal is to assist FreeMind is a consulting in Established funding from non-dilutive sources. their potential to receive with over largest consulting group of its kind FreeMind is the 400 active 1999, proven long-term strategic FreeMind’s academics and Industry alike. clients, over to date. 1.5 billion dollars its clients approach has garnered Our expertise in applying for grants extends throughout every and contracts government FDA, NSF, DoD, including all NIH institutes, mechanism open to funding the life sciences Bill and Melinda as well as private foundations J Fox, such as Michael etc., BARDA, CDC, Gates and Susan G Komen. Analysts and Project Managers are knowledgeable team of and experienced FreeMind’s dedicated to guiding its clients non-dilutive funding efforts from identification the most of Our team of experts suitable opportunity through to submission and subsequent award. funding a keywill assist our clients in making non-dilutive tool in their long-term financial strategy. FreeMind Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.lifesciences.instinctif.com Instinctif Partners is an international business communications consultancy. business communications consultancy. is an international Instinctif Partners the Life Sciences practice delivering trulyWith a track record of creative programmes, partnerships focuses the value proposition for on enhancing seeking investment, companies with clients to communicate Our core skill is working the value of their or customers. crafting science and innovation to key most relevant channels: stakeholders through the Specifically, product or technology. communications solutions that showcase each company, financial, we are unique in offering specialist expertise seamlessly across corporate, industry, healthcare and marketing communications with outreach programmes to media, financial and investment communities. public, professional, Our service offering covers all communications disciplines including strategic counsel, internal communications, crisis communications, public affairs, media relations, IR, PR, Our globally research and event management. design, copywriting, advertising, marketing, integrated and dedicated life sciences team serves from our bases clients around the world Melbourne and Sydney. Boston, Munich, Manchester, in London, Instinctif Partners Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u http://labiotech.eu LaBiotech.eu is the free and extensive European biotechnology news website. news website. biotechnology European and extensive is the free LaBiotech.eu dynamic media is the best way this young and for you 2014, Launched in September to our Thanks to keep a watch and innovations on the business of biotechnologies. your dedicated european biotech events we are also partnerships with major website for subscribe to our weekly can also newsletter to receive You event summaries and agenda. the latest news. LaBiotech.eu Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.lifesciencenation.com Life Science Nation (LSN) accelerates the business of early stage life science via (LSN) accelerates the business of Life Science Nation sourcing platform. a Match.com-like This platform enables executives to find firms that are a fit for their business profile. Professionals leverage to generate LSN prospects, a global target list (GTL) of qualified LSN researches and curates market intelligence on greatly enhancing marketing efficiency. which by their emergingThe first is biotech and medtech companies, two industry sectors: LSN tracks ten categories of Second, ephemeral nature are challenging to find and track. early stage left and identifies who is filling the void life science investors by venture capital. LSN has developed unique methodologies for tracking and keeping up-to-date with both of these dynamic market segments. LSN created and managesEarly the successful Redefining Stage (RESI) Investments which brings together global early stage and medtech companies biotech conference series, The Life Science LSN has also written and published a book, with early stage investors. with a Next Phase, Fundraising Manifesto as well as a weekly newsletter, Executive’s a Fundraising Boot Camp at LSN presents conferences Finally, readership of 15,000. messaging, branding, and provides seminars on and partnering events around the globe outbound marketing and sales to incubators and venture development centers within the life sciences. Life Science Nation Life Science Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.lifescienceaustria.at
Life Science Austria - LISA - is a program acting as a hub for people from all - LISA - is a program acting as a Life Science Austria Together over in Austria. interested in the life science sector the world who are first point of contact for LISA is the in the Austrian regions, with its associates an operation, setting up anyone about scientific collaboration, with questions Austria. projects and businesses in or funding and sponsoring human. Austrian regions – ecoplus, with all existing life science clusters in the Working and Cluster, Technology Health Vienna Region, Austria Life Science technology.styria, The - LISA is able to build on their expertise and services. Tirol Life Science Cluster contribute to the success of life science enterprises in aims of LISA and its partners are: assist in the search Austria by helping to introduce scientific discoveries to the market, to ensure healthy and support and provide general business consultancy for funding, commercial development. is responsible for running this program on Wirtschaftsservice GesmbH (aws), Austria (BMWFJ). Youth Family and Federal MinistryAustrian of Economics, behalf of the +43 (1) 501 75 - 0 Tel.: +43 (1) 501 75 - 900 Fax: [email protected] Email: Wirtschaftsservice mbH, Gesellschaft Austria Ungargasse 37, 1030 Wien, Austria Life Science Austria Life Science Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.onenucleus.com One Nucleus is a membership organisation for international life science and for international life science is a membership organisation One Nucleus the heart of London UK, are based in Cambridge and We healthcare companies. and healthcare cluster. largest life science Europe’s and the top European life science For One Nucleus and our members to be Vision: healthcare network. will achieve this by of our members. maximising the global competitiveness We Mission: One Nucleus is a and formerly known as ERBI, Established in 1997, History: Organisation membership organisation and located in Cambridge and London – the centre not-for-profit, leading life science and healthcare cluster. of Europe’s biotech, The company has over 470 organisations including pharmaceutical, as members medical device and diagnostic companies and associated service technical and commercial providers. For our our members. of mission is to maximise the global competitiveness One Nucleus’s that means being global leaders in the research, science and technology-based members, development and commercialisation of healthcare innovations that radically the improve professional services For our business and lives around the world. quality of people’s it means delivering exceptional services that significantly enhance the business members, performance of their clients. One Nucleus Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.swissbiotech.org SwissBiotech – One Nation – One Biotech Cluster SwissBiotech – One BaselArea, the fourSwiss Biotech unites regions leading biotech (BioAlps, of Switzerland regionsThe have early on combined efforts with Area). and Greater Zurich Ticino Biopolo life-science listings of which holds a leading position in terms the SWX Swiss Exchange and services. Association Represents more Association named Swiss Biotech The National Industry than 150 companies to date and acts as the operational arm for the marketing alliance. profile as an economic center in Europe and profiles Swiss Biotech raises Switzerland’s the biotech industry its key with research institutions and companies. messageSwiss Biotechs’ mission is to spread the of Switzerland as one of the top This will be achieved by presenting a comprehensive biotech locations in the world. finance economics, education, picture of the drivers of biotechnology including research, The bases for success in biotechnology of research are the critical mass and industry. The early integration of industry and institutes and accelerated technology transfer. More well-trained workforce is another critical success factor for rapid economic growth. than 40 technology parks throughout the country support the increasingly important and process. successful TechTransfer Further inquiries: Executive Office SwissBiotech, +41 (0)44 455 56 78 Tel. [email protected] Swiss Biotech Association Swiss Biotech Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS t back :: next u www.tiberendstrategicadvisors.com 1. To enhance valuation To 1. build visibility for partnerships and strategic alliances To 2. Tiberend Strategic Advisors, Inc. Advisors, Strategic Tiberend 5th Floor, 35th Street, W. 35 NY 10001-2205 York, New 212.827.0020 Tel: 212.827.0028 Fax Fax: Tiberend Strategic Advisors, Inc. is a corporate communications firm providing a corporate communications firm is Inc. Strategic Advisors, Tiberend companies – biotech (therapeutics), for life science media strategy and execution emerging work with both public and private We diagnostics. medical devices and growth companies. Tiberend Strategic Advisors, Inc. Advisors, Strategic Tiberend Supporting Organisations Supporting 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS www.sachsforum.com www.sachsforum.com • Conference Sponsor – including workshops and social events • Exhibition stands • Distribution of Promotional Material Sachs Associates a London based international is produces high profile events conference organiser which for Sachs These events are held In Europe and the USA; currently in financial community. the bio-pharmaceutical and Boston and Zurich. The company was established in 1992 and ran emerging growth and emerging forums market investor in association and then Bloomberg LP over a ten year period. with Dow Jones Associates may be summarised as follows: participation with Sachs The benefits of conference Multimedia Exposure Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well Sachs conferences is carried out Regular extensive coverage of all the Company’s focused electronic and print media. through video streaming and extensive events coverage major international through financial news agencies, Associates has a number of long established Sachs In addition, Dow Jones and Reuters. including Bloomberg, which allow further effective distribution on relationships with other financial press organisations globally, behalf of its clients. Eminent Speakers Associates is committed to ensuring that its events continue to provide forums with the participation of Sachs Through its reputation and its long-established the most eminent speakers from the public and private sectors. the Company has attracted the very senior political and economic personalities as speakers local relationships, at its events. Opportunities for forthcoming events Sponsorship and Marketing Associates has developed an extensive knowledge of the key individuals operating within the European Sachs Associates at the This together with a growing reputation for excellence puts Sachs and global biotech industry. forefront of the industry and provides a powerful tool by which to increase the position of your company this in market. profile directly with your potential clients. Sponsorship of any your company’s of our events allows you to raise allowing your organisation to gain the most out All of our sponsorship packages are tailor made to each client, of attending our industry driven events. conferences: at future available opportunities are sponsorship and marketing The following or sponsorship opportunities please call in exhibiting If your company is interested Silvia Kar on +44 203 463 4890. Sachs Associates Sachs Associates Organisers 8th ANNUAL & Exhibition Forum CEO Science Life European
8th Annual European Life Science CEO Forum & Exhibition WELCOME SPEAKERS PRESENTING COMPANIES EXHIBITORS SPONSORS & SUPPORTERS ORGANISERS
27 Belsize Lane 3rd Annual 3rd London NW3 5AS 15th Annual Tel: +44 (0)203 463 4890 +44 (0)203 Tel: Fax: +44 (0)207 691 7919 Fax: www.sachsforum.com/basel15 Biotech in Europe Forum Biotech in Europe www.sachsforum.com Sachs Immuno-Oncology: Sachs Immuno-Oncology: BD&L and Investment Forum BD&L and Investment We look forward to seeing you at: forward to seeing you look We For Global Partnering & Investment Global Partnering For 16th November 2015 • Düsseldorf • Germany16th November Follow us on Twitter – @SachsAssociates Twitter us on Follow Review the 2014 Forum: www.sachsforum.com/mdis14 29th – 30th September 2015 • Congress Centre Basel Centre 29th – 30th September 2015 • Congress 29th May 2015 • Hyatt Chicago Magnificent Mile • USA 29th May 2015 • Hyatt Chicago Magnificent
Medtech & Diagnostics Innovations Summit Innovations Medtech & Diagnostics EUROPEAN LIFE SCIENCE CEO FORUM CEO SCIENCE LIFE EUROPEAN